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Abstract 
Phosphorothioate insecticides such as parathion (0,0, diethyl O-p- 
nitrophenyl phosphorothioate) must undergo metabolic activation to 
form oxygen analogs in order to exert their toxicity. The specific isoforms 
of cytochrome P450 involved in this oxidative desulphuration reaction 
were examined in rat liver microsomes and a panel of sixteen human 
liver microsomes. 
In the rat, parathion (20µM and 200µM) was activated to paraoxon with an 
apparent Km of 10.4±0.25µM (n=3), the metabolic rates were 241±17 and 
256±18 pmol/min/mg protein, respectively. p-Nitrophenol was also 
formed, at 235±15 and 220±23 pmol/min/mg protein. Human liver 
microsomes activated parathion (20µM and 200µM) with an apparent Km 
of 9µM-16µM (n=3), the metabolic rates were 23.3-199.3 and 18.7-310.3 
pmol/min/mg protein (n=16). p-Nitrophenol was also formed, at 321.1- 
769.2 and 406.2-778.3 pmol/min/mg protein. 
The activation of parathion (200µM) by human liver microsomes was 
positively correlated with nifedipine oxidation, indicating the 
involvement of CYP3A. Correlations were not significant with 
ethoxyresorufin-0-dealkylation, pentoxyresorufin-0-dealkylation, p- 
nitrophenol hydroxylation, paraoxon hydrolysis or phenylvalerate 
hydrolysis. Paraoxon formation from parathion by human liver 
microsomes was markedly inhibited by the CYP3A inhibitors 
ketoconazole, quercetin and naringenin (apparent Ki=21µM). Metyrapone 
and a-naphthflavone had some inhibitory effect. The inhibitors were 
generally less effective towards parathion metabolism by rat liver 
microsomes. Experiments with EDTA indicated that A-esterase was not 
functionally important at low levels of paraoxon. Human P450s 3A4 and 
3A5 expressed microsomes were the most efficient at biotransforming 
parathion to paraoxon, although P450s 1A1,2B6 and 2C8 also catalysed the 
reaction. 
The present study has shown marked interindividual variation in the 
metabolism of parathion, which may influence toxicity following 
exposure to this or other phosphorothioates. Co-administration of 
inhibitors or inducers of the enzymes involved may affect the fate of 
parathion and thus enhance or reduce its toxicity. 
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SECTION I: 
GENERAL INTRODUCTION 
Chapter 1 
Chapter 1 Organophosphate pesticides 
1.1 Introduction 
Many thousands of different pesticides are used every year for home and 
agricultural purposes and consequently the potential for exposure to man 
is great. The term "pesticide" is a generic name for a variety of chemical 
substances used to kill or control undesirable plant or animal pests. These 
chemicals are designed to be toxic to certain organisms and are deliberately 
added to the environment. Even with advances in pest control, it is 
estimated that up to 50% of harvested crops can be damaged by post- 
harvest infestation by insects, fungi, rodents etc. Pesticides have thus 
become indispensable in feeding, clothing and protecting the worlds' 
population. 
1.2 Organophosphate Pesticides 
Following the second world war, organochlorine pesticides made a major 
contribution to improvements in agricultural output and in the control of 
disease vectors. While the persistence of these compounds after 
application was of considerable benefit to the user, it also introduced 
problems. As these problems became more widely appreciated, insect pest 
control began to rely more on the anti-cholinesterase organophosphate 
and carbamate ester pesticides. 
The insecticidal action of organophosphate compounds was observed in 
Germany during World War Two in the study of materials closely related 
to the nerve gases sarin, soman and tabun. Initially, the discovery was 
made in search of substitutes for nicotine, which was in very short supply 
1 
in Germany. Organophosphates have two distinctive features. First, they 
are generally much more toxic to vertebrates than are the organochlorine 
insecticides, and, secondly, they are non-persistent. It is this latter quality 
which brought them into agricultural use as substitutes for the 
organochlorines. The chemically unstable organophosphate insecticides 
have virtually replaced the persistent organochlorine compounds, 
especially with regard to use around the home and garden. However, 
while there has been a considerable increase in the annual use of 
organophosphate insecticides for crop protection since 1970, the overall 
increase has been less since the early 1980's although many new uses and 
formulations have been introduced. Phosphorothioate compounds, eg 
parathion, chlorpyrifos, form a group of pesticides which are generally less 
acutely toxic to man since they require metabolic activation to the oxon in 
order to exert their anti-cholinesterase effects. Table 1.1 gives a list of 
several phosphorothioate pesticides used occupationally. 
Organophosphates exert their acute toxic action by inhibiting 
acetylcholinesterase ("anti-cholinesterase") in neural tissue and at the 
neuromuscular junction, which results in the accumulation of 
acetylcholine. This action , together with their chronic effects in man, is 
discussed more fully in chapter 2. In insects, the effects of 
organophosphates and carbamates are primarily those of poisoning of the 
central nervous system, since the insect neuromuscular junction is not 
cholinergic, as in mammals. 
1.3 Chemical structure and classification of organophosphates 
The general chemical structure of organophosphates is shown in figure 
1.1. The pentavalent phosphorus has a double bond attached to either a 
2 
Table 1.1 Several phosphorothioate pesticides used occupationally. 
Phosphorothioate (Rl and R2) P X 
Chlorpyrifos 
CA S \11 CI CI 
P -O CI 
C H 2 s. O 
Diazinon 
CA 
II 
0\ S CH3 
P / 
CH3 
/ -0 Cý-I 
`CH 
C2Hs0 s 
S CH3 
Propetamphos II 1 
CH3O -P -0- C= CHOOCH(CH3)2 
CH3CH2NH 
Chlorpyrifos is 
0,0-diethyl O-(3,5,6-trichloro-2-pyridyl) phosphorothioate 
Diazinon is 
0,0-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate 
Propetamphos is 
2- Butenoic acid, 3((ethylamino) methoxyphosphinothioyl)oxy)-isopropyl 
ester 
sulphur or an oxygen. Only P=O compounds (oxons), formed by metabolic 
oxidative desulfuration of parent P=S esters (phosphorothioates) are active 
as inhibitors of esterases because of a sufficiently electropositive centre at 
the phosphorus atom. The acidic X group, for which a wide range of 
chemical structures is possible, is also attached to the phosphorus. This 
group leaves when the phosphorus moiety undergoes nucleophilic attack 
by the activated serine hydroxyl group of esterases. The R groups might 
also be chemically very different and be attached to the phosphorus either 
directly (phosphinates), or through an oxygen (phosphates), or a nitrogen 
(phosphoramidates). When one of such groups is attached directly to the 
phosphorus and the other through an oxygen, the compound is called a 
phosphonate. 
Ri- qS(p) 
\II 
p- O- X 
RZ- 0/ 
Figure 1.1 
The general chemical structure of phosphorothioates (and their oxons). 
Oxygen atoms bound to Rl and R2 may be replaced with nitrogen. The R 
groups and the X leaving group can be chemically different. 
1.4 Parathion 
Parathion is 0, O-diethyl-O-(p-nitrophenyl) phosphorothioate. It is a broad 
spectrum, phosphorothioate pesticide used to control many insects and 
mites. It has non-systemic, contact and fumigant actions and has a wide 
range of applications on many crops, against numerous insect species. Its 
structure is as follows (figure 1.2): - 
4 
S 
CH3 CH2 ON 11 
P-o-cý N32 
CH3 CH2 0 
Figure 1.2 The structure of parathion. 
Parathion may also be called ethyl parathion. Proprietary names include 
Aileron®, Aphamite®, Bladan®, Folidol®, Fosferno®, Niram®, 
Paraphos® and Rhodiatox®. The CAS registry number is 56-38-2. 
Physical and chemical properties 
Parathion has the empirical formula C10H14NO5PS and a molecular weight 
of 291.3. The pure material is a yellowish liquid at temperatures above 6°C. 
Parathion is freely soluble in alcohols, esters, ethers, ketones and aromatic 
hydrocarbons, but is practically insoluble in water (20ppm) or in 
petroleum ether, kerosene or spray oil. Parathion is stable at a pH below 
7.5. 
History. formulations and uses 
Parathion was developed by Schrader in 1944 and has since become one of 
the most widely used pesticides in the world. However, because of its 
relatively high mammalian toxicity, its use is now prohibited in some 
countries in favour of pesticides with higher selective toxicities towards 
insects. Parathion is banned for use as a pesticide in the UK but is still 
available in developing countries. 
Parathion currently is used as dilute sprays, which are prepared by the 
operator from 15% or 25% wettable powders, or from emulsifiable 
concentrates of 50% or less. Dusts (5%, w/w) are used also. Aerosol 
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formulations containing up to 10% parathion may be used in 
greenhouses. Cords impregnated with parathion for fly control contain 
about 100mg/ linear foot. Parathion finds almost its entire use in 
agriculture including nurseries and greenhouses. 
Toxicity 
Because of its high acute toxicity, parathion is classified as a Restricted Use 
Pesticide (RUP). RUPs may be purchased and used only by certified 
applicators. The acute oral toxicity (LD50) of parathion varies from about 5 
to 30mg/ kg in experimental animals, depending on species and vehicle, 
and is extremely toxic to birds (LD50 is 2.1 mg/kg in ducks). 
Signs of acute poisoning by parathion are typical of exposure to 
organophosphorus anti-cholinesterases, however, delayed neurotoxicity 
has not been recognised for this compound (Johnson, 1975). Parathion is 
acutely toxic by all routes of exposure and human fatalities have been 
caused by ingestion, dermal adsorption, and inhalation (Hayes and Laws, 
1990). As with all organophosphates, parathion is readily absorbed through 
the skin (Meister, 1987). 
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Chapter 2 
Chapter 2 The mode of action of organophosphates 
2.1 Introduction 
The primary toxic signs and symptoms that characterise poisoning by 
organophosphate compounds are acute and are well understood. They are 
caused by inhibition of acetylcholinesterase by phosphorylation, and 
accumulation of acetylcholine at susceptible receptors. Organophosphate- 
induced delayed neuropathy (OPIDN) also occurs in man and 
experimental animals following intoxication by some organophosphate 
esters (Lotti et al, 1986; Bidstrup, Bonnel and Beckett, 1953), although 
organophosphates with the potential to cause delayed neuropathy are not 
necessarily powerful cholinesterase inhibitors. Improvements in the 
therapy of acute poisoning mean that higher doses of some 
organophosphate can now be tolerated without fatal consequences, 
however, many organophosphates that might theoretically cause 
neuropathy, would only do so at a dose far above the lethal dose. 
2.2 Acute toxic effects of organophosphates 
The acute toxic effects of organophosphates between species will be 
influenced by their route of entry into the body, the level of exposure, the 
metabolism (activation and detoxification) of the compound and the 
kinetics and stability of the inhibited acetylcholinesterase complex. 
7 
2.2.1 Kinetics of acetylcholinesterase inhibition 
The inhibitory power of a compound is usually expressed as IC50, the 
concentration of the inhibitor giving 50% inhibition under defined 
conditions, or as the bimolecular rate constant (Ki), for the reaction: 
Ki 
EOH + IX ------> EOI + HX 
where EOH represents the active enzyme and IX the inhibitor, with the 
leaving group X. 
Aldridge (1950) suggested, for inhibition by an organophosphate, that the 
inhibition proceeds in two steps, with the formation of a reversible 
Michaelis complex preceding the next step. 
K1 Kp 
EOH + IX EOH. IX -------> EOI + HX 
K1 
The inhibition can therefore be characterised by two parameters, the 
affinity equilibrium constant, Ka, which is equal to K-1/Ki and the 
phosphorylation constant, Kp. The ratio between these two constants 
(Kp/Ka) gives an overall rate of inhibition (Ki), which is known as the 
bimolecular inhibition rate constant, 
Ki = -Kp Ka 
8 
Two active sites are recognised in the acetylcholinesterase active centre: an 
anionic site and an esteratic site. The nitrogen atom and methyl groups of 
the choline moiety of acetylcholine interact with the anionic site, while 
the carbonyl atom of the acetate moiety of acetylcholine binds to the 
esteratic site (Koelle and Gilman, 1963). Most organophosphates lack a 
positive charge in the acidic group and react with the esteratic site on the 
acetylcholinesterase molecule, but not with the anionic site. No matter 
whether the anionic site is involved or not, the splitting off of the acidic 
group of the organophosphate compound is analogous to the splitting off 
of choline from acetylcholine. In contrast, the rate at which these two 
reactions occur are very different. The breaking of the phosphorus-enzyme 
bond takes from an hour to weeks, depending on the compound, whilst 
acetylcholine is turned over in a few microseconds (Wilson, 1951). The 
phosphorylation of acetylcholinesterase with paraoxon is shown 
diagrammatically in figure 2.1. 
The inhibited acetylcholinesterase enzyme is usually stable, resulting in 
relatively slow recovery from intoxication. Spontaneous reactivation of 
the inhibited enzyme may occur and this is known to depend on the 
animal species and tissue, as well as on the chemical group attached to the 
enzyme. 
The time course for acetylcholinesterase recovery at target tissues is of 
great importance in determining the clinical features of poisoning and 
differs greatly between componds. Figure 2.2 shows this process 
schematically. For instance, in acute poisoning with dichlorvos (0,0, - 
dimethyl-O-2,2-dichlorovinyl phosphate) there is rapid spontaneous 
enzyme reactivation, with a half-life of 1-2 hours, and a consequent 
improvement clinically. However, with many organophosphates an 
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Figure 2.1 
Reaction of paraoxon with acetylcholinesterase resulting in phosphorylated enzyme. 
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irreversibly inhibited enzyme is formed. In such instances the symptoms 
of intoxication are prolonged and persistent and require medical 
intervention, including reactivation of the enzyme with specific chemical 
antidotes (oximes). 
2.2.2 Clinical features of acute toxicity 
In man, acetylcholine is present at the terminal endings of (a) the central 
nervous system (b) postganglionic parasympathetic nerves, and a few 
sympathetic nerves such as the sweat glands (muscarinic receptors) (c) 
neuromuscular junctions (nicotinic receptors) (d) the autonomic nervous 
system at ganglionic synapses (nicotinic receptors). Inhibition of 
acetylcholinesterase in the nervous system results in accumulation of the 
neurotransmitter acetylcholine at synapses and neuromuscular junctions 
and excessive nervous system stimulation. This may lead to death in 
severe cases. A summary of acute toxicity features can be seen in table 2.1. 
Death is usually caused by respiratory failure and consequent anoxia, but 
may be cardiovascular in origin. Four factors may contribute to respiratory 
failure (a) excessive secretion of the respiratory tract (b) 
bronchoconstriction (c) weakness of the muscles of respiration (d) failure 
of the respiratory centre in the brain. The relative importance of these 
factors depends mainly on the compound, species, route of 
administration, and the passage of the compound into the brain via the 
blood-brain barrier. 
11 
Table 2.1 A summary of acute toxicity features from organophosphate 
U15Ui1111I4. 
Muscarinic features 
Increased bronchial secretion, bronchoconstriction, cyanosis, pulmonary 
oedemia. 
Excessive sweating, salivation and lacrimation. 
Nausea, vomiting, diarrhoea, abdominal cramp. 
Urinary and faecal incontinance. 
Bradycardia, hypotension, heart attack. 
Miosis, blurred vision. 
Nicotinic features 
Muscle fasciculation (including diaphragm and respiratory muscles). 
Generalised weakness. 
Tachycardia, hypertension. 
Pallor. 
Central nervous system (nicotinic) features 
Confusion, headache, restlessness, anxiety, poor concentration, tremor, 
ataxia. 
Hypotension. 
Respiratory depression. 
Convulsions and coma. 
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Figure 2.2 
Inhibition of an esterase system by organophosphate compounds. 
1= Reversible formation of Michaelis enzyme-substrate complex. 
2= Phosphorylation of the enzyme with the loss of the leaving group (X). 
3= Reactivation of the enzyme. May occur spontaneously or on addition of oximes. 
4 ='Aging' of the enzyme on cleavage of an alkyl group. 
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2.2.3 Biological monitoring for acute exposure to 
organophosphates 
Inhibition of acetylcholinesterase in the nervous system and 
neuromuscular junctions is paralleled by inhibition of a similar enzyme 
on the red blood cell and of plasma (or serum) cholinesterase (Mason and 
Lewis, 1989). It is generally accepted that monitoring for inhibition of the 
peripheral enzymes red blood cell acetylcholinesterase and plasma 
cholinesterase is a useful marker for organophosphate exposure. Both of 
these enzymes are recommended for the monitoring of occupational 
exposure to organophosphates (WHO report 513,1973), but if only one test 
is performed, determination of red blood cell acetylcholinesterase is 
preferable. Acetylcholinesterase is found in nervous system tissues and 
therefore is considered a better indicator of biological effect than plasma 
cholinesterase. 
It is possible to estimate absorption of organophosphates by analysis for 
their metabolic products in urine several days after exposure and in 
association with lesser exposures than those necessary to produce 
cholinesterase inhibition (Knaak et al, 1979). This will give information 
on recent exposure, whilst measurement of enzyme levels, especially red 
blood cell acetylcholinesterase values, gives the physiological effect of 
exposure during the preceding month or so. Both kinds of information 
may be of value. 
Health and Safety Executive guideline MS 17 (1987) suggests that workers 
should be medically examined if plasma cholinesterase activity has been 
shown to have fallen by more than 30% of pre-exposure levels during 
routine monitoring. The medical officer may then at his own discretion, 
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having considered the nature of the work involved and the clinical 
symptoms (if any), recommend that the worker be suspended from further 
exposure to organophosphates until considered fit to resume further 
work. A recommendation to resume normal work should be based on 
both clinical evidence and the results of biological monitoring. 
2.3 Delayed neurotoxic effects of organophosphates 
Another syndrome, that of organophosphate-induced delayed neuropathy 
(OPIDN), is caused by some phosphate, phosphonate and 
phosphoramidate esters, only a few of which have ever been used as 
insecticides. Regardless of the severity of anti-cholinesterase effects, there 
is a delay after intoxication before neuropathic signs and symptoms 
appear. Symptoms of OPIDN are well documented in humans following 
exposure to organophosphates such as chlorpyrifos (0,0-diethyl O-(3,5,6- 
trichloro-pyridyl) (Lotti et al, 1986), methamidophos (O, S-dimethyl 
phosphoroamidothioate) (Senanayake and Johnson, 1982), mipafox 
(Bidstrup et al, 1953) and TOCP (tri-ortho-cresyl phosphate) (Inoue et al, 
1988), amongst others. High inhibition of lymphocyte neuropathy target 
esterase predicted the development of OPIDN when measured soon after 
massive poisoning with chlorpyrifos, but several days before clinical signs 
were apparent (Lotti et al, 1986). This suggested a means for monitoring 
exposure to neurotoxic organophosphates. However, unlike in the hen, 
the threshold for neuropathy target esterase inhibition in man has yet to 
be determined. This indicates care when extrapolating between the species. 
A complete account of all organophosphates tested for neurotoxic 
potential has been given by Johnson in three reviews (Johnson 1975a; 
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1975b; 1982). A list of organophosphorus compounds shown to produce 
OPIDN in hens is given in table 2.2. 
Parathion is not believed to cause OPIDN and therefore this syndrome 
will be discussed no further (Johnson, 1988). 
2.4 Long term effects of organophosphates 
The classical picture of acute anti-cholinesterase insecticide intoxication, 
which was first described by DuBois (1948), has become more complicated 
in recent years by the recognition of additional and persistent signs of 
toxicity not previously associated with these chemicals. Recent studies 
have suggested that long term neurological effects may result from a 
single acute episode of poisoning or chronic low level exposure. Studies 
carried out by Ecobichon (1982) have shown that effects involving 
neurobehavioral, cognitive and neuromuscular functions frequently 
persist for several months following single exposure to high 
concentrations of organophosphates. A study of sixteen pesticide workers 
exposed primarily to organophosphate insecticides for 10-15 years reported 
a wide range of persistent signs of toxicity (Ecobichon, 1982). The 
symptoms included tinitus, pyrexia, ataxia, tremor, paraesthesia, paralysis, 
loss of memory, lassitude, generalised weakness, mental confusion, 
restlessness, anxiety and depression. 
In an epidemiological study of long-term effects of organophosphates 
(Savage et al, 1988), 100 pairs of individuals with a previous history of 
poisoning were compared to matched controls. Significant differences 
were not found in blood chemistry or EEG, but were found in 
psychometric analysis and a test of motor reflexes. 
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Table 2.2 
Oreanovhosnhorus compounds shown to produce OPIDN in hens. V1 
Compound Route 
Lowest lethal 
dose (mg/ kg) 
Lowest 
neurotoxic dose 
(mg/ kg) 
DFP S. C. >1 1 
Mipafox S. C. >20 20 
Chlorp rifos S. C. 200 200 
Coumaphos S. C. 100 100 
Disulfoton S. C. >50 32 
Phorate S. C. 48 32 
DEF 1. P. 100 50x5 
Merphos S. C. 600 600 
TOCP P. O. 200 100 PPM 
C anofen hos P. O >10 10 
EPN S. C. 80 40 
Desbromole to hos . o. >50 
50 
DFP is O, O-diisopropyl fluorophosphate 
DEF is S, S, S-tributyl phosphorotrithioate 
TOCP is tri-o-cresyl phosphate 
EPN is O-ethyl 0-4-nitrophenyl phenylphosphonothioate 
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Rosenstock and co-workers (1991) carried out a retrospective study of 
agricultural workers who had experienced a single episode of poisoning 
with organophosphates on average two years earlier. The poisoned group 
performed worse at neuropsychological testing and assessments of visual 
attention, visual memory, visuomotor speed, sequencing and problem 
solving, motor steadiness and dexterity compared to matched controls. 
Other reports have suggested that long-term effects on the central and 
peripheral nervous systems may also be associated with relatively low 
level organophosphate exposure. These effects range from 
neurobehavioural and EEG abnormalities to electrophysiological changes 
in animal diaphragmatic and skeletal muscles (Kelly, 1990). Other studies 
have shown psychological, behavioural or electrophysiological changes 
after exposure of humans to low doses of organophosphates. For example, 
Stephens et al (1995) found neurobehavioural changes in a group of 
farmers who used organophosphate sheep-dips compared to a control 
group of quarry workers. 
The National Farmers Union report acute and long-term toxic effects 
associated with the use of organophosphates present in sheep-dips for the 
control of scab, a mite which lives in the skin of this animal. Studies of 
such workers are difficult to evaluate since clinical symptoms are often 
non-specific in nature and estimations of toxicity are limited by the 
sensitivity of the various analytical, biochemical, neuropsychological and 
neurophysiological tests used. 
A further distinct manifestation of exposure to several organophosphate 
compounds has recently been described by clinicians in Sri Lanka 
involved in the treatment of suicide attempts (Senanayake and 
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Karalliedde, 1987). This paralytic condition, called the "intermediate 
syndrome" consisted of a sequence of neurologic signs that appeared some 
24 to 96 hours after the acute cholinergic crisis but before the expected 
onset of delayed neuropathy. The major effects were muscle weakness, 
primarily affecting muscles innervated by the cranial nerves but some 
limb involvement was also apparent. There was a distinct risk of death 
during this time interval because of respiratory depression and distress 
which required urgent ventilatory support. There were no obvious clinical 
differences during the acute intoxication phase between those patients 
who developed the "intermediate syndrome" and others who did not. 
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Chapter 3 
Chapter 3 Xenobiotic metabolism 
3.1. Introduction 
Man is exposed to a wide variety of chemicals daily in food, at work and in 
the general environment. Many exogenous compounds (xenobiotics) such 
as drugs are taken into the body deliberately, but many environmental 
compounds cannot be avoided and are absorbed into the body through the 
skin, inhaled, or swallowed unintentionally (figure 3.1). 
Xenobiotic metabolism can be divided into two phases: phase 1 introduces 
or exposes a functional group in the molecule which can then be 
conjugated in phase 2. The role of metabolism, therefore, is to introduce 
polarity to otherwise lipophilic xenobiotics to enable their effective 
excretion. 
Table 3.1 Reactions classed as phase 1 or phase 2 metabolism 
Phase 1 Phase 2 
Oxidation involving cyt. P450 Glucuronidation 
Other oxidation reactions Sul hation 
Reduction Meth Tation 
Hydrolysis Acetylation 
Hydration Amino acid conjugation 
Isomerisation Glutathione conjugation 
Dethioacetylation Fatty acid conjugation 
Condensation 
Most xenobiotics are metabolised by a variety of enzymes, and these 
metabolic processes generally produce metabolites that are less toxic than 
the parent compound. However, this is not always the case and some 
processes give rise to metabolites that are more reactive, eg the oxidative 
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desulphuration of phosphorothioates by phase 1 reaction(s) produces 
highly toxic oxons, causing toxic effects. Metabolic profiling is therefore 
necessary to assess the effect and toxicity of xenobiotics, and to indicate 
individual susceptibility to any toxic effects. 
Phase 1 enzymes potentially involved in the metabolism of 
phosphorothioates include the cytochromes P450, esterases and flavin 
monooxygenases. In terms of phase 2 enzymes, it has been suggested that 
glutathione-S-transferases, glucuronyl-S-transferases, sulphotransferases 
and epoxide hydrolase are major pathways in the detoxification of 
exogenous and endogenous compounds (Jakoby and Habig, 1980). 
In this chapter a general review of xenobiotic metabolism is presented 
concentrating on aspects pertinent to this thesis. 
3.2 The cytochrome P450 system 
The cytochromes P450 (EC 1.14.14.1) comprise a family of b-type 
haemoproteins with an identical prosthetic group (a thiolate-bound haem) 
and mechanism of catalysis (activation of oxygen without activating the 
substrates), but widely different apoprotein structures which are 
responsible for their different substrate specificities. The general cataylsed 
reaction of the cytochromes P450 can be summarised as follows: 
RH + 02 NAD(P)H + H+ -------> ROH + H2O NAD(P)+ 
where R is the substrate 
Liver microsomes from all mammalian species contain numerous P450 
enzymes, each with the potential to catalyse numerous xenobiotic 
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transformation reactions, such as hydroxylation, epoxidation, 
dealkylation, desulphuration, oxygenation and dehydrogenation. The 
broad and often overlapping substrate specificity of P450 isoforms 
precludes the possibility of naming these enzymes for the reactions they 
catalyse. 
Cytochrome P450 evolution is believed to have begun 2-3 billion years ago 
and many of the xenobiotic-metabolising enzymes evolved due to a need 
to metabolise plant toxins and similar compounds (Gonzalez and Nebert 
1990). One consquence of human P450 gene evolution is the 
polymorphism of drug metabolism, leading to marked differences in the 
response of individuals to the toxic and carcinogenic effects of drugs and 
other environmental chemicals. The differences between human 
individuals, races or ethnic groups, are either at the level of expression of 
some forms (eg CYP1A1 after induction), or at the presence or absence of a 
particular form (eg CYP2D6, CYP3A5), and may become clinically manifest 
in quantitative differences in the metabolism of certain drugs resulting in 
"poor" or "extensive" metabolisers (Gonzalez et al, 1991). 
The amino acid sequence of numerous P450 enzymes has been 
determined, largely by recombinant DNA techniques, and such sequences 
now form the basis for classifying and naming P450 enzymes (Nelson et al, 
1996). In general, P450 enzymes with less than 40% amino acid sequence 
identity are assigned to different gene families (gene families 1,2,3,4 etc). 
P450 enzymes that are 40-50% identical are assigned to different 
subfamilies (eg 2A, 2B, 2C, 2D, 2E). P450 enzymes that are more than 55% 
identical are classified as members of the same subfamily (eg 2A1,2A2, 
2A3). 
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The liver microsomal P450 enzymes involved in xenobiotic 
biotransformation belong to three main P450 gene families of both 
humans and rodents, namely, CYP1, CYP2 and CYP3. Liver microsomes 
also contain P450 enzymes encoded by the CYP4 gene family, substrates for 
which include several fatty acids, but relatively few xenobiotics. The liver 
microsomal P450 enzymes in each of these gene families generally belong 
to a single subfamily (ie CYP1A, CYP3A and CYP4A). A notable exception 
is the CYP2 gene family, which comprises five subfamilies (ie CYP2A, 
CYP2B, CYP2C, CYP2D and CYP2E). The number of P450 enzymes in each 
subfamily differs from one species to the next. 
Man, in contrast to experimental animals, shows large interindividual 
variations in P450-catalysed biotransformations, due to the many factors 
discussed in the next few chapters. Difficulties often arise when 
extrapolating animal data to man because P450 isoforms are not conserved 
between species and differences are known to occur in catalytic and 
regulatory specificities between human P450 isoforms and their rat 
orthologues (table 3.2). Differences in the levels of individual P450 
isoforms and indeed the expression of distinct isoforms may lead to 
differences in the metabolism of alleged probe substrates between species, 
and may also influence the selectivity of inhibitor probes. 
The major human P450 subfamilies are CYP3A and CYP2C, which account 
for about 30% and 20% of the total P450 pool based on immunochemically 
detectable proteins, with CYPs 1A2,2E1,2A6,2D6 and 2B6 comprising 13%, 
7%, 4%, 2% and <1%, respectively (Shimada et al, 1994). Levels of P450 
isoforms in male rats are very different with CYP2C11 accounting for 54% 
of the total P450 content, CYP3A2 being 17% abundant and CYP1A2 being 
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expressed at much lower levels (2%) in untreated rat liver (Nedelcheva 
and Gut, 1994). 
Table 3.2 Sequential homoloev between rat and human P450 fnrmc 
P450 form Sequential homologya 
Rat Human orthologue 
CYP1A1 CYP1A1 80 (78) 
CYP1A2 CYP1A2 75 (70) 
CYP2A3 CYP2A6 (85) 
CYP2B1 CYP2B6 78 (74) 
CYP2B2 -- -- 
b 
CYP2C6 CYP2C1O* (75) 
CYP2C11 CYP2C9 80 (77) 
CYP2C13 CYP2C8 74 (68) 
CYP2D1 CYP2D6 (71) 
CYP2E1 CYP2E1 75 (78) 
CYP3A1 CYP3A4 (78) 
CYP3A2 CYP3A5 (71) 
CYP4A1 CYP4A9 -- 
b 
a Similarity of cDNA and amino acid (in parenthesis) sequence stated 
b No data available regarding existence of orthologous form 
* Discontinued number; existence in doubt 
(Nelson et al (1996). Pharmacogenetics 6: 1-42) 
Table compiled by Soucek and Gut (1992). Xenobiotica 22: 83-103. 
3.3 The flavin monooxygenase system 
The action of the flavin monooxygenases (FMO, EC 1.14.13.8) constitutes 
an important means of terminating the pharmacological and toxicological 
action of a wide number of xenobiotics, including some organophosphate 
pesticides. Like the cytochromes P450, FMO are located in the endoplasmic 
reticulum of mammalian cells. It is believed that FMO evolved to detoxify 
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nucleophilic heteroatom-containing chemicals, or their metabolites, 
present in plants that would otherwise inactivate or be metabolised by the 
cytochromes P450, or covalently modify critical tissue macromolecules. 
The FMO catalyse the N-oxygenation of tertiary amines, and also the 
oxygenation of organosulphur-, selenium-, phosphorus- and other 
heteroatom-containing chemicals that are likewise more efficiently 
excreted after oxygenation. In contrast to the cytochromes P450, FMO 
generally converts heteroatom-containing compounds to products with 
decreased potential for toxic or carcinogenic properties. Cytochromes P450 
can oxidise nucleophilic heteroatoms to heteroatom oxides that, in some 
cases, are the same as the products from FMO, but the P450s do, so 
considerably less efficiently than FMO. 
The mechanism of action of FMO involves reaction of the FAD prosthetic 
group, firstly with NADPH and then molecular oxygen. These initial 
reactions occur in the absence of substrate and the energy for catalysis is 
therefore present before any contact with the xenobiotic. Organophosphate 
pesticides known to be substrates for the FMO include phorate (0,0, - 
diethyl-S-(ethylthiomethyl) phosphodithioate) and disulfoton (0,0, - 
diethyl-S-(ethylmercaptoethyl) phosphodithioate) (Tynes and Hodgson, 
1985). 
There are five distinct FMO gene families encoding five forms of 
mammalian FMO, but the most functionally prominant form of the 
enzyme in adult human liver, FMO3, does not appear to be expressed to a 
great extent in adult rat liver. Little is known about the factors that control 
FMO regulation, but hormone and dietary factors appear to largely 
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regulate its expression. This is, however, species and tissue specific and 
probably occurs independently of other factors. 
3.4 The esterases 
Depending on their interaction with organophosphates, the esterases are 
loosely divided into three classes: The first hydrolyse organophosphates 
and consequently play an important detoxification role while a second 
group are inhibited by them; another small group do not react with 
organophosphates compounds and are of no interest in connection with 
these pesticides. Interindividual variations in some of the esterases 
involved in organophosphate toxicity, notably the detoxification enzymes, 
could be expected to influence susceptibility to toxic effects. 
A simple, clear classification of esterases is extremely difficult to set out 
since many have overlapping substrate specificity and will hydrolyse more 
than one substrate, albeit to varying degrees. Esters, amides, hydrazides 
and carbamates can be hydrolysed by various esterase enzymes present in 
body tissues and fluids. The hydrolysis of esters is as follows: 
RCOOR1 + H2O ------> RCOOH + R1OH 
RCOORI is the hydrolysable ester substrate, RCOOH and R1OH are the acid 
and alcohol products. 
The classification of the esterases by the International Enzyme 
Commission (EC) is based on the substrate type for which these enzymes 
show the greatest affinity. Many substrates have been used in an attempt 
to further classify esterases which has resulted in a very confusing picture. 
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This has particularly been the case with carboxylesterases which possess a 
high degree of multiplicity with a large number of isoenzymes coded for 
by separate gene loci (Hendrich and von Diemling, 1987). Carboxylesterase 
isoenzymes have many common substrates and this has added to 
confusion over their classification. 
Heymann (1989) reasoned that carboxylesterases must be present to 
hydrolyse endogenous compounds and attempted to simplify the 
literature by identifying such substrates. He proposed that these substrates 
alone should form the basis of a new classification system, hence 
eliminating the situation where the same isoenzyme had different names 
from different laboratories. 
An additional classification introduced by Aldridge in 1953 was used 
mainly in toxicological literature and paralleled the EC system. It is based 
on the observation that paraoxon (0,0 diethyl p-nitrophenyl phosphate), 
an irreversible inhibitor of serine-containing esterases, may, in fact, act as a 
substrate for others. Thus, paraoxon is a substrate for A-esterases, an 
inhibitor of B-esterases and without influence on C-esterases. C-esterases 
are not included in this chapter since they are not affected by 
organophosphate compounds. 
The A-esterase "paraoxonase", and B-esterases cholinesterase, 
acetylcholinesterase and carboxylesterase, will be discussed in this chapter. 
3.4.1 A-esterases 
A-esterases are a group of enzymes with the ability to detoxify 
organophosphorus anti-cholinesterase nerve gases and insecticides, and 
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carbamate insecticides by hydrolysis, without themselves being inhibited. 
The mechanism by which the A-esterases hydrolyse organophosphates is 
unclear. However, the complex formed between organophosphate and 
enzyme appears to be unstable and this is shown in a high turnover rate 
leading to rapid regeneration of free enzyme (Mackness 1989). 
The most common substrate for studying A-esterase activity is paraoxon, 
which has led to the common name "paraoxonase" being used in the 
literature. The highest levels of activity for this enzyme have been found 
in the liver microsomes and plasma of man and small rodents 
(McCracken et al 1990). Paraoxonase has the ability to detoxify paraoxon by 
hydrolysis to p-nitrophenol and diethylphosphate with an apparent Km of 
0.4mM (Gil et al 1993). 
Paraoxonase requires calcium for maximum catalytic activity and stability, 
although the mechanism for the interaction with calcium is unknown at 
this time (Vitarius and Sultatos, 1995b). Unlike the cholinesterases, 
paraoxonase is not inhibited by physostigmine or organophosphate 
compounds, and indeed, some of the latter are substrates for the enzyme. 
It is, however, inhibited by chelating agents such as EDTA and by the 
organomercurial sulfhydryl reagent, p-hydroxymercuribenzoate. Recent 
studies (Sorenson et al 1995) have shown that paraoxonase does not have 
a cysteine residue at its catalytic centre as commonly thought for many 
years. Sorenson suggests that inhibition of the activity of paraoxonase by p- 
hydroxymercuribenzoate may be due to steric hindrance resulting from 
the introduction of a large substituent near a region of the molecule 
critical for substrate binding, rather than the presence of a free sulfhydryl 
group at the enzymes' active centre. 
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Studies carried out by Little et al (1989), have shown that the A-esterases 
responsible for hydrolysis of organophosphates with P-F and P-CN bonds 
(including DFP, mipafox, soman and sarin) are poor substrates for 
paraoxonase. These organophosphates are hydrolysed by the esterase 
currently classified as organophosphorus acid anhydrase (EC 3.1.8.1, OPA) 
which requires Mn++ or Co++ for maximum activity. Organophosphorus 
acid anhydrase activity is localised almost exclusively in the soluble 
fraction of the liver and is distinct from paraoxonase, which is only 
present in the microsomes (Broomfield et al 1989). 
Like many other esterases, no known endogenous substrates have been 
identified. However, the human serum enzyme is closely associated with 
the high density lipoprotein (HDL) complex (Kelso et al 1994) and there is 
growing evidence that it may protect against low density lipoprotein (LDL) 
oxidation and so prevent atheroma formation (Watson et al 1995) through 
hydrolysis of leukotriene-like compounds. Further links between HDL 
and paraoxonase activity have been based on observations of patients with 
medical conditions such as fish-eye disease and Tangier disease which are 
associated with disturbances in lipid levels (Mackness et al 1987; Dumon et 
a! 1986). 
Human plasma paraoxonase activity has been found to vary considerably 
between individuals (Eckerson et al 1983; Mutch et al 1992). The observed 
individual variability in the ability to detoxify the active oxons of 
phosphorothioate pesticides by hydrolysis may be of considerable 
importance in protection against the inhibition of B-esterases, such as 
acetylcholinesterase and neuropathy target esterase (NTE), at target tissues. 
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Recent studies (La Du, 1996) have shown that human serum paraoxonase 
(PON1) is polymorphic occuring as two forms that differ only by the 
amino acid at position 192, which is glutamine in type Q (formerly known 
as type A) and arginine in type R (formerly type B). Furlong and co- 
workers (Furlong et al 1989) determined that 48% of Caucasians are 
homozygous for the Q allozyme, 43% are QR heterozygotes and the 
remainder classified as RR homozygotes. The PON1 R variant was eight 
times more active towards paraoxon than the Q allozyme, although the 
two forms were shown to be similar in their ability to hydrolyse the 
aromatic acid ester phenylacetate and chlorpyrifos-oxon. The two human 
allozymes are presumed to be products of the PON1 gene which has now 
been assigned to chromosome 7 through its linkage with the cystic fibrosis 
gene (Eiberg et al 1985). The human paraoxonase/arylesterase (PON1) 
enzyme has now been reclassified as aryldialkylphosphatase (EC 3.1.1.2). 
A study by Davies et al (1996) investigated the ability of PON1 to hydrolyse 
diazoxon and the nerve gases sarin and soman, in addition to paraoxon. It 
was shown that diazoxon, sarin and soman were hydrolysed far less 
efficiently by type R than type Q sera, which is the opposite to that noted 
for paraoxon. The authors suggested that these results help to explain the 
large individual differences in sensitivity to organophosphate pesticides 
processed through the P450/PON1 pathway or hydrolysed directly by 
PON1. However, saturating substrate concentrations were used in order to 
determine the rates of hydrolysis of each organophosphate and no attempt 
was made to assess the situation at concentrations relevant to those 
experienced in the workplace or environment. 
Several species of bird and fish have been shown to have low paraoxonase 
activity (Brealey et al 1980). The low serum paraoxonase activity for birds 
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and fish compared to mammals is believed to greatly influence the 
observed selective toxicity of organophosphate insecticides towards avian 
and fish species. Recent studies (Primo-Parmo et al 1996) with turkey and 
chicken sera have shown that these species have a PON-like gene with 
approximately 70% identity to human PON1. The authors suggest that the 
product of this gene, "PONT', if expressed in these species, would be 
unable to hydrolyse paraoxon. Conversely, a wide variety of mammalian 
species have high paraoxonase activity. For example, paraoxonase activity 
was 7-fold greater in rabbit serum than rat, with the dose of paraoxon 
required to produce similar degrees of cholinesterase inhibition and 
similar signs of toxicity differing by 4-fold for the two animals (Costa et al 
1990). 
In summary, fish and birds are extremely susceptible to organophosphate 
toxicity, whereas certain mammals, eg rabbits, that have relatively high 
paraoxonase activity show greater resistance to poisoning by these agents. 
This observation appears to hold true particularly when the exposure is 
low and chronic, rather than a high acute dose. 
3.4.2 Cholinesterase 
Cholinesterase (EC 3.1.1.8), formerly pseudocholinesterase, is found in 
almost all major systems of the mammalian body, although there is 
considerable variation in the level of activity between species (Silver, 
1974). Despite its widespread presence, no biological function has been 
established to date, although involvement in lipid and lipoprotein 
metabolism has been suggested (Chu et al, 1978). Cholinesterase is, 
however, known to hydrolyse a range of drugs including 
suxamethonium, aspirin, diacetylmorphine, substance P, cocaine, procaine 
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and other local anaesthetics as well as steroid esters (Lockridge et al, 1980; 
Lockridge, 1982; Lockridge, 1990; Stewart et a1,1977). 
In the past, gross deficiency of cholinesterase activity sometimes caused 
fatalities by much prolonging the effects of succinyicholine, a usually very 
short-acting muscle relaxant used in anaesthesia (Lockridge, 1990). One 
report (Prody et al, 1989) has suggested that individuals with a 
cholinesterase deficiency may be more susceptible to poisoning by certain 
organophosphate insecticides, but this is largely unsubstantiated. 
The specificity of cholinesterase is due to the arrangement of its active 
centre which consists of an anionic site and a serine esteratic site. Charged 
N- and methyl groups of choline esters bind to the anionic sites and 
hydrolysis of the substrate occurs as a two stage process. Firstly, the acyl 
group binds to the serine residues of the esteratic site and choline is 
released. Next the transiently acetylated enzyme reacts with water to yield 
acetic acid and regenerate the enzyme (Williams, 1985). 
In man, cholinesterase is synthesized in the liver and occurs in the blood 
plasma in four main molecular forms, designated as C1, C2, C3 and C4 
according to their electrophoretic mobility on gels (Masson, 1989). Serum 
cholinesterase is controlled by at least four allelomorphic genes at the 
same locus which are autosomal and co-dominant. The alleles have been 
designated ChEu, ChEa, ChEf, ChEs (Whittaker, 1986). The homozygous 
genotype ChEu ChEu (u = usual) is found in 95% of Caucasians, whereas 
4% will be ChEu ChEa (a = atypical), and 0.5% ChEu ChEs (s = silent) 
(Whittaker, 1986). Heterozygous atypical individuals exhibit an average 
cholinesterase activity corresponding to about 75% of the average activity 
of homozygous "usual" individuals. The average cholinesterase activity 
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in plasma from individuals with the genotypes ChEu ChEf (fluoride) and 
ChEu ChEs corresponds to about 85% and 50% respectively of homozygous 
"usual" individuals. The silent phenotype (genotype ChEs ChEs) occurs in 
about 1: 100 000 Caucasians and the plasma of these individuals contains 
no detectable cholinesterase activity (Brock and Brock, 1990). 
There is a single copy of the gene BUChE for butyrylcholinesterase. It is 
located on chromosome 3 in region 3q21-25. The first genetic variant of 
cholinesterase was identified in 1956, designated "atypical cholinesterase", 
and characterised as a high Km variant (Kalow and Genest, 1957). Other 
variants were discovered later and the molecular basis of all except some 
extremely rare variants has been elucidated in recent years (La Du et al, 
1992). The "atypical" variant represents the amino acid alteration 70 Asp--- 
>Gly. The existence of an 'f' variant has been recognised for several 
decades, but DNA data has now shown that there are actually two 'f' 
variants (243 Thr--->Met and 390 Gly--->Val). There are a series of "silent" 
variants, a special case being the K variant (Bartles et al, 1992) (with amino 
acid change 539 Ala--->Thr) which reduces enzyme activity by about one- 
third without affecting affinities. This mutation occurs in linkage 
disequilibrium with the "atypical" variant, i. e. the 70 Asp--->Gly mutation 
tends to be accompanied by the 539 Ala--->Thr mutation. About 1% of 
Caucasians are homozygous for the K variant which makes this the most 
frequently encountered BUChE mutation. 
The atypical forms of the enzyme can be distinguished from "normal" 
species by their increased resistance to inhibition by dibucaine (Kalow and 
Genest, 1957) and fluoride (Harris and Whittaker, 1961) using 
benzoylcholine as substrate. Normal serum cholinesterase is inhibited 
about 80% by this compound while atypical homozygotes show only about 
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20% inhibition. Heterozygotes exhibit an intermediate value of about 60% 
inhibition, that is they have a dibucaine number (DN) of 60. 
Determination of the DN therefore distinguishes between normal 
homozygotes, atypical heterzygotes and atypical homozygotes, which is 
not possible by assay of cholinesterase activity alone because of the overlap 
of activity ranges. 
Depression of serum cholinesterase activity has been reported in persons 
with liver disease, anaemia, malignant neoplasia, pulmonary tuberculosis, 
acute infections and chronic debilitating diseases, and malnutrition. A 
nutrition survey of elderly people in Great Britain (DHSS, 1979) found that 
serum cholinesterase activity correlated significantly with arm 
circumference, skin fold thickness, protein intake and serum albumin 
concentration. This has been corroborated by Lepage et al (1985). The 
serum cholinesterase activity of a population of frail hospitalised elderly 
subjects was shown (Summerbell et al, 1993) to be significantly lower than 
their fit elderly counterparts, although the lower activities of the frail 
elderly failed to respond to dietary supplementation for a period of eight 
weeks. These factors are closely related to protein synthesis and, as such, 
serum cholinesterase appears to reflect them. 
It has been shown over the years that serum cholinesterase activity is 
greater in men than women (Lepage et al, 1985; Moses et al, 1986) and this 
has been explained on the basis of hormonal differences. Apart from 
possible hormonal effects per se, the fluctuating hydration status of 
females through their menstrual cycle could be expected to influence the 
concentration of plasma proteins. Studies carried out by Mueller et al, 
(1983) and Krisch (1968) have suggested that females have higher 
paraoxonase activity in comparison to males. 
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A number of plasma esterases have been shown to be affected by age. 
Lehman et al, (1957) observed plasma cholinesterase activity to be slightly 
lower in the newborn than in the adult human. After about two months 
the activity reached adult levels and then continued to increase so that 
values during childhood were considerably higher than for adults. No 
significant change in paraoxonase activity was found in individuals aged 
between three months and seventyeight years (Mueller et al, 1983), 
although activity was reduced in infants less than one year old (Ecobichon 
and Stevens, 1973). 
3.4.3 Acetylcholinesterase 
Acetylcholinesterase (EC 3.1.1.7) is found in neurons, at neuromuscular 
junctions and in some other tissues, such as the red blood cell. It is present 
on the post-synaptic membrane and on the plasma membrane of the 
entire cholinergic neuron where its physiological function is to hydrolyse 
acetylcholine which is released as the, result of cholinergic stimulation, so 
permitting the nerve fibre to accommodate the next impulse. This esterase 
therefore plays an essential role in the physiology of the nervous system 
and is present in great excess at cholinergic synapses. Inhibition of 
acetylcholinesterase will result in the accumulation of acetylcholine in 
nervous tissue and effector organs and lead to the development of signs 
and symptoms that mimic the muscarinic, nicotinic and central nervous 
system actions of acetylcholine. 
Hydrolysis of acetylcholine, the endogenous substrate for 
acetylcholinesterase, is thought to be facilitated by its attachment to two 
sites recognised in the acetylcholinesterase active centre: the anionic site 
and the esteratic site. Although the bond formed is highly specific, 
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acetylation of the enzyme is rapidly followed by breakage of the ester 
linkage and the elimination of choline. The acetylated enzyme then reacts 
with water in order to regenerate and release acetic acid. It has been 
estimated that hydrolysis of acetylcholine by acetylcholinesterase is 
complete in a few microseconds (Wilson, 1951). The reaction is shown in 
figure 3.2. 
Organophosphorus compounds are potent acetylcholinesterase inhibitors 
and act by phosphorylating the enzymes' active site; the enzyme is also 
very sensitive to carbamates including physostigmine, being completely 
inhibited at concentrations as low as 10-6M. Alkaloids such as prostigmine, 
cocaine and nicotine are also powerful inhibitors, as are many quarternary 
ammonium compounds, thiol agents and redox dyes. 
Acetylcholinesterase exists as a number of molecular forms, the relative 
proportions of which vary from tissue to tissue. The various forms appear 
to be equivalent in catalytic activity but differ in their sensitivity to anti- 
cholinesterases, including organophosphates and carbamates (Ogane et al, 
1992). However, although Volpe and co-workers (1990) found differential 
inhibition of the various molecular forms in brain by both DFP (0,0 
diisopropylfluorophosphate) and paraoxon in vivo, they found no 
significant difference in vitro. These results were interpreted as differences 
in the in vivo access of the inhibitor to the different molecular forms of 
acetylcholinesterase. 
Sedimentation analysis of rodent diaphragm has shown that the globular 
monomeric G1 (4s) and tetrameric G4 (10s) forms predominate. The 
globular 4s and 10s forms are most abundant in diaphragm, although only 
26% of the total number is believed to be specifically associated with the 
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Hydrolysis of acetylcholine by acetylcholinesterase resulting in reactivated enzyme. 
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end-plate region (Younkin et al, 1982). End-plate specific forms, are 
predominantly asymmetric A8 (12s) and A12 (16s) structures 
(approximately 40% are non-extractable) and are associated with the basal 
lamina of neuro-muscular junctions (Dettbarn, 1984). The A8 and A12 
forms have been shown to be mainly external (cell surface) components of 
diaphragm and it is these sub-populations which are essential in the in 
vivo removal by hydrolysis of acetylcholine from synaptic clefts (Dettbarn, 
1984). 
Inhibition of red blood cell acetylcholinesterase and plasma cholinesterase 
by phosphorylation plays an important role in detoxification by removing 
circulating oxons prior to reaching target tissues. In man, the plasma 
cholinesterases may influence the available blood concentration of oxon 
by irreversible binding to the serine active centre of the enzyme. As a 
metabolic "sink" for organophosphates, plasma cholinesterase will reduce 
the concentration of agent available for interaction at the neuronal and 
neuromuscular junctions. Whilst inactivation of red blood cell 
acetylcholinesterase and plasma cholinesterase does not result in any 
significant deleterious effects to the individual, monitoring for inhibition 
of these enzymes is a useful index for organophosphate exposure, with 
certain limitations. 
3.4.4 Carboxylesterases 
The carboxylesterases (EC 3.1.1.1) are non-specific serine hydrolases with 
differing substrate and inhibitor specificities and are present in the 
membranes and cytosol of most cells. Suitable substrates for measurement 
of carboxylesterase activity in vitro include a-naphthylacetate, 
phenylacetate and phenylvalerate, although none of these are specific for 
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the enzyme. The human carboxylesterase, EsD, is distinguishable from 
other esterases by its' specificity for the hydrolysis of 4-methylumbelliferyl 
esters. This group of enzymes catalyse the hydrolysis of ester, thioester, 
and sometimes amide bonds during the course of metabolism of 
endogenous compounds, environmental contaminants and some drugs. 
The general mechanism for hydrolysis by carboxylesterases is given in 
figure 3.3. This generally results in formation of more polar, readily 
excreted products and therefore constitutes a detoxification process. A list 
of environmental contaminant esters, and drugs which are detoxified by 
carboxylesterases are given in table 3.3 and table 3.4, respectively. 
0 11 
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Figure 3.3 
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Hydrolysis of an ester, a thioester, or an amide to a carboxylic acid and an 
alcohol, a thiol or an amine, respectively. 
Carboxylesterases have been sub-classified according to their isoelectric 
focussing points (Mentlein and Heymann, 1984) and were shown to have 
differing substrate specificities with a range of ester compounds. Heymann 
and Mentlein (1988) then went on to describe four rat carboxylesterases 
according to their putative natural substrates. 
The first carboxylesterase described by Heymann and Mentlein, 
lysophospholipase, shows five pI bands, but is usually associated with pI 
band 5.6. It has been identified variously as esterase EA (Arndt et al, 1978) 
or RL2 (Hosokawa et al, 1987). Its xenobiotic substrates include phenacetin. 
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Table 3.3 
Some environmental contaminant esters that are detoxified by the 
carboxylesterases. 
Ester Class Chemical Example Carboxylesterase 
Herbicides Fluazifop-butyl 
Human liver, skin, 
plasma 
Carbamates Carbofuran Rat tissues 
Pyrethroids 
Permethrin, 
cypermethrin Rat tissues 
Acrylates 
Methyl, ethyl, butyl 
acr ylate Mouse nasal mucosa 
Glycol monoalkyl ether 
acetates Ethylene, propylene Mouse nasal mucosa 
Trichothecenes T2 toxin Rat liver 
Nitrosomides 
N-nitroso-N-methyl-N- 
nitro guanidine (MNNG) Rat liver 
Table 3.4 
Some drugs that are detoxified by human carboxylesterases. 
Drug Carboxylesterase Source 
Aspirin 
Purified from human liver, 
intestinal mucosa 
Clofibrate 
Purified from human liver, 
intestinal mucosa 
Procaine 
Purified from human liver, 
intestinal mucosa 
Cocainea Purified from human liver 
Meperidine Human liver 
Mebeverine Human plasma 
Lorazepam 3-acetate Human liver 
aHydrolysis of the methyl ester of cocaine. 
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Long-chain acyl-CoA hydrolase exists as two isoenzyme forms that 
separate at pIs 6.2 and 6.4. It has been identified (Hosokawa et al, 1987) as 
RL1 and palmitoyl-CoA hydrolase and substrates for this enzyme include 
aspirin and the phosphorothioate, malathion. Medium-chain monoacyl 
glycerol lipase is the predominant carboxylesterase in rat liver, its pI value 
is 6.0. It has been identified as RH1 (Hosokawa et al, 1987) and esterase El 
(Arndt et al, 1973), and substrates include clofibrate and malathion. The 
fourth carboxylesterase is diacylglycerol lipase. This enzyme has multiple 
forms with pI values of 5.0 and 5.2 (Robbi and Beaufay, 1983) and its main 
xenobiotic substrates are the phorbol esters. 
Carboxylesterases predominate in mammals in comparison to the other 
esterases (Hedrich and von Deimling, 1987) and are also widely distributed 
in insects (Brooks, 1979). Of the various mammalian organs, the liver and 
small intestine has the highest carboxylesterase activity, although there is 
appreciable activity in most other tissues. They are mainly membrane 
bound, but not exclusively, as demonstrated by McCracken et al (1993), 
who found cytosolic activity for some carboxylesterase substrates. The 
membrane bound esterases are found lumenally orientated in the 
endoplasmic reticulum (Mentlein et al, 1988; Robbi et al, 1990). Human 
plasma, however, has negligible carboxylesterase activity (Mackness, 1989). 
Rodents have much higher endogenous levels of carboxylesterases than 
man, and this difference could partly account for the lower sensitivity of 
rats to xenobiotics that are more toxic as the ester than as the hydrolysis 
product (Chambers et al, 1991). 
The carboxylesterases of non-target tissues play a very important role in 
the detoxification of some phosphorothioates by covalently binding their 
oxons to the serine active centre of the enzyme (figure 3.4). In contrast 
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with the interaction of oxons with A-esterases, dephosphorylation of the 
B-esterase active centre is very slow and consequently the enzyme is 
inhibited by the oxon "suicide" substrate. In rodent plasma especially, 
carboxylesterases function as scavengers which remove circulating oxons 
before they reach target organs (Gaustad et al, 1991). Rodent plasma 
carboxylesterases will therefore play a very important role in detoxification 
following organophosphate administration by the sub-cutaneous route, 
since detoxification will take place concurrently with absorption. 
For phosphorothioate pesticides such as malathion the distal carboxylic 
acid ester is the primary target for hydrolysis by the carboxylesterases, 
which results in detoxification products containing the corresponding 
carboxylic acid (figure 3.5). Hydrolytic detoxification by carboxylesterases 
has been shown to occur primarily in the liver and plasma of mammals, 
although recent studies have shown that human skin carboxylesterases 
may also function to detoxify simple phosphorothioates such as 
malathion (Heymann et al, 1993). Once activation of malathion to the 
oxon has occured, hydrolysis of the carboxylic acid ester does not occur and 
detoxification is then by way of binding to the carboxylesterase serine 
active centre resulting in its' inhibition. Carboxylesterase inhibition has 
been shown (Chambers and Chambers, 19901 to occur more quickly than 
inhibition of acetylcholinesterase and therefore serves to protect this 
physiologically important enzyme at target tissues. Further support for a 
protective role for carboxylesterases was obtained in a study by Chambers 
et al (1991) who demonstrated that pretreatment of rats with 
carboxylesterase inhibitors such as bis-p-nitrophenyl-phosphate (BNPP) 
potentiated the toxic effects of phosphorothioates. 
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Hepatic carboxylesterases from rodents have for many years provided a 
convenient source of a model enzyme, although more recently researchers 
have been prompted to use the human enzyme directly. A human 
carboxylesterase (human esterase D, EsD) has been purified from 
erythrocytes providing a supply of the enzyme so that its' specific role in 
detoxification may be more fully examined (Okada and Wakabayashi, 
1988). Like many of the other human esterases, the physiological function 
of EsD is not well understood. However, it has been suggested that an 
endogenous role for the enzyme may involve the reuse of sialic acids 
since they have been shown to be its' natural substrate (Varki et al, 1986). 
Human EsD has a molecular weight of 34kDa as determined by SDS-PAGE 
(sodium dodecyl sulphate-polyacrylamide gel electrophoresis) and its' Km 
for the substrate 4-methylumbelliferyl was determined to be 10µM (Lee et 
al, 1986). Purification of EsD has allowed the preparation of polyclonal and 
monoclonal antibodies from rabbit and mouse, respectively, that have 
been useful for immunoquantification studies. More recently (Long et al, 
1991), the human EsD gene (from human erythrocytes and human liver) 
has been cloned and sequenced, and comparison of EsD to the genes for 
human cholinesterase and cholesterol esterase suggest an evolution from 
a common ancestral gene (Shibata et al, 1993). The human liver 
carboxylesterase has been shown to have significant sequence homology to 
various mammalian carboxylesterases. 
Quantification of EsD in various tissues has been accomplished by using 
the specific substrate 4-methylumbelliferyl acetate (Lee et al, 1986). The 
results from this study showed that most EsD activity was present in the 
liver but, perhaps of greater toxicological importance, significant activity 
was also found in the lung, blood monocytes, skin and nasal mucosa. This 
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is in agreement with a study conducted by Clark et al (1993) who detected 
carboxylesterase activity in human skin using fluazifop butyl as substrate. 
Human carboxylesterases therefore appear to be present in all tissues 
which present themselves as portals of entry for xenobiotics and 
consequently esterase-mediated detoxification in these tisssues may 
influence the toxicity of potentially toxic esters. 
3.4.5 Neuropathy target esterase 
Neuropathy target esterase (NTE) is a membrane bound carboxylesterase 
present in brain and neural tissue, although it can also be detected in most 
other organs, including adrenal, kidney, liver and spleen (Moretto and 
Lotti, 1988). The physiological function of this esterase is unknown, but its 
catalytic activity does not appear to be necessary for the health of nerve 
axons. NTE has been proposed as the target site at which certain 
neuropathic organophosphates, such as DFP and mipafox, act to initiate 
organophosphate-induced delayed neuropathy (OPIDN) (Johnson, 1969; 
1982). 
Parathion is not believed to cause OPIDN and therefore neuropathy target 
esterase will be discussed no further. 
3.5 Phase 2 enzymes 
3.5.1 Glutathione-S-transferases 
Glutathione is a tripeptide (cysteine-glycine-glutamate) found in all 
eukaryotic cells. It has many roles: as a reducing agent and antioxidant, a 
cysteine reservoir, involvement in the synthesis of some prostaglandins, 
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and in the conjugation of many xenobiotics. This review will be concerned 
only with the involvement of glutathione in the conjugation of 
xenobiotics. 
Glutathione-S-transferases (EC 2.5.1.18) catalyse the nucleophilic addition 
of the tripeptide glutathione to substrates that have electrophilic 
functional groups. They exist as a family of, isoenzymes in the 
endoplasmic reticulum and cytosol of liver and extrahepatic tissues, each 
with a unique substrate specificity. The primary function of these enzymes 
is considered to be the detoxification of both endogenous and xenobiotic 
alkylating agents such as epoxides, a-, ß-unsaturated aldehydes and 
ketones, and alkyl and aryl halides (Armstrong, 1991). The general reaction 
equation is given below. 
RX + GSH ------------> GSR + XH 
where RX may potentially be any xenobiotic or phase 1 reaction product. 
3.5.2 UDP glucuronosyltransferases and sulphotransferases 
The most common conjugation pathway for xenobiotics is 
glucuronidation (Jakoby and Habig, 1980). The enzyme family calalysing 
glucuronidation is the membrane-bound uridine diphospho- 
glucuronosyltransferase (EC 2.4.1.17). Conjugation takes place when UDP- 
a-D-glucuronic acid (UDPGA) and the xenobiotic are at the same enzyme 
site, but the exact mechanism is not yet understood. Hydroxyl groups are 
the most commonly conjugated groups, although carboxyl, amino and 
sulphydryl groups may also be conjugated. The general reaction is given 
below. 
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ROH + UDP-GA -----------> R-GA + UDP 
where ROH may potentially be any xenobiotic or phase 1 reaction product. 
There exists two UGT families: UGT 1 enzymes are dioxin inducible, 
whereas the UGT 2 family are not. Marker substrates for UGT 1 enzymes 
have included p-nitrophenol, and bilirubin and testosterone for UGT 2 
enzymes (Burchell et al, 1994). 
Sulphate conjugation occurs in the cytosol, the enzymes catalysing this 
reaction are the sulphotransferases (EC 2.8.1,2,4,9 or 14). The sulphate 
conjugating group is donated by 3'-phosphoadenosine 5' phosphosulphate 
(PAPS) which is generated from ATP and inorganic sulphate. Thirteen 
forms of rat sulphotransferase have been identified, compared to only five 
in man (Weinshilboum, 1997). The human forms have been divided into 
phenolsulphotransferases (P-PST1, P-PST2, M-PST) and hydroxysteroid 
sulphotransferases (EST and HST). The general reaction is given below. 
ROH + PAPS ---------> RS + PAP 
where ROH may potentially be any xenobiotic or phase 1 reaction product. 
There is significant variation in sulphotransferase activity between 
individuals and there is some evidence that expression is under genetic 
control. P-PST is the most studied form, with approximately 40 fold 
variations in activity, and activity has been shown to vary due to several 
allelic variants in man (Coughtrie, 1996). It has been suggested that low or 
high sulphotransferase expression may indicate a risk factor with reduced 
detoxification and increased bioactivation of a xenobiotc. 
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3.6 The proposed metabolism of parathion 
Phosphorothioate pesticides such as parathion are believed to undergo 
metabolic activation and detoxification as a result of P450-dependent 
oxidative desulphuration as proposed in figure 3.6 (Nakatsugawa and 
Dahm, 1967; Kamataki et al, 1976). Until very recently, the cytochrome(s) 
P450 involved in the reaction had not been investigated. 
Studies with 32P and 35S labelled parathion and phenobarbital induced 
rabbit liver microsomes suggested that P450 donates an atom of singlet 
oxygen to the sulphur moiety of the phosphorothioate to form an unstable 
phosphooxythiran. This intermediate structure is then believed to 
spontaneously rearrange to form paraoxon, p-nitrophenol and their 
associated dialkylphosphates. Because of its unstable nature, the 
phosphooxythiran has never been positively identified. 
Production of oxygen analogues (oxons) such as paraoxon represents the 
metabolic activation of phosphorothioates, since the parent compounds 
have little or no capacity to inhibit acetylcholinesterase. For example, 
activation of parathion to paraoxon has been shown to increase its 
anticholinesterase potential by three orders of magnitude (Forsyth and 
Chambers, 1989). Since P450-dependent oxidative desulphuration of 
parathion plays a critical role in controlling the extent of 
acetylcholinesterase inhibition following exposure, factors that alter the 
metabolism of such insecticides can potentially alter their acute toxicity. 
Rat liver carboxylesterases have been shown to be capable of removing 
about 11 nmoles paraoxon per gram of tissue by covalent binding which 
represents a significant means of acetylcholinesterase protection 
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(Chambers et al, 1994). In contrast, detoxification of paraoxon by the 
hydrolytic A-esterases is catalytic which, in a practical sense, is a non- 
saturable process in vivo, and should therefore not be limited in capacity. 
The extent of the capacity of the liver to detoxify paraoxon was 
demonstrated by Sultatos (1986) who showed that relatively little 
parathion or paraoxon perfused into mouse liver in situ, was capable of 
escaping. 
Although the glutathione-S-transferases are known to be effective for 
parathion detoxification in vitro, several researchers have shown that 
they are not important at biologically relevant concentrations, in vivo 
(Sultatos, 1992; Chambers et al, 1994). Glucuronic acid and sulphate have 
been shown to aid in the elimination of some primary degradation 
products, such as those produced following ester hydrolysis or oxidation by 
the cytochromes P450. For example, p-nitrophenol, the detoxification 
metabolite of parathion metabolism, may follow conjugation with 
sulphate or glucuronic acid prior to excretion in some instances (Sultatos 
and Minor, 1985). 
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Chapter 4 
Chapter 4 Pharmacogenetic polymorphisms 
4.1. Introduction 
The early definitions of genetic polymorphism (Ford 1940; Cavalli-Sforza 
and Bodmer 1971; Vogel and Motulski 1986) were designed to distinguish 
between common and rare phenotypes, "A polymorphism is a Mendelian 
or monogenic trait that exists in the populaton in at least two phenotypes 
(and at least two genotypes), neither of which is rare - that is, neither of 
which occurs with a frequency of less than 1-2%" (Vogel and Motulski, 
1986). This definition therefore distinguished polymorphisms as common 
traits from spontaneous mutations, which occur at a much lower 
frequency. However, it did not specify if the rare phenotype was of 
heterozygous or homozygous genotype for the variant allele. 
Analysis of genomic DNA by restriction fragment analysis on Southern 
blots or sequencing frequently reveals "DNA polymorphisms", which may 
be unrelated to a "clinical phenotype" since many of the DNA variations 
are silent polymorphisms, i. e. they have no consequence at the protein 
level (Antonarakis 1989). Many of the genetic polymorphisms so defined 
at the DNA level (genotype) will be of no clinical consequence at the level 
of protein amount or function, i. e. they will not cause the appearance of 
different "pharmacological or toxicological" phenotypes in the population. 
The majority of xenobiotic-metabolising enzymes show considerable 
interindividual variation in expression even when they exhibit a 
unimodal distribution of activity. However, polymorphisms have also 
been detected for some of these enzymes at both the genotypic and 
phenotypic level. The major polymorphisms that have received clinical 
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attention are those relating to the cytochromes P450: CYP2D6 
(debrisoquine hydroxylase), CYP2C19 (S-mephenytoin 4' hydroxylase), 
CYP1A1 (aryl hydrocarbon hydroxylase), CYP1A2 (arylamine oxidations), 
CYP2E1 (N, N- dimethylnitrosamine N-demethylase). Polymorphisms 
have also been shown for flavin monooxygenase (trimethylamine N- 
oxidation), acetylation by N-acetyltransferase (NAT2), S-methylation by 
thiopurine methyl transferase, conjugation reactions by glutathione S- 
transferase g and 0, and ester hydrolysis by plasma cholinesterase and 
plasma paraoxonase. Examples of these polymorphisms are given in 
figure 4.1. 
It has been suggested (Daly et al 1993) that polymorphisms of the 
xenobiotic-metabolising enzymes have occured because these enzymes 
lack a normal metabolic role and are only of importance when the 
individual is challenged either by environmental xenobiotics or by drug 
administration. The author bases this hypothesis on the discovery that 
wide interindividual variations have not been detected in enzymes with 
essential physiological roles. 
The pharmacokinetic and pharmacodynamic consequences of the activity 
of a polymorphic enzyme depend upon whether it mediates metabolism 
of parent drug or primary metabolite (or both), and whether parent drug 
or primary metabolite (or both) are active. Furthermore the consequences 
will reflect the enzyme's overall contribution to clearance from the 
affected pathway, the potency of the active species, and the influence of 
competing pathways of elimination. 
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The clinical significance of the interindividual variability in the activity of 
an enzyme relates to possible acute drug toxicity and drug-drug 
interactions, such as seen with the immunosuppressive drug cyclosporine 
A which is metabolised by CYP3A. The daily dose necessary to achieve a 
target blood level for this drug has been demonstrated to vary at least 
tenfold among different patients, necessitating monitoring of plasma 
levels during treatment (Watkins et al 1990). It has also been reported that 
some transplant patients who had received inhibitors of CYP3A, such as 
ketoconazole, had pronounced increases in their cyclosporine A blood 
level, resulting in potentially serious central nervous system and kidney 
toxicity. In addition, chronic effects have been demonstrated. Over one's 
lifetime, differences in the metabolism of drugs, occupational chemicals 
and pesticides, and other environmental pollutants can lead to 
interindividual differences in the buildup of DNA damage (e. g. 
mutations, chromosomal breaks) and nongenotoxic signals (e. g. signal 
transduction pathways without DNA damage) leading to toxicity, and 
tumor initiation and progression. 
The extent and implications of interindividual variations in the 
cytochromes P450 2D6,2C19,2C8/9,1A2,1A1,2A6,2E1,3A4/5 and the 
FMOs will be discussed in this chapter since they are of potential 
importance in the activation of parathion. 
4.2 Xenobiotic-mediated polymorphisms 
By far the best studied polymorphism is that of debrisoquine 
hydroxylation by CYP2D6. Debrisoquine and Sparteine are commonly used 
to probe the activity of CYP2D6 in vivo and in vitro. For both drugs two 
phenotypes can be discerned, extensive and poor metabolisers (EM and 
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PM, respectively) with 5-10% of Caucasian PMs not expressing this enzyme 
(Idle, 1991). Previous pharmacological studies of the debrisoquine 
polymorphism have used metabolic phenotyping for the identification of 
poor metabolisers. These studies required administration of the drug 
followed by quantitation of the urinary metabolites produced. In contrast, 
genotyping methods require a small blood sample which can be taken at 
any time. A clear relationship has been demonstrated between genotype 
and phenotype for debrisoquine hydroxylase in ninety-three Caucasian 
volunteers and is shown in figure 4.2 (Cholerton et al 1992). The potential 
clinical significance of the CYP2D6 polymorphism relates mainly to drugs 
acting on the cardiovascular and central nervous systems e. g. flecainide, 
mexiletine, propranolol, thioridazine, amitriptyline. Some of the drugs 
metabolised by CYP2D6 have a narrow therapeutic index (e. g. mexiletine) 
and there is therefore considerable potential for an adverse clinical 
outcome in certain cases. There is some evidence that the poor 
metaboliser phenotype is associated with more adverse effects, particularly 
sedation from neuroleptics, and many of these drugs are potent inhibitors 
of CYP2D6. 
The 4'-hydroxylation of S-mephenytoin by the cytochrome P450 CYP2C 
subfamily exhibits a genetic polymorphism in humans, with individuals 
being characterised as either extensive or poor metabolisers (Inaba 1989). 
The PM phenotype has a higher frequency in Oriental populations (18- 
23%) compared with Caucasians (3-5%) (Bertilsson et al 1992). After many 
years of effort CYP2C19 was finally identified as the principal S- 
mephenytoin hydroxylase in humans (Goldstein et al 1994) and the 
molecular basis of the polymorphism has now been clarified (de Morais et 
al 1994). Metabolism of a number of therapeutically important drugs has 
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Figure 4.2 
The relationship between debrisoquine metabolic ratio and genotype. 
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been shown to co-segregate with mephenytoin metabolism eg 
hexobarbital, omeprazole, propranalol, imipramine and proguanil. 
Another member of the CYP2C subfamily, CYP2C9, has been implicated in 
a rare polymorphism for the metabolism of tolbutamide (Page et al 1991) 
and possibly also of phenytoin (Goldstein and de Morais 1994), although 
no information is available at the DNA sequence level for these P450 
isoforms. 
A trimodal distribution for the metabolism of caffeine by CYP1A2 has been 
demonstrated for a population of non-smokers with 12-13% of subjects 
classified as slow metabolisers (Butler et al 1992). The molecular basis for 
this polymorphism has not yet been unambiguously demonstrated but it 
is possible that low CYP1A2 activity will be associated with altered 
susceptibility to disease since a wide range of procarcinogens are known to 
be substrates for the enzyme (Eaton et al 1995). CYP1A1 is found primarily 
in extrahepatic tissues and known to metabolise a range of procarcinogens 
and promutagens, and is inducible by various polycyclic aromatic 
hydrocarbons which act by binding to the Ah receptor. In a study of 207 
lung cancer patients and 283 Caucasian controls, and using the restriction 
enzyme Mspl, a polymorphism was detected in CYP1A1 (Xu et al 1996). 
The frequencies of the the MspI homozygote and heterozygote variant 
genotypes were found to be 1% and 17%, respectively, for both lung cancer 
patients and controls. This study demonstrated that the MspI variant 
CYP1A1 genotype is significantly associated with an increased risk of lung 
cancer after controlling for confounding factors and, moreover, an 
elevated risk was noted in heterozygotes. 
CYP2A6 carries out the 7-hydroxylation of coumarin and an inactive 
variant (CYP2A6v) appears to be associated with a reduced recovery of 
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metabolites (Daly et a! 1994). A recent study by Hu et al (1997) of almost 200 
individuals described several rare mutant alleles of CYP2E1, one of which 
caused reduced protein expression and a 60% reduction in catalytic activity 
towards the probe substrate, chlorzoxazone. This polymorphism is of 
major toxicological interest since CYP2E1 is known to metabolise several 
procarcinogens, drugs and solvents to reactive metabolites. 
A polymorphism in flavin monooxygenase activity was demonstrated in 
169 white British subjects using the dietary component triethylamine 
(Cholerton and Smith, 1991). One of these subjects (0.6%) was shown to 
excrete significantly increased concentrations of free triethylamine in their 
urine and, since this amine has a strong fish-like odour, said to suffer 
from "fish-odour syndrome". Over 5000 people in Great Britain are 
believed to have this syndrome (Waring and Emery, 1995). The N- 
oxidation of triethylamine, to the non-odorous metabolite triethylamine 
N-oxide, is mediated by flavin monooxygenase and the variant allele 
appears to give rise to a form of flavin monooxygenase with reduced 
activity with respect to this pathway (Higgins et al 1972). Flavin 
monooxygenase-mediated metabolism of a wide group of agricultural 
chemicals, such as aldicarb, methiochlor and diethyldithiocarbamate, has 
also been observed (Hodgson and Levi, 1992). Although oxidative 
desulphuration of phosphorothioates is not directly catalysed by the flavin 
monooxygenases, the thiono group of fonofos (S-phenyl ethyl 
ethylphosphonodithioate), and other phosphorothioates containing a 
phosphorus-carbon bond, appears to be metabolised by these enzymes 
leading to production of the active oxon (Smyser and Hodgson, 1985). The 
extent of interindividual variability in flavin monooxygenase-mediated 
capacity to activate phosphorothioate pesticides, has not been determined. 
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4.2.1 The cytochrome P450 3A subfamily 
Cytochrome P450 3A is the most abundant subfamily in human liver and 
accounts for about 30% of the total P450 pool as determined 
immunochemically (Shimada et al 1994). CYP3A3, originally purified by 
Watkins et al (1985) and termed 'HLp', and CYP3A4, purified by 
Guengerich et al (1986) and termed P450NF, were originally presented as 
distinct isoforms. CYP3A3 was then shown to be 98% homologous with 
CYP3A4 (Nelson et al 1993) but no significant differences in catalytic 
properties were identified (Aoyama et al 1990). CYP3A3 has been recently 
discontinued and it is therefore assumed that CYP3A3 and CYP3A4 are the 
same isoform, i. e. CYP3A4 (Nelson et al, 1996). Another CYP3A enzyme, 
CYP3A5, appears to be detectable in approximately 20% of adult human 
livers (Wrighton et al 1989) and has been found to be 90% homologous 
with CYP3A4 (Aoyama, 1989). 
Several reports have suggested that CYP3A4 and CYP3A5 have a similar, 
but not identical, substrate specificity. It therefore seems reasonable to 
suggest that those livers expressing the polymorphic CYP3A5 along with 
CYP3A4 would influence the wide range in activities observed for those 
xenobiotics, eg nifedipine (Aoyama et al 1989) and midazolam (Gorski et al 
1994), which are metabolised by both isoforms. 
CYP3A isoforms are also abundant in the intestinal mucosa and have a 
six-fold variation in catalytic activity (midazolam hydroxylation, Lown et 
al 1994). There was an excellent correlation (p=0.0001) between intestinal 
CYP3A4 protein level and catalytic activity for the patients studied (n=20), 
although neither parameter significantly correlated with hepatic CYP3A4 
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activity. CYP3A5 protein was also found in the small intestine of 70% of 
these patients. 
A recent study (Haehner et al 1996) of a panel of human kidney 
microsomes (n=27) showed a bimodal distribution for midazolam 
hydroxylase (CYP3A) activity which was also suggested by the distribution 
of CYP3A4 and CYP3A5 proteins. All kidneys expressed CYP3A5 protein 
but, in contrast to hepatic tissue, CYP3A4 was detected in only 28% of the 
samples. The authors hypothesised that the bimodal distribution of 
CYP3A5 may represent induction of this isoform in a select population 
and/ or a genetically determined organ-specific pattern of expression. 
A fourth identified member of the human CYP3A subfamily is termed 
CYP3A7. CYP3A7 protein was first isolated from human foetal liver where 
it is the major P450 present (Kitada et al 1988), although the mRNA for 
this isoform has more recently been detected in approximately 50% of 
adult human livers (Schuetz et al 1994). It is, however, uncertain whether 
CYP3A7 protein is expressed in adult liver. In addition, it has been 
reported that CYP3A7, but not CYP3A4 or CYP3A5, protein is expressed in 
the human endometrium and placenta (Schuetz et al 1993). The substrate 
specificity for CYP3A7, unlike CYP3A4 and CYP3A5, remains poorly 
characterised but it is possible that this isoform plays an important role in 
the metabolism of specific steroid precursors and/or xenobiotics in order 
to protect the foetus from toxic insult. 
The list of drugs metabolised chiefly by CYP3A is expanding rapidly and 
includes several drug categories, including immunosuppressants, calcium 
channel blockers, cancer therapeutic agents, antihistaminics, sedatives, 
and synthetic estrogens. Indeed, it has been estimated that up to one-third 
62 
of the orally administered pharmaceuticals currently in use, and up to 
one-third of the new chemical entities currently under development, are 
capable of being metabolised by CYP3A (Inaba et al 1995). Table 4.1 gives a 
list of drugs known to be metabolised by CYP3A. 
Wide interindividual variations are seen in the metabolism of all CYP3A 
substrates and this may account, at least in part, for differences amongst 
patients in response to these, and other, medications metabolised by the 
CYP3A subfamily. In addition to the variation in expression in CYP3A4 
and the polymorphic expression of CYP3A5, it appears that some drug 
interactions result from concurrent administration of other drugs, or 
dietary components (eg the natural flavonoids naringenin and quercetin) 
which are also metabolised by CYP3A. Furthermore CYP3A4, but not 3A5 
(Wrighton et al 1989), is highly inducible by many medications in 
common use, such as dexamethasone, phenobarbital and rifampicin, and 
this will further influence the level of variability observed in the CYP3A- 
mediated metabolism of xenobiotics. 
A study by Hoyo-Vadillo et al (1989) of the in vivo metabolism of 
nifedipine demonstrated bimodal distributions for the recovery of 
metabolites and provided some evidence for a polymorphism in CYP3A at 
the phenotypic level. Other in vivo studies with nifedipine (Renwick et al 
1988; Schellens et al 1988) have failed to confirm this bimodality, although 
again a considerable variability in recovery of urinary M-II metabolite was 
observed. The isolation and sequencing of cDNA clones for CYP3A4 have 
now been carried out and the gene, CYP3A4, has been localised to human 
chromosome 7q (Gonzalez et al 1988). Chromosome 7q also contains the 
defective cystic fibrosis (CTFR) gene, although it appears to be only weakly 
linked to CYP3A4 (Brooks et al 1988). A study by Daly et al (1992) showed 
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Table 4.1 
Use or occurence of chemicals metabolised by human hepatic cytochrome 
P450 3A4. 
XENOBIOTIC USE/OCCURRENCE 
Acetaminophen Analgesic 
Aflatoxin Bi Food he atocarcino en 
Alfentanil Opioid anaesthetic 
Amiodarone Antiarrhythmic 
Androstenedione Steroid 
Benzo a pyrene Combustion product 
Caffeine Dietary 
Cocaine Narcotic 
Cortisol Hormone 
C clophos hamide Anticancer 
C clos orine Immunosuppressant 
Dextromethorphan Antitussive 
17a-Eth n lestradiol Oral contraceptive 
Estradiol Steroid hormone 
Ifosfamide Anticancer 
Imipramine Antidepressant 
Lidocaine Anaesthetic; antiarrhythmic 
Lovastatin Cholesterol-lowering 
Nifedipine Calcium channel blocker 
Progesterone Steroid 
Terfenadine Antihistamine 
Testosterone Steroid 
Zonisamide Anticonvulsant 
Reference 
List compiled by AP Li et al (1995). Toxicology 104: 1-8. 
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that a group of cystic fibrosis patients and their first-degree relatives 
exhibited significantly slower metabolism of nifedipine compared with a 
control group and that there was no evidence for bimodality in the 
controls. 
Interethnic differences in capacity to metabolise nifedipine have also been 
observed. A study by Ahsan et al (1991) compared the pharmacokinetics of 
a single dose of nifedipine (20mg) in five South Asian volunteers with 
data for twentyseven Caucasian volunteeers. A threefold higher area 
under the plasma drug concentration-time curve (AUC) was shown in 
this study for the Southern Asians when compared with Caucasians, 
although this difference was not verified for triazolam, another CYP3A 
substrate (Kinirons et al 1996). In the Asian study it was noted that 
consumption of a spicy curry diet for three days by the Caucasians did not 
significantly affect the pharmacokinetics of a single dose of nifedipine. 
These data suggest that the large inter-ethnic differences in nifedipine 
clearance are not generalisable to all CYP3A substrates but the treatment of 
patients of South Asian origin with nifedipine should be initiated with 
lower doses than would be given to Caucasians. 
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Chapter 5 
Chapter 5 Factors influencing phosphorothioate toxicity 
5.1. Introduction 
The availability of phosphorothioates for metabolism will be influenced 
by the physicochemical properties of the chemical such as its lipophilicity, 
stereoisometric form, and protein and tissue binding affinity. Several 
physiological and environmental factors will also influence metabolism. 
Physiological factors include polymorphisms of the xenobiotic 
metabolising enzymes (discussed in chapter 4), interethnic variations, 
gender, age and hormonal status. Altered enzyme activity may also occur 
as a result of external factors such as exposure to inducers/ inhibitors of 
the drug metabolising enzymes. The route of absorption will also be an 
important consideration since this will influence the rate of delivery of 
the compound. In addition, first pass extrahepatic metabolism may be of 
significance in some cases. 
All of these factors will be discussed in the following chapter. It should be 
noted that the influence of these modifying factors on phosphorothioate 
metabolism has been poorly investigated. The majority of existing data is 
derived from studies of drugs. 
The above modifiers contribute to variations in the kinetic parameters of 
enzymes involved in the metabolism (activation and detoxification) and 
thence toxicity of phosphorothioates. The kinetic parameters and 
metabolic pathways of the enzymes involved in phosphorothioate toxicity 
were discussed in chapters 2 and 3, respectively. 
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5.2 Physicochemical properties 
There is no evidence of prolonged storage of phosphorothioates in the 
body, since they are very quickly degraded by the metabolic reactions 
previously described. In this context, an in vitro study by Sultatos et al 
(1985) showed that incubation of various concentrations of paraoxon with 
heparinised mouse blood resulted in its detoxification to p-nitrophenol by 
apparent first-order kinetics with an average elimination half-life for 
paraoxon of 8.6 minutes. The rapid elimination half-life for paraoxon was 
corroborated by experiments in which mouse livers were perfused in situ 
with the parent phosphorothioate, parathion, in a perfusate containing 4% 
bovine serum albumin (Sultatos and Minor, 1986). In these studies the 
half-life associated with the approach to steady state of parathion was 6.2 ± 
0.4 minutes, under which conditions the fraction of unbound 
phosphorothioate was 4%. 
Phosphorothioates are less lipophilic than organochlorine pesticides as 
denoted by their relatively lower log octanol/ water coefficients. For 
example, chlorpyrifos and parathion have coefficients of 4.7 and 3.0, 
respectively (The Agrochemicals Handbook, 1991), while the 
organochlorine pesticide DDT (1,1,1-trichloro-2,2-bis[4-chlorophenyl] 
ethane) has a value of 6.2 (Moody, 1993). Organochlorine pesticides are 
known to accumulate in adipose tissue and the environment and are 
poorly metabolised. However, although phosphorothioates are 
extensively metabolised once in the general circulation, limited storage in 
fat of the more lipophilic compounds (eg chlorpyrifos) may somewhat 
delay excretion in some cases. The elimination half-life for chlorpyrifos 
(dermal application, human) and diazinon (i. p., rat) has been shown 
(Fenske and Elkner, 1990; Wu et al, 1996) to be about 27h and 4.5h, 
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respectively, with no unchanged phosphorothioate or oxon detected in the 
urine. 
5.3 Physiological factors 
There exists a considerable body of information regarding the cytochromes 
P450 in rats, although the human forms have been less extensively 
studied. It should be noted that the impact of the modifying factors to be 
discussed in this chapter are different for animals and humans. It is 
therefore important to know how these factors influence metabolism of 
the compound of interest in order to allow more effective extrapolation 
from animal and human data obtained in vitro, and thence to the human 
population. In addition, identification of species differences for a particular 
xenobiotic will help ascertain a suitable animal model for man. 
Numerous studies (Waxman, 1988; Lee and Werlin, 1995) have shown 
that the activities of some of the cytochrome P450 isoforms in animals are 
subject to the influence of modifiers such as strain, species, gender, age and 
diurnal rhythm. Of these strain, species and gender appear to be the most 
effective. For humans, genetic predisposition is probably most important 
(discussed in chapter 4), although the influence of inducing/ inhibiting 
xenobiotics and nutritional status (for esterases) will considerably 
contribute to interindividual variations and may mask a genetic 
polymorphism. Age and gender seem to be of minor impact for man. 
5.3.1 Interethnic differences 
Interethnic differences in drug response have been recognised for many 
years, and the international pharmaceutical industry, as well as many 
68 
regulatory agencies, pay increasing attention to these differences in 
pharmacologic and toxic response characteristics (Hahn, 1992). Particular 
reference to ethnic differences in the cytochromes P450 and esterases 
involved in the metabolism of phosphorothioates will be made in this 
chapter since the use of these pesticides is far greater in developing 
countries with a concurrent increase in potential for exposure compared to 
the UK. 
The cytochromes P450 2D6,2C9 and 3A4 have provided most information 
of interethnic differences in enzyme activity. The incidence of PMs of 
debrisoquine, a CYP2D6 substrate, was found to be very low (1.01%) in four 
different Chinese nationalities compared to Caucasians (Bertilsson et al, 
1992). A similarly low incidence of PM has been demonstrated in studies 
of Japanese (Nakamura et al, 1985) and Korean (Sohn et al, 1991) 
populations. Bertilsson and associates (1992) also demonstrated that the 
distribution of the urinary debrisoquine/ 4-hydroxydebrisoquine metabolic 
ratio (MR) was shifted to the right for his population of Chinese EMs 
compared to Swedish EMs. These results suggest that the mean rate of 
debrisoquine hydroxylation is lower in Chinese EMs compared with 
Caucasian EMs. This corroborates the results of a study by Rudorfer et al 
(1984) who gave a single dose of desipramine, a CYP2D6 substrate, to 
sixteen Caucasian and fourteen Chinese healthy subjects. The mean total 
plasma clearance of the antidepressant was found to be higher in 
Caucasians than in Chinese. These data, and those of others (eg Lin et al, 
1991), indicate that Chinese metabolise antidepressants more slowly than 
do Caucasians, which is consistent with the right shift of the debrisoqine 
MR in Chinese discussed above. 
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Several studies (Alvan et al, 1990; Wilkinson et al, 1992) have shown that 
the incidence of PMs of S-mephenytoin in Caucasians is about 3%. In 
contrast, the incidence of PMs of S-mephenytoin in Japanese (Horai et al, 
1989), Chinese (Horai et al, 1989), Koreans (Sohn et al, 1992) and Black 
subjects (Pollock et al, 1991) is much higher: 23%, 17.4%, 12.6% and 18.5%, 
respectively. 
Interethnic differences in the disposition of substrates of CYP3A have been 
studied in populations of limited size. A study by Ahsan et al (1991) 
compared the pharmacokinetics of a single dose of nifedipine (20mg) in 
five South Asian volunteers with data for twentyseven Caucasian 
volunteeers. A threefold higher area under the plasma drug 
concentration-time curve (AUC) was shown in this study for the Southern 
Asians when compared with Caucasians, although this difference was not 
verified for triazolam, another CYP3A substrate (Kinirons et al, 1996). { 
Similar results using nitrendipine were shown in Japanese compared with 
Caucasians (Fujimura et al, 1989). In the Asian study it was noted that 
consumption of a spicy curry diet for three days by the Caucasians did not 
significantly affect the pharmacokinetics of a single dose of nifedipine. 
These data suggest that the large interethnic differences in nifedipine and 
nitrendipine clearance are not generalizable to all CYP3A substrates, 
however the treatment of patients of South Asian origin with 
dihydropyridine calcium blockers should be initiated with lower doses 
than would be given to Caucasians. These studies taken together indicate 
that Asians have lower CYP3A activity and/or level than Caucasians. 
Whether this possible interethnic difference is genetic or environmental 
in origin is unknown. CYP3A is inducible and can also be inhibited by low 
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levels of certain dietary components, and therefore differences in, for 
example, diet could contribute to interethnic variations. 
The worldwide distribution of serum paraoxonase activity has been 
investigated (Geldmacher-von-Mallinckrodt and Diepgen, 1988), although 
it should be emphasised that these data were based on measurements of 
only paraoxon hydrolysis, and only saturating substrate concentrations 
were used. These data suggest that paraoxonase activity divides European 
populations into about half with slow and half with rapid activity, but 
everywhere else the slow variant appears to be the more rare. However, a 
study by Williams et al (1993) showed that serum paraoxonase levels of 
male Caucasians were higher than male Ghanaians. Similarly, Williams 
et al (1986) found arylesterase (phenylacetate esterase) activity to be lower 
in Ghanaians compared to a group of Caucasian subjects. 
The silent phenotype for cholinesterase, which gives rise to extremely low 
levels of activity, occurs in about 1: 100 000 Caucasians but a relatively 
higher incidence of this enzyme was found in Alaska and some regions of 
India (Whittaker, 1986). Studies of aspirin esterase and cholinesterase in 
Nigerians at home and in the UK showed increased albumin levels when 
in the UK which were associated with increased esterase levels (Isah et al, 
1988). This indicates that diet, rather than interethnic differences, 
influence plasma albumin levels and thence aspirin esterase and 
cholinesterase activity. 
Although very difficult to substantiate, it is possible that the interethnic 
differences which exist in esterase activity are mainly due to 
environmental factors such as nutrition (Kalow, 1982), especially since 
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paraoxonase and cholinesterase have been shown to be closely linked with 
high and low density lipoprotein, respectively. 
5.3.2 Other physiological modifying factors 
In general terms, children and young animals are more susceptible than 
adults to poisons in food. The most common reason is simply because the 
young eat more in proportion to their weight. Thus, when given the same 
contaminated food, young animals receive a higher dose of the 
contaminant. 
However, other factors are involved. It is well known that the 
cytochromes P450 are present at comparatively low levels in neonatal 
animals, but activity develops to approximate the adult level early in 
maturation (Fouts and Deveroux, 1972). An extensive study by Cazeneuve 
et al corroborated the evidence of others (Kitada et al, 1988) that CYP3A 
activity is present in foetal liver, but that neither CYP1A1 or CYP1A2 is 
present at this time. In the Cazeneuve study foetal liver was shown to 
have the capacity to C-8 hydroxylate caffeine, mainly a CYP1A2 substrate in 
adult liver microsomes. This suggested that the metabolism of this drug 
depends on CYP3A at the foetal stage of development. 
It is recognised (Waxman, 1988) that the cytochrome P450 families CYP2 
and CYP3 are sex-specific, rat P450s 2A2 and 3A2 are male expressed 
enzymes and 2A1 is a female expressed form. This has been shown to 
have an important influence on the clearance of drugs metabolised by 
these P450 families, but the effects are complex and not easily summarised. 
A recent study by Mahnke et al (1997) demonstrated that rat CYP3A genes 
are variably expressed depending on age and sex. Analysis of mRNA 
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derived from four CYP3A genes, CYP3A2, CYP3A9, CYP3A18 and 
CYP3A23, showed that CYP3A2 and CYP3A9 gene expression was age- and 
sex- dependent, whereas CYP3A18 and CYP3A23 mRNA were observed 
before and after puberty at fairly constant levels. CYP3A18 and and 
CYP3A23 mRNA levels were about 20% higher in males than females, 
whereas CYP3A9 mRNA was detected only in adult rats, with a nearly 
twofold higher expression in females. 
Many pharmacokinetic investigations of the elderly reveal decreased 
clearance of lipophilic drugs metabolised by the cytochromes P450. For 
example, the clearance of quinidine, midazolam, triazolam, erythromycin 
and lidocaine, which are metabolised mainly by CYP3A, have been shown 
to decline with age. However, studies in vitro (Hunt et al, 1992a) and in 
vivo (Hunt et al, 1992b) have established that the activity of CYP3A is 
stable throughout normal ageing (27-83 years) although it is about 24% 
higher in females than males. These studies suggested that age-related 
changes in clearance of CYP3A substrates is secondary to changes in liver 
blood flow, liver size, drug binding and distribution with ageing. 
Hooper and Qing (1990) investigated the effects of both age and gender on 
the stereoselective elimination of racemic mephobarbital in adult 
humans. The apparent total body clearance of R-mephobarbital, a CYP2C19 
substrate, was found to be much greater, and the elimination half-life 
much shorter, in young men (18-25 years) compared to young women (18- 
25 years), elderly women (>60 years) and elderly men (>60 years). The 
apparent total body clearance of the S-enantiomer, did not differ between 
subject groups. 
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A study by Fujita et al (1990) explored in some detail the hypothesis that 
the livers of old male rats are functionally feminised. Their data enabled 
them to propose that senescence-associated feminisation of the drug 
metabolising capacity of male rat liver may be partly attributable to the 
decrease in testosterone levels in old age and partly attributable to the loss 
of neonatal imprinting. 
Female rats appear to be more sensitive to the toxic effects of 
phosphorothioates compared to males, for example the oral LD50 for 
parathion is 3.6mg/kg and 13mg/kg for females and males, respectively 
(Gaines, 1960). A study by Chambers et al (1994) set out to elucidate the 
influence of metabolism on this phenomenon. Their data allowed the 
authors to suggest that differences between the sexes in capacity to activate 
and detoxify parathion may have contributed to subtle differences in 
development of toxicity in their animal model. However, as emphasised 
earlier, it is recognised that sex differences are more important in the rat 
than man. 
Age related factors also appear to influence the development of neurotoxic 
effects following exposure to certain phosphorothioates. Chicks do not 
develop OPIDN when treated with doses of phosphorothioate known to 
be effective in the adult hen (Johnson and Barnes, 1970). However, the 
resistance of chicks is not absolute since a marginal neuropathic response 
was obtained either with repeated doses (Johnson and Barnes, 1970) or by 
substantially increasing the single dose. The clinical features of OPIDN 
were different in chicks from those seen in adult hens because young 
animals displayed a spastic gait and not the classical flaccid paralysis. These 
effects may be interpreted as differential sensitivity of the spinal cord 
compared to that of the peripheral nerves, or more reasonably, relate to 
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the faster growth pattern of peripheral nerves in the young. Furthermore, 
chicks were seen to recover more quickly from OPIDN. Typically, chickens 
recovered three weeks post development of OPIDN, whilst adult animals 
took in excess of seven weeks (Lotti, unpublished results). Children are 
also relatively resistant to OPIDN (Goldstein et al, 1988) and when affected 
they rapidly recover. Age-related resistance to OPIDN may therefore be 
most easily explained by the faster growth of peripheral nerves in young 
animals and/ or with the more efficient repair capabilities of the 
developing nervous system. 
5.4 Environmental factors 
As discussed above, the levels and activities of the cytochromes P450 vary 
from one individual to the next due to physiological, including genetic, 
factors. Cytochrome P450 enzyme activity can also be influenced by 
environmental factors, such as exposure to a xenobiotic that inhibits or 
inactivates it. This will, in fact, mimic the effects of a genetic deficiency in 
P450 enzyme expression and may be a cause of serious adverse clinical 
consequence. Exposure to xenobiotics in vivo may also increase the 
activity and/ or level of the cytochromes P450. As an underlying cause of 
serious adverse drug reactions, P450 induction is generally less important 
than P450 inhibition, because the latter can cause a rapid and profound 
increase in blood levels of a drug which may then cause symptoms of drug 
overdose. However, drug interactions have been noted following 
induction of the cytochromes P450 since one xenobiotic can stimulate the 
metabolism of a second and thereby decrease its effect. Inhibition and 
induction/ activation of the cytochromes P450 will be discussed in the 
following chapter. 
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Inhibition may be the result of competition of two substrates for the same 
enzyme but it can also be mechanism-based, involving what are termed 
"suicide" substrates as they require conversion by the enzyme to a reactive 
species. Non-competitive inhibition occurs when a xenobiotic binds to the 
enzyme in such a way as to alter the activity of the enzyme towards its 
substrate. The requirement for catalysis adds an extra degree of potential 
selectivity compared with reversible inhibitors, which rely solely on 
binding (Rando, 1984). A further advantage of mechanism-based 
inactivators in vivo is that the enzyme inhibition persists after the free 
compound has been cleared, in contrast to a reversible inhibitor, which 
must be present continuously. Table 5.1 gives examples of substrates and 
inhibitors of the major human liver microsomal P450 isoforms involved 
in xenobiotic transformation. 
The ability of the macrolide antibiotic erythromycin to influence the 
pharmacokinetics of other drugs was exemplified by a report (Olkkola et al, 
1993) of the "undesirably severe and excessively long-lasting hypnotic 
effects" seen when young adults were treated with erythromycin prior to 
oral administration of the usually short-acting hypnotic agent, 
midazolam. Both erythromycin (Watkins et al, 1985) and midazolam 
(Kronbach et al, 1989) are metabolised by CYP3A and would therefore 
compete for the active site of the enzyme. Similarly, toxic responses have 
been seen with the immunosuppressant cyclosporine A and the 
antihistamine terfenadine following pre-treatment with ketoconazole, an 
antimycotic agent (Watkins, 1994). All three drugs are metabolised by 
CYP3A. 
Compounds containing olefinic functionalities (eg the CYP3A inhibitor, 
gestodene) destroy the haem prosthetic group of cytochrome P450 
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Table 5.1 Examples of substrates and inhibitors of the major human liver 
microsomal P450 isoforms involved in xenobiotic transformation. 
CYP Substrates Inhibitors 
involved 
CYP1A2 Acetaminophen Furafyllinea 
Caffeine a-Naphthoflavone Estradiol 
Ethoxyresorufin 
Phenacetin 
Theo h lline 
CYP2A6 Butadiene Diethyldithiocarbamatea 
Coumarin 8- Methoxypsoralena 
Nicotine 
CYP2B6 Cyclophosphamide Metyrapone 
Ifosphamide Orphenadrinea 
CYP2C8 Carbamazepine Quercetin 
CYP2C9 Diclofenac Sulphaphenazole 
Phenytoin 
Tolbutamide 
Warfarin 
CYP2C18/ 19 Hexobarbital Tranylcypromine 
Lansoprazole 
S-Mephenytoin 
Omeprazole 
Proguanil 
Propranolol 
CYP2D6 Debrisoquine Ajmalicine 
Flecainide Quinidine 
Imipramine Yohimbine 
Mexilitine 
Paroxetine 
S parteine 
CYP2E1 Alcohols Diethyldithiocarbamatea 
Aniline Dimethyl sulphoxide 
Benzene Disulfiram 
Chlorzoxazone 4-Methylpyrazole 
p-Nitrophenol 
Styrene 
CYP3A4/ 5 Gestodenea 
see table 4.1 Ketoconazole 
Naringenin 
Troleandomycina 
Quercetin 
a Mechanism-based inhibitor 
From A. Parkinson (1996). Toxicologic Pathology 24: 45-57. 
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following oxidative activation of the xenobiotic (Murray and Reidy, 1990), 
whereas piperonyl butoxide, an insecticide synergist, forms a stable 
inhibitory complex with the haem of P450, thereby inhibiting the enzyme. 
Some of the currently available anti-HIV drugs, which are marketed to 
inhibit the HIV protease enzyme, have been shown to be substrates for 
CYP3A and therefore can competitively interact with other xenobiotics 
metabolised by this isoform (Lipsky, 1996). 
Studies with both microsomes (Morelli and Nakatsugawa, 1978) and 
purified enzymes (Halpert et al, 1980) and phosphorothioates such as 
parathion that contain a P=S moiety have demonstrated that, during 
oxidative desulphuration, the released sulphur exists as a highly reactive 
molecule which then binds to P450, inactivating the enzyme. This binding 
of reactive sulphur is accompanied by loss of P450 as detected by 
measurement of the dithionite-reduced CO complex as well as loss of 
enzyme activity (Neal, 1985). A more recent study (Butler and Murray, 
1993) of rat hepatic microsomal fractions has shown that the NADPH- 
mediated conversion of parathion to paraoxon occurs with concomitant 
inhibition and inactivation of the major constitutive P450s, 3A2 and 2C11. 
Exposure of humans to phosphorothioate pesticides such as parathion 
therefore raises the concern that the metabolic capacity of the individual 
may be compromised and that untoward effects from subsequent drug 
therapy to alleviate the anticholinergic effects of intoxication may be 
experienced. In this context there has been a report that the tranquilliser 
promazine, given as supportive therapy following parathion intoxication, 
produced hypotension, convulsions, apnea and then death (Arterberry et 
al, 1962). Because these are symptoms of promazine overdosage, and not of 
parathion toxicity, it seems that phosphorothioate exposure can, in some 
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instances, produce a significant decrease in the metabolic capacity of 
certain human cytochromes P450. 
Dietary components may also influence the cytochromes P450. For 
example, the consumption of a single glass of grapefruit juice can cause up 
to a fivefold increase in the area under the curve of nifedipine or 
felodipine, CYP3A substrates (Bailey et al, 1991). This was believed to be 
due to the bioflavonoid aglycone naringenin (4,5,7-trihydroxyflavanone), 
the so-called "bitter principle" of this beverage. However, recent studies 
(Edwards and Bernier, 1996) have suggested that other compounds, 
present in both grapefruit and Seville orange juice, may add to this 
inhibitory effect. Quercetin, a bioflavonoid aglycone present in high 
concentrations in some fruits and vegetables, but not grapefruit juice, also 
appears to be a potent CYP3A inhibitor in vitro (Kuhnau, 1976). 
Cigarette smoke condensate has also been shown to contain strong 
inhibitors, as well as substrates, of CYP1A (Shimada and Guengerich, 
1991). Foodstuffs such as watercress and green tea also contain P450 
inhibitors (Chung et al, 1992). 
Induction is the process whereby enzyme activity increases through the 
action of a xenobiotic, thereby increasing the amount of enzyme present in 
the cell. This action was first described during early studies of the 
metabolism of carcinogens and barbituates. Studies included those of 
Conney et al (1956) who demonstrated that as little as 0.1mg of 3- 
methylcholanthrene could triple the demethylase activity of mature male 
rats, and this action could be repeated using other polycyclic aromatic 
hydrocarbons (PAHs). Independently, Remmer (1958) showed that the 
metabolism of various xenobiotics was increased on barbiturate 
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administration, and that phenobarbital was the classical model compound. 
It is now known that five classes of inducers exist for the cytochrome P450 
isoforms and these are given in table 5.2. 
Enhanced P450 enzyme activity can result from: 
(i) Gene duplication leading to overexpression of a P450 enzyme, eg 
demonstrated in individuals classified as "ultrarapid hydroxylators". The 
molecular basis for two individuals who were ultrarapid hydroxylators of 
the CYP2D6 substrates nortriptyline and clomipramine was shown to be 
an XbaI 42kb fragment which contained two different functionally active 
CYP2D6 genes in the CYP2D locus causing extra enzyme to be expressed 
(Bertilsson et al, 19931. 
(ii) Exposure to environmental factors, such as xenobiotics, that induce the 
synthesis of cytochrome P450. This is the most common mechanism by 
which activity is increased. 
(iii) Activation of a preexisting enzyme by a xenobiotic. Although 
activation of the cytochromes P450 has been documented in vitro, it 
appears to occur in vivo only under special circumstances. 
In general terms, increased xenobiotic metabolism can be the result of 
several effects including increased de novo synthesis of drug metabolising 
enzymes, increased stability of mRNA coding for the enzyme and reduced 
degradation of the enzyme. PAHs induce CYP1A1 by transcription 
activation via the Ah receptor, and CYP1A2 via stabilising already 
transcribed mRNA, enabling more protein to be translated from it. 
Phenobarbital induction of CYP2B and CYP3A1/2 is by transcriptional 
activation, similar to CYP1A1 induction by PAH but no Ah receptor 
equivalent has yet been identified. CYP3A1/2 induction by 
troleandomycin and CYP2E1 induction by acetone is through stabilisation 
(reduced degradation) of the specific cytochrome P450 protein (Koop and 
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Table 5.2 
Examples and characteristics of five classes of inducers of rat liver 
microsomal cytochromes P450. 
Representative inducers Major inducible P450 Characteristic enzymatic 
enzyme(s) reaction 
3-Methylcholanthrene CYP1A1 and CYP1A2 
7-Ethoxyresorufin 0- 
dealkylation 
ß-Naphthoflavone 
Benzo[a]pyrene 3- 
TCDD hydroxylation 
Planar PCBs Caffeine N-3-demethylation 
Phenobarbital CYP2B1 and CYP2B2 
Testosterone 16ß- 
Antioxidants hydroxylation 
Antihistamines 
7-Pentoxyresorufin 0- 
dealkylation 
Nonplanar PCBs 7-Benzyloxyresorufin 0- 
dealkTation 
PCN* CYP3A1 and CYP3A2 
Testosterone 2ß-, 60; 15ß- 
Dexamethasone hydroxylation 
Erythromycin N- 
Troleandomycin demethylation 
Nifedipine N- oxidation 
Isoniazid CYP2E1 
Chlorzoxazone 6- 
Pyrazole 
hydroxylation 
p-Nitrophenol hydroxylation 
Ethanol 
Acetone 
Lauric acid 12-hydroxylation 
Clofibric acid and other CYP4A1-3 
peroxisome proliferators 
* PCN is pregnenolone-16a-carbonitrile 
Compiled from A. Parkinson (1996). Toxic Patho124: 45-57 
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Tierney, 1990). Glucocorticoid (eg dexamethasone) and clofibrate induction 
of P450s 3A and 4A, respectively, is via a receptor mediated transcription 
stimulation pathway and stabilisation of the newly synthesised protein, 
similar to that of the Ah induction pathway (Waxman and Azaroff 1992). 
The induction of CYP3A by macrolide antibiotics, such as troleandomycin 
and erythromycin, primarily involves their transformation to metabolites 
that bind tightly to the haem moiety of P450, thereby inhibiting the 
enzyme. The induction of CYP3A by macrolide antibiotics, as described 
above, is often masked by their capacity to function as mechanism-based 
inhibitors. Similarly, the enzyme-inducing effects of imidazole antifungal 
agents, such as ketoconazole, are often masked by their ability to bind and 
inhibit CYP3A (as well as other cytochromes P450). This phenomenon was 
demonstrated by Thompson et al (1988) who found inhibition of hepatic 
microsomal ethoxyresorufin O-deethylation (CYP1A) and aldrin 
epoxidation (CYP3A and CYP2B) activity 2hr after oral dosing of rats with 
ketoconazole (50mg/ kg and 100mg/ kg) which was followed by induction 
iday and 7days later. 
As discussed earlier, CYP3A is highly inducible by treatment with many 
medications in common use (e. g. dexamethasone, phenobarbital, 
rifampicin), and this appears to explain why patients administered with 
these drugs require increased dosing of cyclosporine A (a CYP3A substrate) 
(Pichard et al, 1990). 
In general, highly chlorinated compounds are resistant to 
biotransformation and cause prolonged induction of the cytochromes P450 
and other enzymes. For example, CYP3A also appears to be inducible, at 
least in rodents, by many environmental contaminants, including 
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polyhalogenated biphenyls (PCBs and PBBs) (Dannan et al, 1983). In the 
human population, workers occupationally exposed to the organochlorine 
pesticides lindane or DDT exhibited shortened plasma half lives of 
antipyrine and phenylbutazone (Conney et al, 1971; Kolmodin-Hedman, 
1973). In the study conducted by Conney et al, the DDT workers were 
shown to have an elevated 6ß-hydroxy cortisol excretion, a marker of 
enzyme induction. 
Induction of other enzyme systems has also been demonstrated. 
McCracken et al (1992) investigated the effects of phenobarbital, clofibrate 
and ß-naphthoflavone (a PAH type inducer) on carboxylesterase, 
paraoxonase and arylesterase activity of rat liver, lung and skin. They 
found that ß-naphthoflavone and clofibrate did not induce 
carboxylesterase, paraoxonase or arylesterase activity, while phenobarbital 
induced carboxylesterase in the liver and skin, paraoxonase in the liver 
only, and arylesterase in the lung only. 
Phase 2 enzymes can also be enhanced by the classical inducers. Rat liver 
glutathione-S-transferases are induced by both phenobarbital and 3- 
methylcholanthrene, for example Pickett et al (1984) reported elevated a 
and µ class glutathione-S-transferases in rat liver on treatment with these 
inducers, while Primiano et al (1992) showed increased glutathione 
transferase expression in the rat using imidazoles as inducers. 
Evaluation of the effects of chemical inhibitiors and inducers on the 
cytochromes P450 may be used in vitro to help elucidate the catalytic 
specificity of the various isoforms in a particular metabolic reaction. 
Advantages of using chemical inhibitors as a tool in metabolism studies 
include the fact that they are commercially available (or can be easily 
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synthesised), may be used with intact cells and also in vivo, even with 
human subjects in many cases eg sulphaphenazole (CYP2C), furafylline 
(CYP1A2). However, chemical inhibitors of the cytochromes P450 must be 
used with caution because most of them can inhibit more than one 
isoform. 
The classical inducers described above and in table 5.2 may be used as a 
tool to indicate the specificity of the cytochromes P450 in a particular 
metabolic pathway. In order to achieve this a range of inducers may be 
administered to groups of rodents in vivo, followed by evaluation of 
changes in the levels of microsomal cytochromes P450 (and other 
enzymes) in vitro. The inhibitors and inducers used in this thesis to 
indicate the enzymes responsible for parathion metabolism is shown 
schematically in figure 5.1. 
5.5 The route of absorption 
Most phosphorothioate pesticides are not ionised and are relatively 
lipophilic, they therefore require metabolic transformation prior to 
excretion. They may be easily taken up by a variety of natural routes 
including ingestion, inhalation and dermal absorption. Most exposures 
involve more than one route, and in these cases it is the character of the 
chemical involved that determines which of the routes will be of practical 
importance. Their low vapour pressures under normal useage means that 
they do not often enter the body by inhalation and the skin is the usual 
route of exposure. 
Following ingestion, the absorbed phosphorothioate will gain access to the 
venous circulation via the liver where it will undergo first pass 
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detoxification and/ or activation, depending on the compound. The 
uptake of most phosphorothioate following administration by the oral 
route is rapid and efficient under test conditions. However, there is 
evidence of comparatively inefficient absorption in hens administered 
large doses of very insoluble phosphorothioates with a high relative 
molecular mass, for example leptophos (phosphonothioic acid, phenyl-, 0- 
(4-bromo-2,5-dichlorophenyl) O-methyl ester). Thus, divided doses may 
exert a greater toxic effect than the same amount given as a single large 
dose. 
Following inhalation of phosphorothioates in spray formulations or 
powders, particles of diameter larger than 5-10µm are efficiently trapped in 
the upper respiratory tract where they become impinged on its surface 
mucous layer and carried upward into the pharynx by ciliary action. Here 
they are swallowed. Particles of diameter between approximately 1-5µm 
are retained by the alveolar region of the lungs where they are 
subsequently absorbed. They are cleared from the lungs by way of the 
macrophages and pulmonary blood supply. Absorption from the alveoli 
tends to be rapid compared with the rate by other portals, because the 
alveolar membrane is thin and the blood supply abundant. 
Many phosphorothioates are effectively absorbed through the skin and 
this route of absorption is especially important in connection with 
modern pesticides because many of them were selected as contact poisons. 
The same chemical properties that make phosphorothioate pesticides able 
to penetrate the insect cuticle permit their dermal absorption by 
mammals. However, in practice, only a small portion of the skin may 
become contaminated and, therefore, only that part will participate in 
absorption. A compound's solubility and particle size are the main factors 
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which will influence percutaneous absorption but, in general terms, 
absorption will be greater for the more lipophilic phosphorothioates. 
It is likely that percutaneous absorption will be greater for liquid 
formulations than for powders, but that powders may adhere longer 
thereby enhancing an effect, if proper hygiene is not observed. Respiratory 
exposure was noted to be increased 4-fold when applying dusts compared 
with dilute spray, and 10-fold when using aerosols of concentrated 
pesticide. Thus, in the latter case, the respiratory route could be very 
important when the efficiency of absorption is allowed for. 
Other routes such as subcutaneous (sc), intra-peritoneal (ip) and 
intravenous (iv) injection are more frequently used in laboratory studies 
of the effects of chemicals and administration by these routes assures that 
an entire, carefully measured dose can be given without loss. The route of 
absorption will be a major factor influencing metabolism. 
Organophosphates administered by the sc, ip and iv routes will enter the 
peripheral venous circulation directly and distribute into tissues and 
organs, thus bypassing extensive first-pass hepatic metabolism. On the 
other hand, if the chemical is delivered orally, it will gain access to the 
venous circulation via the liver prior to any distribution into the systemic 
circulation. First-pass metabolism may account for the loss of a large 
proportion of the parent compound prior to its reaching the systemic 
circulation where the blood esterases will play a significant detoxification 
role. 
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5.6 Extrahepatic metabolism 
Although the liver is generally the organ with the highest drug- 
metabolising activity, the P450s are also present in other tissues, including 
the small intestine, kidney, brain and lung. In fact, because CYP3A is 
abundant in the intestinal mucosa, xenobiotic substrates for this subfamily 
may have poor oral bioavailability due to extensive metabolism at the 
level of the intestine (Watkins, 1994). Indeed, the small intestine and lung 
could present the first line of defence against absorbed toxins. Any local 
biotransformation may be important for the compounds having these 
tissues as their targets, and may also considerably influence the general 
metabolism, activity and toxicity of xenobiotics. 
Both microsomal and mitochondrial forms of cytochrome P450 have been 
found in the brain. In addition to the estimation of the total amount of 
cytochrome P450 in the brain by its carbon monoxide difference spectrum 
following partial purification, several specific isoforms have been detected 
by their catalytic activities, by immunohistochemical techniques and the 
mRNA for some isoforms have been detected by Northern Blotting 
(Warner and Gustafsson, 1993). Cytochrome P450 levels in the brain are 
very low, in untreated rats the concentration is approximately 1% - 3% of 
that found in the liver. The distribution throughout the different brain 
regions is uneven with the highest levels to be found in the cerebellum 
and the lowest in the substantia nigra. 
Cytochromes P450 are of particular importance in lung since the lung is 
the main portal of entry for various airborne contaminants. It is now clear 
that, although the level of cytochrome P450 content and enzyme activities 
are quite low in lung when compared to those in liver, the lung 
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cytochrome P450s have the capacity to metabolise a wide variety of 
xenobiotics (Arinc, 1993). The lung may play an important role in the local 
activation of phosphorothioates which have the potential to enter the 
body via aerosols generated occupationally, eg during spraying of wasps 
and other pests. Phosphorothioates contained in sheep dips may also enter 
the lung by way of the fine spray generated during the dipping process. 
The skin is the main portal of entry for phosphorothioate pesticides and 
therefore deserves to be discussed in this chapter. Cytochrome P450 levels 
in the skin, as in all extrahepatic tissues, are low with activities around 0- 
5% of that seen in the liver. Activities are typically lower in human skin 
compared to rodent (Damen and Mier, 1982). In contrast to the P450s, 
several studies have shown relatively high esterase activity in the skin 
(Cheung et al, 1985; McCracken et al, 1993). In addition, Venkatesh et al 
(1992) reported that the FMO-mediated sulphoxidation of the pesticide 
phorate in skin microsomes was about four fold higher than that seen in 
the liver. 
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Chapter 6 
Chapter 6 Experimental aims 
6.1 Experimental aims 
It has been known for over thirty years that the cytochromes P450 are 
involved in the activation of phosphorothioate pesticides to the toxic 
oxon (Neal, 1964). However, until very recently, there was a huge deficit in 
the literature regarding involvement of the individual P450 isoforms in 
the reaction. Moreover, the role of detoxification enzymes in 
phosphorothioate metabolism in man has been poorly investigated, even 
though it is recognised that a polymorphism exists in the plasma A- 
esterases which hydrolyse the toxic oxons (Geldmacher-von-Mallinckrodt 
and Diepgen, 1988). 
It is recognised that individuals vary widely in their toxic response to 
exposure to phosphorothioates, but few reasons have been put forward as 
to why this should be so. This thesis investigated the hypothesis that 
variations in toxic response may be influenced by individual differences in 
the capacity to metabolise phosphorothioates following exposure. 
The phosphorothioate parathion was chosen as the main 
phosphorothioate pesticide to study differences in xenobiotic metabolising 
potential of human liver microsomes. Parathion was chosen because: - 
a) It has a relatively simple metabolism, and requires oxidative 
biotransformation to the oxon for toxicity. 
b) It is a typical anti-cholinesterase compound which is not believed to be 
neurotoxic, and therefore is relatively safe to handle. 
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c) It has been in use for a number of years and therefore an extensive 
toxicity data base exists in the literature. 
The experimental section of the thesis was essentially in two parts: an 
animal and a human study. In the first part, male Wistar rat liver P450s 
and esterases were modulated in vivo and in vitro in order to elucidate 
the metabolic pathways involved in parathion metabolism. Next, the 
human section concentrated on studies with sixteen liver microsomal 
preparations and commercially available human P450-expressed 
microsomes. These studies indicated the P450 isoforms and esterases 
involved in parathion metabolism and assessed variation between 
individuals in their capacity to carry out the reactions. 
The experimental aims of the thesis were therefore: - 
1) To define the capacity of control microsomes to metabolise parathion to 
paraoxon and p-nitrophenol and to determine the kinetics of the reaction 
and to characterise control rat liver microsomal activities for the 
cytochromes P450, FMO and esterases which may be involved in 
parathion metabolism. 
2) To investigate the various groups of induced liver microsomes for 
capacity to metabolise parathion and to determine the efficacy of the 
induction regimen by measuring the increase in activity of the 
cytochromes P450 and esterases compared to control. 
3) To modulate control rat liver microsomes with various P450 inhibitors, 
in vitro in order to indicate the constitutive P450 isoform(s) involved in 
parathion metabolism. 
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4) To define interindividual variations in capacity of the microsomal 
panel to metabolise parathion and to determine the kinetics of the 
reaction and to characterise the panel of human liver microsomes for CYP 
1A1/2,2B6,2E1,3A4/5, A-esterase, B-esterase and glutathione-S- 
transferase activities. 
5) To correlate the P450 and esterase activities determined for the human 
liver microsomes with their capacity to produce paraoxon and p- 
nitrophenol from parathion. 
6) To modulate human liver microsomes with P450 and esterase 
inhibitors in vitro in order to indicate the constitutive P450 isoform(s) and 
esterases involved in parathion metabolism. 
7) To compare the capacity of commercially available microsomes from 
cell lines expressing human P450s 3A4,3A5,1A1,2B6,2E1,2C8 and 2C9- 
Arg144 to metabolise parathion. 
8) To define the way in which a balance between activation and 
detoxification of parathion could contribute to interindividual differences 
in circulating/ local levels of oxon and thus toxic effects. 
9) To use this data to extrapolate to other phosphorothioates. 
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SECTION II: 
METHODS 
Chapter 7 
Chapter 7 General methods 
7.1 Chemicals 
Unless otherwise specified general laboratory chemicals were obtained 
from BDH Chemicals Ltd., Dorset, UK; Sigma-Aldrich Company Ltd., 
Dorset, UK; or Fisons Scientific Equipment, Loughborough, UK. GC and 
HPLC columns were obtained from Hewlett-Packard Ltd., Cheadle Heath, 
Cheshire and Fisons Chromatography, Loughborough, UK., respectively. 
Parathion and paraoxon were obtained from British Greyhound 
Chromatography and Allied Chemicals, Birkenhead, Merseyside, UK and 
p-nitrophenol from Sigma-Aldrich Company Ltd. Pure substance M1 
(BAY b4759), the major metabolite of nifedipine oxidation, was supplied by 
A. G. Bayer, Bayer House, Newbury, U. K. 
Caution paraoxon is a potent anti-cholinesterase organophosphate. Take 
great care especially when handling concentrated solutions; refer to 
COSHH safety procedure. 
7.2 Animals 
Male Wistar rats were obtained from the Comparative Biology Centre, 
University of Newcastle upon Tyne. The rats were 8-9 weeks of age, 
weighed approximately 250g and were housed on wood shavings with a 12 
hour light cycle. The animals were fed standard rodent laboratory diet 
(RM3 expanded. Specialist Diet Services, Witham, Essex. ) and allowed free 
access to water unless otherwise stated. 
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7.3 Buffer solutions 
1) O. IM potassium phosphate (KH2P04)/ 0.1M potassium chloride 
buffer Adjust pH to pH 7.4 with sodium hydroxide prior to use. 
2) 50mM glycinel 1mM calcium (CaC12) buffer Adjust pH to pH 7.0, 
7.4,8.0,9.0,10.0 or 10.5 with sodium hydroxide prior to use. 
3) 50mM Tris/ 0.2mM EDTA buffer (pH 8.0 at 37°C) was prepared by 
adding EDTA to Trizma pre-set crystals (pH 8.0 ). 
4) 500mM Tris buffer (pH 8.5 at 37°C) was prepared from Trizma pre- 
set crystals (pH 8.5). 
5) 50mM glycine buffer Adjust pH to pH 8.5 with sodium hydroxide. 
6) 10mM potassium phosphate (KH2P04) buffer Adjust pH to pH 7.4 
with sodium hydroxide. 
7) 100mM potassium phosphate (KH2P04)1 1mM ascorbic acid/ 5mM 
magnesium chloride buffer Adjust pH to pH 6.8 with sodium 
hydroxide. 
8) 2M Tris buffer (pH 9.0 at 37°C) was prepared from Trizma pre-set 
crystals (pH 8.5). 
9) 50mM Trisl 1mM calcium buffer (pH 7.4 at 37°C) was prepared by 
adding CaC12 to Trizma pre-set crystals (pH 7.4). 
10) 100mM potassium phosphate (KH2P04) buffer Adjust pH to pH 6.5 
with sodium hydroxide. 
94 
7.4 Preparation of rat and human liver subcellular fractions 
All steps were carried out on ice or at 40C. 
Human or rat liver homogenates (10%, w/v) were prepared in ice cold 
potassium chloride/ phosphate buffer (0.1M KCl/ 0.1M KH2PO4, pH 7.4) 
using a Polytron cell homogeniser (Kinematica AG, Littau-Luzern, 
Switzerland). Homogenates were centrifuged in a Mistrall refrigerated 
centrifuge at 1 500g for 5 minutes at 40C to remove tissue debris. The 
supernatants were further centrifuged at 12 500g for 10 minutes to remove 
cellular nuclei and mitochondria. The post-mitochondrial fractions were 
then centrifuged in a Sorvall ultra-centrifuge at 100 000g for one hour and 
ten minutes at 40C. 
The supernatants (cytosol) were removed and the surface of the resulting 
microsomal pellet washed carefully with potassium chloride/ phosphate 
buffer. Microsomal pellets were then resuspended in the same buffer 
using a glass to glass homogeniser. The suspensions were vortexed gently 
to free the microsomes of trapped debris and then re-centrifuged at 100 
000g for one hour. The microsomal pellets were then resuspended in 2m1 
potassium chloride/ phosphate buffer using a hand held glass to glass 
homogeniser. Samples were stored in aliquots at -700C prior to analysis. 
7.5 Determination of the protein concentration of subcellular 
fractions 
The method used in the study was an adaptation by Peterson (1977) of the 
original Folin-Ciocalteu reagent method as given by Lowry and co-workers 
in 1951 for estimation of total protein. The original procedure was 
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modified to provide a method which was simple, rapid, objective and 
more generally applicable. SDS (sodium dodecyl sulphate) was added to 
alleviate possible non-ionic and cationic detergent and lipid interferences 
and to provide mild conditions for rapid denaturation of membrane and 
proteolipid proteins. 
Reagents 
Stock Reagents 
1) Copper-Tartrate-Carbonate (CTC) 
10g sodium carbonate ------> 100ml dist. H2O 
Add 100mg CuSO4. and 200 mg KNa tartrate. 4H20 
2) 10% (w/v) sodium dodecyl sulphate (SDS) 
10g SDS ----> 100ml dist. H2O 
3) 0.8N sodium hydroxide 
32g ----> 1litre dist. H2O 
4) Folin-Ciocalteu phenol solution 
Commercially available from BDH 
Working Solutions 
1) Bovine Serum Albumin ("Precimat" protein standard) 
Purchased from Boehringer as a 6g/100ml solution. 
1: 100 dilution was prepared in dist. H2O 
(100µl ------> 10ml dist. H20). 
This working solution was 600µg protein/ml. 
2) Reagent A 
Mix equal volumes of stock CTC, NaOH, SDS and dist. H20- 
The solution is stable for 1-2 weeks in the dark at 200C 
(discard solution when a dark precipitate begins to appear). 
3) Reagent B 
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20m1 Folin-Ciocalteu phenol reagent + 100ml dist. H2O 
The solution is stable for several months in the dark at 200C. 
Procedure 
A known aliquot of microsomal suspension or cytosol was made up to a 
total volume of 1ml with distilled water. 1ml reagent A was added to each 
tube, the tubes mixed and allowed to stand for 10min at room 
temperature. 0.5m1 reagent B was then added and the tubes mixed 
immediately. After 30min the samples were put in quartz cuvettes of 1cm 
pathlength and their absorbances read using a Kontron 930 
spectrophotometer set at 750nm. Samples were read against a reagent 
blank placed in the reference position. 
A standard curve (0 - 72µg protein) was prepared in 1ml aliquotes of 
distilled water and then treated in the same manner as the samples. The 
standard curve was best fitted to a quadratic equation. Samples were 
quantitated by comparison to the standard curve using a small 
programmable calculator, or directly by the Kontron 930 
spectrophotometer. 
7.6 Spectral determination of the P450 content of rat liver 
microsomes 
Cytochrome P450 is a haemoprotein and use is made of the fact that when 
the haem iron is reduced and complexed with carbon monoxide, a 
characteristic absorption spectrum results. The reduced carbon, monoxide 
difference spectrum of cytochrome P450 absorbs maximally at around 
450nm and the extinction coefficient for the wavelength couple 450nm - 
490nm has been accurately determined to be 91mM-1 cm-1, thus allowing 
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quantitative determination of this haemoprotein. The method used was 
an adaptation of that described by Omura and Sato (1964). 
Procedure 
Liver microsome preparations were diluted in KCl/ phosphate buffer (pH 
7.4) to approximately 1mg protein/ ml. A 2m1 aliquot of the diluted 
sample was added to matched sample and reference quartz cuvettes and a 
baseline recorded between 400nm and 500nm. A Kontron 930 double- 
beamed spectrophotometer was employed. A few grains of solid sodium 
dithionite was added to each cuvette and then mixed by gentle inversion. 
The sample cuvette was then placed in an extraction hood and bubbled 
gently (approximately 1 bubble/ sec) with carbon monoxide for 
approximately 1min. The spectrum was then re-scanned from 400nm to 
500nm. The absorbance difference between 450nm and 490nm was then 
calculated. 
Using Beer's Law and assuming a pathlength of 1cm, a difference spectrum 
of 0.03, a cuvette protein concentration of 10mg/ ml which had been 
diluted 1: 20, the cytochrome P450 concentration is given by: 
0.03 x 20 x 1000 = 0.659 nmol P450/ mg protein 
91 x 10 
7.7 Statistical methods 
Unless otherwise stated statistical analysis was by ANOVA followed by 
Newman-Keuls post test for multiple comparisons which was used to 
identify which of the means actually differed. 
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Animal data were expressed as the mean ± standard error of the mean 
(sem). Data derived from human studies were summarised as enzyme 
activity ranges and medians since the data could not be considered to be 
homogenous. 
In the human studies, the correlation coefficient (r) was calculated by least 
squares linear regression fit and from this values of t were determined: 
t=r n-2 
(1 - r2) 
The calculated value of t was compared with the tabulated value at p<0.05 
or less, using a two-tailed test and (n-2) degrees of freedom. The data were 
also analysed by non-parametric statistics, the Spearman rank correlation 
coefficient (Rho) using the Statworks+TM application for the Apple 
Macintosh. Values for Rho were compared with the tabulated values at 
p<0.05 or less, using a two-tailed test. 
99 
Chapter 8 
Chapter 8 Biochemical methods 
8.1. Measurement of the activity of cytochromes P450 1A and 2B 
Ethoxyresorufin and pentoxyresorufin can be O-dealkylated by 
cytochromes P450 1A1/2 and 2B1/2, respectively, in the presence of 
NADPH and oxygen to produce the common metabolite resorufin. These 
two substrates are often used as highly sensitive markers for the afore 
mentioned P450 isoforms. The continuous monitoring fluorimetric 
method used in this study was based on that of Burke and Mayer (1974). 
Reagents 
Ethoxyresorufin, pentoxyresorufin and resorufin were purchased from 
Sigma-Aldrich, Dorset, UK. It was necessary to protect all three chemicals 
from the light. Stock solutions (2mM) of resorufin, ethoxyresorufin and 
pentoxyresorufin were prepared in DMSO. Resorufin was then diluted to a 
working concentration of 0.01mM with DMSO. The incubation medium 
was 10mM phosphate buffer, pH 7.4 (chapter 7). NADPH (1.2 mg/ml) was 
freshly prepared in phosphate buffer and kept on ice. 
The influence of protein, time and substrate concentrations 
The ethoxy- and pentoxyresorufin O-dealkylase activities were determined 
at saturating substrate concentration (2µM) to ensure that Vmax rates were 
measured. Under these conditions the rate of ethoxyresorufin 0- 
dealkylation was linear up to 0.2mg microsomal protein/ incubation. The 
initial rate of reaction was assessed and was visually judged to be linear 
with time. 
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Procedure 
A Perkin-Elmer LS-5 fluorimeter fitted with a water jacketed cell holder 
set to 370C and connected to an Amstrad computer with a kinetics package 
(ELMER) was used. The rate of formation of resorufin was measured with 
the following fluorimeter parameters: excitation wavelength 530nm, 
emission wavelength 585nm, excitation and emission slit widths 10nm. 
The best-fit for the reaction (positive slope) was determined by the kinetics 
package. 
Liver microsomes were equilibrated to 370C in a microcuvette with 
NADPH (0.6mg) and phosphate buffer to a final volume of 1ml. The 
reaction was started on addition of 2 nmoles (1µl) of substrate, to give a 
final concentration of 2µM, and the reaction followed for up to 5 minutes 
at 37°C. Analysis was carried out in duplicate. 
Quantitation of the reaction 
Quantitation of the reaction and determination of quenching of the 
fluorescence by protein was carried out by measuring the fluorescence 
produced by 10 pmoles (1µl) of authentic resorufin in 1ml phosphate 
buffer containing microsomal protein. This value was used to calculate 
the enzyme activity which was expressed as pmol resorufin produced/ 
min/ mg microsomal protein. 
pmol resorufin produced/ min/ mg microsomal protein 
Slope for the reaction (fluorescence units change/min) 
fluorescence units produced by lpmol resorufin 
x mg protein/ incubation 
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8.2 Measurement of the activity of cytochrome P450 2E1 
The hydroxylation of p-nitrophenol to 4-nitrocatechol has been used as a 
marker reaction for cytochrome P450 2E1 activity in both rat and human 
liver microsomes. The method used in this study for the detection of 4- 
nitrocatechol was based on that of Tassaneeyakul et al, 1993. 
Reagents 
100mM potassium phosphate/ 1mM ascorbic acid/ 5mM magnesium 
chloride buffer, pH 6.8 (chapter 7). Stock solutions of p-nitrophenol 
(10mM) and 4-nitrocatechol (10mM) were prepared in buffer and diluted 
1: 10 and 1: 100, respectively, before use. p-Nitrophenol solutions were 
freshly prepared prior to each assay and stored on ice in the dark. A stock 
solution of salicylamide (8mg/ ml) was prepared in methanol and diluted 
1: 100 with buffer prior to use. NADPH (1.2 mg/ml) was freshly prepared in 
phosphate buffer and kept on ice. 
The influence of protein, time and substrate concentration 
Tassaneeyakul et al (1993) reported that human liver microsomes 
produced 4-nitrocatechol with a Km of 26.3µM, therefore this study used a 
p-nitrophenol concentration of 200µM to ensure that Vmax rates were 
measured. Under these conditions rates of 4-nitrocatechol formation were 
linear with time and protein concentration to 30 minutes and 0.5mg/ 
incubation, respectively. 
Procedure 
A Kontron HPLC system fitted with u. v. / visible detector set at 250nm was 
used to measure the absorbance of the metabolites. A reverse-phase 
separation was employed using a 5g Spherisorb ODS1 column (25cm x 
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4.6mm, Fisons Chromatography, Loughborough, UK) and pBondapak C18 
precolumn (Waters Chromatography, Hertfordshire, UK). The mobile 
phase comprised of 40% methanol/ 60% phosphoric acid (0.07%, w/v, pH 
3.0) at a flow rate of 1ml/ minute. Using these conditions the retention 
times for 4-nitrocatechol, salicylamide (internal standard) and p- 
nitrophenol were 24.6,28.5 and 33.6 minutes, respectively. 
Liver microsomes were equilibrated to 370C in glass test tubes with 
NADPH (0.3mg) and buffer to a final volume of 0.5m1. Analysis was 
carried out in triplicate. The reaction was started on addition of 100nmoles 
(100µl) of substrate, to give a final concentration of 200µM. After a suitable 
period the reaction was terminated by the addition of 0.6M perchloric acid 
(0.25m1). Salicylamide (50µ1) was added to serve as the internal standard 
and the tubes mixed well. The tubes were then centrifuged for 15 minutes 
at 500g to pellet the denatured protein. Approximately 0.25m1 of each clear 
supernatant was subsequently removed to glass vials and 80gl aliquots 
injected onto the HPLC system. 
Quantitation of the reaction 
A standard curve was constructed for 4-nitrocatechol (5µM - 40µM) in the 
presence of boiled microsomes (0.5mg protein) and treated in exactly the 
same manner as the samples. The amount of 4-nitrocatechol produced by 
the microsomal samples was quantitated by comparison to the standard 
curve. Enzyme activity was expressed as nmol 4-nitrocatechol produced/ 
min/ mg microsomal protein. 
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8.3 Measurement of the activity of cytochrome P450 3A 
Several research groups (Iribarne et al, 1996; Niwa et al, 1995; Shimada et 
al, 1997) have used nifedipine oxidation as a marker reaction for P450 3A 
activity in rat and human microsomes, as well as other species. This 
sensitive, efficient, capillary gas chromatographic (GC) method for the 
detection of nifedipine and its primary metabolite, M1, was based on that 
of Schmid et al, 1988. 
Reagents 
0.1M potassium phosphate/ 0.1M potassium chloride (pH 7.4) and 2M Tris 
buffers (pH 9.0) buffers, (chapter 7). Stock solutions of nifedipine (25mM) 
and nitrendipine (0.50mg/ ml, internal standard) were prepared under a 
sodium lamp in methanol and stored in amber bottles. Stock nitrendipine 
was diluted 1: 20 in water for use. NADPH (6mg/ ml) was freshly prepared 
in phosphate buffer prior to each assay and kept on ice. 
The influence of protein, time and substrate concentration 
The apparent Vmax, 1.9 nmol/ min/ mg protein, and apparent Km, 
21.2µM, for M1 formation by control rat liver microsomes (n=1) was 
determined using an Eadie Hofstee plot (figure 8.1) based upon data from a 
range of nifedipine concentrations (2-200µM) in which conditions of 
linearity with respect to time and protein concentration were employed. 
This relates to the reported Km of 6-27µM for nifedipine oxidation by 
human liver microsomes (Guengerich et al, 1986). The present study used 
a saturating substrate concentration of 100µM to ensure Vmax rates. Under 
these conditions rates of M1 formation were linear with time (figure 8.2) 
and protein concentration (figure 8.3) to 30 minutes and 1.2mg/ 
incubation, respectively. 
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Figure 8.1 
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Procedure 
A Hewlett Packard (HP 5890A) gas chromatograph (GC) equipped with an 
unheated on-column injector and a 63Ni electron capture detector (ECD) 
was employed. Injection (0.2gl) was achieved directly into a wide-bore HP- 
1 capillary column (30cm x 0.53mm, 2.65µm film thickness) which was 
connected by a dead volume butt connector to a capillary HP-1 column 
(25m x 0.25mm, 0.25µm film thickness). The detector temperature was 
3000C and the oven temperature was maintained at 240°C. Carrier gas was 
hydrogen (1ml/ min) with a nitrogen make-up flow rate of 40m1/ min. A 
suitably programmed integrator (HP3396A) was used to process the 
chromatographic signals. Under these conditions the retention times 
obtained for M1, an unknown metabolite, nifedipine and nitrendipine 
were 3.3,4.0,5.6 and 7.4 minutes, respectively (appendix V). 
Microsomal protein was equilibrated to 370C in amber glass tubes with 
NADPH (0.6mg) and phosphate buffer (pH 7.4) to a final volume of 1.0ml. 
Incubations were carried out in a room fitted with a sodium lamp to 
exclude daylight in order to prevent decay of nifedipine. Analysis was 
carried out in triplicate. A "buffer blank" (as above but no protein) was 
carried out in parallel to ascertain non-enzymatic formation of M1. The 
reaction was started by addition of 100nmoles (4µl) of nifedipine (25mM), 
to give a final substrate concentration of 100µM and methanol 
concentration of 0.4% (v/v). 
After a suitable period the reaction was terminated by addition of 4O0gl 
Tris buffer (pH 9.0). The bottles were capped, vortexed and immediately 
placed on ice. Nitrendipine (l00µ1) was then added to each to serve as the 
internal standard. The mixture was extracted with 2m1 toluene (rotary 
mixer for 30 minutes) followed by centrifugation for 5min x1 000g. The 
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upper organic layer (-4ml) was removed to clean GC vials for detection of 
nifedipine, nitrendipine (I. S. ) and the major metabolite, M1. 
Quantitation of the reaction 
A standard curve (figure 8.4) was constructed for authentic M1 (0.5 - 8µg/ 
incubation, i. e. 1.38 - 22.1nmol/ incubation) in the presence of boiled 
microsomes (0.5mg protein) and treated in exactly the same manner as the 
samples. Standards were expressed as area Ml/ area internal standard 
ratios. The amount of M1 produced by the microsomal samples was 
quantitated by comparison to the standard curve. Enzyme activity was 
expressed as nmol M1 produced/ min/ mg microsomal protein. 
8.4 Method for the study of parathion metabolism 
Parathion metabolism has been mostly studied in rodent liver 
microsomal fractions (Sultatos and Murphy, 1983; Ma and Chambers, 
1995), although a few investigators (Nakatsugawa et al, 1980) have used 
hepatocytes where microsomal and cytosolic enzymes function in parallel 
within the intact cell. Liver metabolism was studied since this organ is 
classically the most active catalytically and used microsomal fractions, 
rather than hepatocytes, so that the participating P450 isoform(s) could be 
more easily identified. 
Several analytical methods have been used to detect parathion and 
associated metabolites. High performance liquid chromatography (HPLC) 
techniques, either reverse or normal phase, with u. v. detection have been 
most often employed since all three compounds contain a benzene ring 
moiety and therefore absorb well in the ultra-violet range of the spectrum. 
A study by Butler and Murray (1983) measured paraoxon and p- 
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nitrophenol production following incubation with [14C]parathion and 
separation by HPLC. This method could infer increased sensitivity 
compared to other techniques, although the costs involved in obtaining 
[14C]parathion would be prohibitive for many researchers. 
The analytical method chosen for this study was similar to that of 
Anderson et al (1992) in which microsomal incubations were terminated 
by protein precipitaton and then analytes separated and quantitated by 
reverse phase HPLC with u. v. detection. 
Reagents 
50mM Tris buffer (pH 7.4), (chapter 7). Perchloric acid (20% v/v) was 
prepared by diluting the commercially available concentrated solution 
(60% v/v) with water. NADPH (6mg/ ml) was freshly prepared in buffer 
prior to each assay and kept on ice. Stock solutions of parathion (50mM 
and 5mM) and paraoxon (100µM) were prepared in methanol from 
commercial (Greyhound Chromatography, Merseyside, U. K. ) parathion 
(4.33M) and paraoxon (4.64M). Both are oily liquids. Stock p-nitrophenol 
(100µM) was also prepared in methanol. 
The influence of protein, time and substrate concentration 
Parathion metabolism by rat liver microsomes was carried out at 
saturating substrate concentration (200gM) in order to measure Vmax 
rates of paraoxon and p-nitrophenol formation, and also at 20µM. Under 
these conditions the rate of p-nitrophenol and paraoxon formation was 
linear with time and protein concentration to 10 minutes and 0.4mg 
protein per incubation, respectively (figures 8.5 and 8.6). Preliminary 
experiments showed that the volume of methanol (2µl) required to 
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introduce the substrate did not affect P450-mediated metabolism of 
parathion. 
High Performance Liquid Chromatography Conditions 
Separation of parathion, paraoxon and p-nitrophenol was by high 
performance liquid chromatography with ultra-violet detection (290nm). 
The HPLC system consisted of a Kontron autosampler (460), pump (420), 
gradient former (425) and u. v. / visible detector (430) set at 290nm. 8Oµ1 
aliquots of supernatant were injected onto a Spherisorb ODS1 5µm reverse 
phase column (25cm x 4.6mm, Fisons Chromatography, Loughborough, 
UK) and µBondapak C18 precolumn (Waters Chromatography, 
Hertfordshire, UK). The mobile phase (lml/ min) consisted of methanol/ 
phosphoric acid (0.07% w/v) with the following run parameters: - 20%% 
methanol held for 5min followed by a linear gradient to 100% methanol 
over 40min. Conditions were returned to 20`%o methanol/ 80`% phosphoric 
acid by linear gradient (5min) and held at this proportion for 5min. Using 
the chromatographic conditions described retention times for p- 
nitrophenol, paraoxon and parathion were 23.8min, 30.8min and 33.5min, 
respectively (appendix V). 
Preparation of standards 
Calibration curves were prepared in the range 0.05-2 nmol p-nitrophenol 
and paraoxon per incubation in the presence and absence of 0.4mg 
microsomal protein but without NADPH. Parathion was not included in 
these standards. Standards were then treated in the same manner as the 
samples, without incubation at 37°°C. 80µ1 aliquots were injected onto the 
HPLC system. The analytical limit of detection was 10pmol/incubation 
and 35pmol/incubation for p-nitrophenol and paraoxon, respectively. 
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Incubation procedure 
The incubation system consisted of liver microsomes in 0.5m1 of Tris/ 
calcium buffer (pH 7.4) containing 0.3mg NADPH. Control incubations 
were carried out as described above except that microsomal protein or 
NADPH was omitted. The reaction was started by addition of 2µl 
parathion stock solutions (5mM or 50mM) in methanol which gave final 
parathion concentrations of 20µM or 200µM, respectively. The incubations 
were conducted at 37°C in a shaking water bath and terminated after a 
suitable period by adding an equal volume of 20% (v/v) perchloric acid 
followed by rapid cooling on ice. Samples were centrifuged at 1 000g for 
15min and then the clear supernatants carefully removed to clean vials 
prior to analysis by HPLC for p-nitrophenol and paraoxon formation. 
8.4.1 Results and discussion 
Linear calibration curves were produced for paraoxon (figure 8.7) and p- 
nitrophenol (figure 8.8) over the range studied (0.5-5 nmol/ incubation). 
There was no difference between the curves for paraoxon (or p- 
nitrophenol) measured in the presence and absence of microsomal 
protein. However, it is possible that the paraoxon concentration of the 
standards would have been reduced by binding to carboxylesterases if they 
had been incubated at 37°'C. It is therefore possible that rates for paraoxon 
formation determined by this method may have been slightly 
underestimated. In this context, Norman eßt al demonstrated that up to 
20%% of the paraoxon formed in vitro could be bound to the microsomes 
and therefore accurate measurements of paraoxon formation should 
include the concentration of free metabolite in the incubation media plus 
the amount bound to the microsomes. 
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Initial experiments showed that the rate of parathion metabolism to p- 
nitrophenol and paraoxon rapidly departed from linearity with respect to 
protein and time. This observation indicated rapid inhibition of the 
metabolism of parathion which corroborates the early hypothesis of 
Norman et al (1974). These researchers suggested that the sulphur atom of 
phosphorothioates is released during their oxidative metabolism and 
transferred to the haem moiety of P450 leading to amino acid modification 
and enzyme destruction. 
8.5 Measurement of flavin monooxygenase activity 
The N-oxidation of dimethylaniline (DMA) has been used as a sensitive 
marker reaction for flavin monooxygenase (FMO) activity (Sadeque et al, 
1993). The flavin monooxygenases are located in the microsomal fraction 
of mammalian liver and their capacity to form dimethylaniline N-oxide 
was determined in this study by a modification of the gas chromatographic 
method of Damani and Houdi (1988). 
Reagents 
Glycine buffer, pH 8.5 (chapter 7). Stock solutions of N, N-dimethylaniline 
(0.5M) and N-ethylaniline (1mM, internal standard) were prepared in 
methanol prior to use. A solution of authentic N, N-dimethylaniline N- 
oxide (1mM in water) was provided by Dr A Rettie (Seattle, USA). NADPH 
(6mg/ ml) was freshly prepared in buffer prior to each assay and kept on 
ice. 
The influence of protein, time and substrate concentration 
The substrate concentration, 12.5mM N, N-dimethylaniline, used in this 
study was similar to that reported in the literature (Sherratt and Damani, 
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1989) although it was recognised that oxidation of a xenobiotic by FMO is a 
second order reaction not saturable by substrate. Under the conditions 
described below the rates of dimethylaniline N-oxide formation were 
linear with time and protein concentration to 10 minutes and 0.15mg/ 
incubation, respectively. 
Procedure 
A Hewlett Packard (HP 5890A, series II) gas chromatograph (GC) equipped 
with an automatic injector (HP 7673), ' integrator (HP 3396A) and flame 
ionisation detector (FID) was employed. Injection (2p1, splitless) was 
achieved into a heated (2300C) injection port connected to a capillary HP-1 
column (25m x 0.32mm, 0.52µm film thickness). The detector temperature 
was 2000C, the oven temperature commenced at 600C and followed a linear 
gradient (10C/min) until 900C where it was held for 50 minutes. The 
carrier gas was nitrogen (1.3 ml/ min, total flow). Under these conditions 
the retention times obtained for N, N-dimethylaniline (dimethylaniline 
N-oxide) and N-ethylaniline (internal standard) were 17.8 and 21.1 
minutes, respectively. 
Control liver microsomes were equilibrated to 37°C in glass test tubes with 
NADPH (0.5mg) and glycine buffer to a final volume of 0.2ml. Analysis 
was carried out in triplicate. The reaction was started on addition of 
2.5gmoles (5p1) of N, N-dimethylaniline, to give a final substrate 
concentration of 12.5mM. After a suitable period the reaction was 
terminated by addition of 0.1ml of sodium hydroxide (5M), the tubes were 
vortexed and placed on ice. The mixture was then twice extracted (vortex, 
30 seconds) with diethyl ether (5ml) to remove excess N, N- 
dimethylaniline, the organic layer was removed to waste on each occasion. 
Following addition of a third aliquot (5m1) of diethyl ether, the tubes were 
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vortexed, centrifuged 10min x1 000g, the organic layer removed to waste 
and 0.15ml N-ethylaniline (1mM, internal standard) added. 1.0ml of HCl 
(1.2M) and 20µl Titanium (III) chloride (15%, w/v) was then added and the 
mixture allowed to stand for 5 minutes, this reduced dimethylaniline N- 
oxide, produced by the microsomes, back to N, N-dimethylaniline. 
Finally, 1ml of sodium hydroxide (5M) was added, the mixture vortexed 
and then centrifuged for 10 minutes x1 OOOg to remove any remaining 
protein. The resulting supernatant was removed to clean tubes containing 
approximately 1g sodium chloride and 14m1 hexane and vortexed for one 
minute. The hexane (top) layer was then transferred to clean tubes and 
concentrated to approximately 250µ1 under nitrogen. This was removed to 
clean G. C. vials for detection of N, N-dimethylaniline (dimethylaniline N- 
oxide) and N-ethylaniline (internal standard). 
Quantitation of the reaction 
A standard curve was constructed for authentic dimethylaniline N-oxide 
(20 - 80 nmol/ incubation) in the presence and absence of boiled 
microsomes (0.1mg protein) and treated in the same manner as the 
samples from the final addition of 1.0ml sodium hydroxide (5M). 
Inspection of the standard curves for dimethylaniline N-oxide in the 
presence and absence of microsomal protein showed that they were 
similar. Standards were expressed as area dimethylaniline N-oxide/ area 
internal standard ratios. The amount of dimethylaniline N-oxide 
produced by the microsomal samples was quantitated by comparison to 
the standard curve. Enzyme activity was expressed as nmol 
dimethylaniline N-oxide produced/ min/ mg microsomal protein. 
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8.6 Measurement of paraoxonase activity 
Paraoxon is the most common substrate for studying paraoxonase 
(aryldialkylphosphatase) activity and measurement of its hydrolysis to p- 
nitrophenol is considered to be a marker reaction for the detoxification of 
organophosphates. Paraoxonase has been located exclusively in the 
microsomal fraction of mammalian liver (McCracken et al, 1990) and its 
activity was determined in this study by a modification of the method of 
Eckerson (1983) in which appearance of p-nitrophenol was monitored 
photometrically. 
Reagents 
Glycine/calcium buffers (chapter 7). Paraoxon was purchased from 
Greyhound Chromatography (Merseyside, U. K. ) as an oily liquid (4.6M) 
and a working stock (100mM) prepared by diluting 1: 45 in dry acetone 
prior to use. 
The influence of pH 
Initial studies with human liver microsomes (n = 4) determined the 
optimal pH for the enzyme. 
Paraoxonase activity was assessed at pHs 7.0,7.4,8.0,9.0,10.0 and 10.5. 
Approximately 0.2mg protein was incubated with paraoxon (1mM) at 300C 
and formation of p-nitrophenol monitored continuously, as described 
below. 
Activity was shown to be optimal at pH 9.0 with rates at pH 7.4 
approaching the limit of sensitivity for the assay (figure 8.9). 
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The influence of protein, time and substrate concentration 
The paraoxon concentration (1mM) used in this study was more than two- 
fold greater than the reported Km (0.4mM, Gil et al, 1993) to ensure that 
Vmax rates were measured. Under these conditions at pH 9.0 the rate of p- 
nitrophenol formation was linear up to 0.25mg microsomal protein/ 
incubation. The initial rate of reaction was assessed and was visually 
judged to be linear with time. 
Procedure 
Microsomal protein was added to quartz cuvettes containing glycine/ 
calcium (pH 9.0) buffer to a total volume of 3m1. Duplicate measurements 
were carried out. A reagent blank was measured at the beginning and end 
of each batch of samples to quantitate the non-enzymatic hydrolysis of 
substrate. This was generated by substituting the volume of microsomes 
for buffer. 
Incubation mixtures were then held in the heated cuvette chamber of a 
Kontron 930 spectrophotometer for 5 minutes until they had attained 
30°C. The reaction was started on addition of 3gmoles (30µl) of paraoxon 
(100mM), to give a final substrate concentration of 1mM. Samples were 
held at 300C and continuously monitored for formation of p-nitrophenol 
at 412nm for up to 4 minutes. The rate of absorbance change (positive 
slope) was recorded. 
Quantitation of the reaction 
Enzyme activity was determined by an adaptation of Beer-Lamberts law. 
Under the assay conditions described: 
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E=0.128 absorbance units (AU) for a 10nmol/ ml solution p- 
nitrophenol in phosphate buffer (pH 7.4), i. e. 1.0 AU = 78.1nmol p- 
nitrophenol/ ml. 
E=0.176 absorbance units (AU) for a 10nmol/ ml solution p- 
nitrophenol in glycine buffer (p 9.0), i. e. 1.0 AU = 56.8nmol p- 
nitrophenol/ ml. 
A= the rate of reaction (0 AU/ min, slope) 
C= mg microsomal protein/ 1ml incubation mixture 
L= cuvette pathlength (1cm) 
Therefore, 
nmol p-nitrophenol formed/ min/ mg protein = 
A AU /min x 78.1 at pH 7.4 
mg protein/ lml incubation 
A AU/ min x 56.8 at pH 9.0 
mg protein/ iml incubation 
8.7 Measurement of phenylvalerate hydrolase activity 
The hydrolytic activity of serine-containing esterases (carboxylesterases 
and cholinesterases) of liver microsomes was measured in this study by a 
sensitive spectrophotometric method based on that of Johnson (1977) 
modified by Mutch et al, 1995. In this method phenol liberated on 
hydrolysis of the substrate, phenylvalerate, was coupled to 4- 
aminoantipyrine and the colour developed by addition of potassium 
ferricyanide. The resultant red aminoantipyrine dye was measured 
photometrically. 
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Reagents 
Tris/ EDTA (pH 8.0) and 500mM Tris (pH 8.5) buffers (chapter 7). 
Phenylvalerate was synthesized by Mutch (1992) following the method of 
Johnson (1977) and a stock solution (15mg/ ml) prepared in redistilled 
dimethylformamide. Phenylvalerate stock solution was diluted 1: 30 in 
TritonX 100 (0.03% (v/v) in water) prior to use. 4-aminoantipyrine (0.5% 
(v/v) in 500mM Tris buffer) was diluted 1: 20 in stock sodium 
dodecylsulphate (1.05% (w/v) in Tris/EDTA buffer) prior to use. A stock 
solution of potassium ferricyanide (4% (v/v) in water) was diluted 1: 10 in 
water for use. 
The influence of protein, time and substrate concentration 
Liver microsomal phenylvalerate hydrolase activity was carried out at 
saturating substrate concentration (1.4mM) to ensure that Vmax rates were 
measured. Under these conditions the rate of phenol formation was linear 
with time and protein concentration to 15 minutes and 100ng/ incubation, 
respectively. 
Procedure 
Liver microsomes were equilibrated to 370C in 0.2ml Tris/EDTA buffer in 
parallel with a reagent blank which was carried out in order to determine 
non-enzymatic production of phenol. This was generated by substituting 
liver microsomal suspension with an equal volume of Tris/ EDTA buffer 
and following through the assay. The reaction was started on addition of 
0.2m1 phenylvalerate in TritonX 100, to give a final substrate 
concentration of 1.4mM. After a suitable period the reaction was stopped 
by addition of 0.2m14-aminoantipyrine/ sodium dodecylsulphate working 
stock and the tubes placed on ice. Phenol liberated during the incubation 
period was coupled to 4-aminoantipyrine and the red colour developed on 
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addition of O. lml potassium ferricyanide working solution. The absorbance 
at 510nm was read in quartz micro-cuvettes against a blank (reagents other 
than phenylvalerate) in the reference position. A Kontron 930 double- 
beamed spectrophotometer was employed. 
Quantitation of the reaction 
A standard curve was constructed for authentic phenol (20 - 50 nmol/ 
incubation) in the absence of microsomal protein and treated in the same 
manner as the samples. The amount of phenol produced by the 
microsomal incubations was quantitated by comparison to the standard 
curve. Enzyme activity was expressed as mmol phenol produced/ min/ 
mg microsomal protein. 
8.8 Measurement of glutathione-S-transferase activity 
A convenient spectrophotometric method (Habig et al, 1974) has been 
developed for the analysis of glutathione-S-transferase based on the 
enzyme catalysed condensation of glutathione with the model substrate 
2,4-dinitro-l-chlorobenzene. The product formed (2,4-dinitrophenyl- 
glutathione) absorbs at 340nm. 2,4-dinitro-l-chlorobenzene is a good 
substrate for most of the glutathione-S-transferase isoforms and therefore 
the observed activity will be a composite result of the isoforms present in 
the tissue preparation. 
Reagents 
100mM potassium phosphate buffer, pH 6.5, (chapter 7). Stock solutions of 
reduced glutathione (GSH, 30mM in buffer) and 2,4-dinitro-l- 
chlorobenzene (DNCB, 30mM in ethanol) were prepared prior to each 
assay and stored on ice. 
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The influence of protein, time and substrate concentration 
An apparent Km of 250µM was determined for formation of the DNCB 
adduct by human liver cytosol (n=1) using an Eadie Hofstee plot based 
upon data from a range of DNCB concentrations (0.075-2.0mM) in which 
conditions of linearity with respect to time and protein concentration were 
employed. The present study used a saturating substrate concentration of 
1mM to ensure Vmax rates. Under these conditions the rate of DNCB 
adduct formation was linear with protein to 75µg/ incubation; the initial 
rate of reaction was assessed which was visually judged to be linear with 
time. 
Procedure 
Liver cytosol was equilibrated to 370C with 33µl GSH (30mM), 33µl DNCB 
(30mM) and phosphate buffer (pH 6.5) to a total volume of 1.0ml. This 
gave a final substrate concentration of 1mM. The reaction mixture was 
prepared in duplicate in disposable microcuvettes. A reagent blank was 
carried out with every run and generated by replacing cytosolic protein 
with the same volume of buffer and placing the cuvette in the reference 
position of the spectrophotometer. This automatically subtracted non- 
enzymatic formation of the DNCB adduct (<10% of enzymatic formation) 
from enzymatic catalysis. The reaction was started on addition of cytosolic 
protein and the increase in absorbance at 340nm followed for about 3 
minutes at 37°C. 
Quantitation of the reaction 
Using Beer's law (and a cuvette pathlength of 1cm), the specific activity of 
DNCB glutathione-S-transferase is given by: 
P= protein concentration (mg) in 1m1 incubation 
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E=9.6mM (extinction coefficient for glutathione/ DNCB adduct at 
340nm) 
A= the rate of reaction (A absorbance units/ min, slope) 
Therefore, 
gmol product formed/ min/ mg protein = 
A 
9.6 xP 
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SECTION III: 
EXPERIMENTAL STUDIES 
Chapter 9 
Chapter 9 Rat induction studies in vivo 
9.1 Introduction 
The inclusion of an animal component in xenobiotic metabolism studies 
has several advantages. Particularly, rat enzyme systems can be modulated 
in vivo and in vitro in order to elucidate the metabolic pathways 
involved in a particular reaction which is not possible for human studies. 
It was therefore decided to study the metabolising capacity of rat liver in 
order to complement the data derived from the limited supply of human 
tissue. The methods for measurement of these enzymes had been 
previously established to ensure valid analysis. 
Initial studies were concerned with the characterisation of control rat liver 
microsomes for the cytochromes P450, FMO and esterases which may be 
involved in parathion metabolism. Next the capacity of control 
microsomes to metabolise parathion to paraoxon and p-nitrophenol at 
saturating substrate concentration using optimal assay conditions was 
defined. 
The efficacy of the induction regimen was assessed by measuring the 
increase in activity of the cytochromes P450 and esterases compared to 
control. Increased parathion metabolism by the various groups of induced 
liver microsomes was then determined in order to investigate the P450 
isoform(s) involved in the catalysis of this phosphorothioate. 
As the literature (Guengerich, 1977) suggested the involvement of 
phenobarbital-inducible isoforms (CYPs 2B and 3A) one group of rats was 
to be induced by phenobarbital. Another was induced by dexamethasone 
129 
in order to increase the level of the CYP3A subfamily (Okey et al, 1990), the 
predominant human liver P450 isoform. Cytochromes P450 1A and 2E1 
were induced with ß-naphthoflavone (a 3-methylcholanthrene-type 
inducer) and ethanol pre-treatment, respectively. 
9.2 Methods 
9.2.1 Induction regimen 
Male Wistar rats weighing approximately 250g were randomised into 6 
treatment groups: saline control, phenobarbital, ethanol, corn oil control, 
dexamethasone and ß-naphthoflavone. Within each group of five each 
rat was tail-marked and weighed. The saline-treated and corn oil-treated 
animals served as controls for the phenobarbital and ethanol groups, and 
dexamethasone and ß-naphthoflavone-treated groups, respectively. 
Dosing regimens were adapted from Verschoyle et al (1993) and Fentem et 
al (1991). All animals were sacrificed by cervical dislocation 24 hours after 
the last dose, their livers weighed and then stored at -70oC. 
Saline control group received 2m1 normal saline/ kg body weight/ day by 
i. p. injection for 3 days. 
Phenobarbital group received 80mg sodium pentibarbital in normal 
saline/ kg body weight/ day by i. p. injection for 3 days. 
Ethanol group received 15% ethanol (v/v) in their drinking water for 5 
days. 
Corn oil control group received 2m1 corn oil/ kg body weight/ day by oral 
gavage for 3 days. 
Dexamethasone group received 300mg dexamethasone in corn oil/ kg 
body weight/ day by oral gavage for 4 days. 
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ß-Naphthoflavone group received 80mg ß-naphthoflavone/ kg body 
weight/ day by oral gavage for 3 days. 
9.2.2 Biochemical methods 
Ethoxyresorufin- and pentoxyresorufin-O-dealkylase activity 
Approximately 0.05mg or 0.15mg microsomal protein was incubated with 
ethoxyresorufin or pentoxyresorufin, respectively, in 1ml phosphate 
buffer (pH 7.4). Formation of the common metabolite, resorufin, was 
monitored continuously at 370C for about 5min. 
p-Nitrophenol hydroxylase activity 
Approximately 0.25mg - 0.5mg protein in 0.5m1 potassium phosphate 
buffer (pH 6.8) was incubated with p-nitrophenol for 10min at 37°C. 
Formation of 4-nitrocatechol was determined by u. v. detection (250nm) 
following separation by reverse-phase HPLC. 
Nifedipine oxidase activity 
Approximately 0.5mg microsomal protein in 1ml KC1/ phosphate buffer 
(pH 7.4) was incubated with nifedipine for 10min. The reaction was 
terminated by addition of 400gl Tris buffer (pH 9.0) and samples analysed 
for formation of the metabolite Ml by GC with electron capture detection. 
Flavin monooxygenase activity 
Approximately 0.1mg microsomal protein was incubated with N, N- 
dimethylaniline (12.5mM) in a total volume of 0.2m1 glycine buffer, pH 
8.5. The reaction was terminated after 10min and formation of 
dimethylaniline N-oxide determined by GC with FID detection. 
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Paraoxonase activity 
Approximately 0.1mg microsomal protein was incubated with paraoxon in 
a total volume of 3m1 glycine buffer (pH 9.0) held at 300C. Production of 
the metabolite, p-nitrophenol, was monitored continuously at 412nm for 
about 3min and the rate of reaction determined. 
Phenylvalerate hydrolase activity 
Liver microsomes were diluted appropriately so that approximately 0.5ng 
microsomal protein was incubated with phenylvalerate in a total volume 
of 0.4m1 Tris/ EDTA buffer, pH 8.0. Incubations were terminated after 
10min and formation of phenol determined photometrically at 510nm. 
Parathion metabolism 
Approximately 0.3mg microsomal protein was incubated for 10min in the 
presence of NADPH and parathion (20µM and 200µM, final concentration) 
with Tris/ calcium buffer (pH 7.4) to 0.5m1. Samples containing either no 
microsomal protein or no NADPH were carried through the procedure in 
parallel. Formation of p-nitrophenol and paraoxon was determined by 
HPLC with u. v. detection. 
Data from each of the treatment groups were compared to appropriate 
control measurements and percentage change in enzyme levels calculated. 
Methods for liver microsome preparation, and total P450 and enzyme 
measurements are described in chapters 7 and 8, respectively. The 
microsomal protein concentration of each of the preparations was 
determined by the method of Lowry adapted by Peterson (1977) using 
bovine serum albumin as standard, as described in chapter 7. 
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9.3 Results 
9.3.1 Control enzyme activities 
The control measurements for P450, FMO and esterase activities given in 
this chapter relate to the saline treatment group of rats of the induction 
study. Control P450 content was 0.534 ± 0.062 nmol/ mg protein. 
Table 9.1 Ethoxy- and pentoxyresorufin-O-dealkylase activities of control 
rat liver microsomal fractions. Results are the mean ± sem, n=5. The 
substrate concentrations were 24M. 
Expression of activity Ethoxyresorufin-O- Pentoxyresorufin-O- 
dealkylase activity dealkylase activity 
pmol/ min/ mg protein 28.1 ± 2.4 4.2 ± 0.33 
pmol/ min/ g liver 317.8 ± 33.5 47.0 ± 4.9 
pmol/ min/ nmol total 
t 
P450 
I 
53.8±4.1 
:: 
8.010.66 
The ethoxyresorufin- and pentoxyresorufin-O-dealkylase activities for 
control rat liver microsomes, measured at saturating substrate 
concentrations, are given in table 9.1. Activities quoted in the literature for 
ethoxyresorufin-O-dealkylase activity range from 12pmol/ min/ mg 
protein (Walther et al, 1987) to about 60pmol/ min/ mg protein (Toftgard 
and Nilsen, 1982; Gulyaeva et al, 1993) and the values determined in this 
study (28.1 ± 2.4pmol/ min/ mg protein) are within this range. 
Pentoxyresorufin-O-dealkylase activity, at 4.2pmol/ min/ mg protein, was 
about seven fold lower than that obtained for the O-dealkylation of 
ethoxyresorufin, whether activity was expressed /mg protein, /g liver or 
/nmol total P450. 
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Table 9.2 p-Nitrophenol hydroxylase activities of control rat liver 
microsomal fractions. Results are the mean ± sem, n=5. The substrate 
concentration was 200uM. 
Expression of activity p-Nitrophenol hydroxylase activity 
nmol/ min/ mg protein 0.707 ± 0.065 
nmol/ min/ g liver 7.79 ± 0.66 
nmol/ min/ nmol total P450 1.36 ± 0.13 
Control rat liver microsomes produced 0.707 ± 0.065 nmol 4-nitrocatechol/ 
min/ mg microsomal protein at saturating substrate concentration (table 
9.2) which compares with the rate of 0.740 ± 0.07 nmol 4-nitrocatechol/ 
min/ mg microsomal protein reported by Reinke and Moyer (1985) for 
Sprague Dawley rats. 
Table 9.3 Nifedipine oxidase activities of control rat liver microsomal 
fractions. Results are the mean ± sem, n=5. The substrate concentration 
was 100uM. 
Expression of activity Nifedipine oxidase activity 
nmol/ min/ mg protein 1.74 ± 0.12 
nmol/ min/ liver 23.7 ± 2.6 
nmol/ min/ nmol total P450 3.41 ± 0.41 
Non-enzymatic formation of M1 from nifedipine was <5% of that 
produced by liver microsomes using the conditions described above. This 
value was subtracted from that produced by the microsomal incubations. 
Literature quotes for the rate of nifedipine oxidation by mature male rat 
liver microsomes vary widely. For example, Niwa et al (1995) gave a value 
of 2.69 nmol/ min/ mg protein, while Yamazaki et al (1996) reported 3.40 
nmol/ min/ mg protein. A study by Guengerich et al (1986) determined a 
rate of 5.34 nmol/ min/ mg protein for adult male rats and 1.65 nmol/ 
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min/ mg protein in immature (100g) animals. In the present study control 
rat liver microsomes produced 1.74 ± 0.12 nmol/ min/ mg microsomal 
protein at saturating substrate concentration (table 9.3) which compares to 
0.82 ± 0.19 nmol/ min/ mg microsomal protein given in a recent study by 
Shimada et al (1997). The Shimada (1997) study also expressed the 
formation of M1 per nmol P450 and at 1.22 ± 0.28, relates to that 
determined in this study (3.41 ± 0.41 nmol/ min/ nmol total P450). 
Control liver FMO activity was 25.3 ± 1.39 nmol dimethylaniline N-oxide 
formed/ min/ mg protein (n=5) which is approximately 25 fold greater 
than that reported by Damani and Houdi (1988) for Sprague Dawley rats. 
This inconsistency may reflect differences in husbandry since dietary 
components, notably organic nitrogen and sulphur soft nucleophiles 
which are abundant in food derived from plants, are known to modulate 
FMO activity (Ziegler, 1993). 
Table 9.4 Paraoxonase activity of control rat liver microsomal fractions 
measured at pH 7.4 and pH 9.0. Results are the mean ± sem, n=5. Substrate 
concentration was 1mM. 
Assay pH Paraoxonase activity 
(nmol/ min/ mg protein) (nmol/ min/ g liver) 
7.4 2.06±0.38 26.2 ± 4.6 
9.0 46.3 4.9 591.9±48.6 
Non-enzymatic formation of p-nitrophenol from paraoxon was negligible 
under the conditions described above (pH 7.4 and pH 9.0). Preliminary 
experiments showed that pH 9.0 was optimal for measurement of rodent 
liver paraoxonase activity (see chapter 8). Enzyme activity was 
approximately twentytwo-fold higher at optimal pH compared to that at 
physiological conditions, pH 7.4. Plasma paraoxonase activity (64 ±3 
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nmol/ min/ ml) for Wistar rats measured at optimal pH conditions (pH 
10.5) was almost ten-fold lower than the liver activity at pH 9.0 (Mutch, 
1992). 
Table 9.5 Phenylvalerate hydrolase activities of control rat liver 
microsomal fractions. Results are the mean ± sem, n=5. Substrate 
concentration was 1.4mM. 
ssion of activi Phenvlvalerate ase activi 
mmol/ min/ 
mmol/ min/ g liver 
5.65 ± 0.30 
68.9 ± 4.6 
Non-enzymatic formation of phenol from phenylvalerate was <10% using 
the conditions described above. Control liver microsomal activities are 
given in table 9.5. 
Table 9.6 Parathion metabolism by control rat liver microsomal fractions. 
Results are the mean ± sem (n=5). 
Parathion conc. 
(µM) 
Paraoxon formation 
(pmol/ min/ mg protein) 
p-Nitrophenol formation 
(pmol/ min/ mg protein) 
20 241±17 235±15 
200 256 ±18 220 ± 23 
Formation of p-nitrophenol and paraoxon from parathion (20µM and 
200µM) by control rat liver microsomes are shown in table 9.6. There was 
no difference between p-nitrophenol and paraoxon levels at either 
parathion concentration. The reaction was entirely dependent on 
microsomal protein and NADPH. 
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9.3.2 The effect of induction on physiological parameters 
The effects of the inducers on physiological parameters are given in tables 
9.7 and 9.8. 
Table 9.7 Body weights of rats at the beginning and end of the induction 
study. Results are expressed as the mean ± sem (n = 5). 
Treatment group Body weight at start (g) Body weight at end (g) 
Saline control 332 ±9 337 ±8 
Phenobarbital 325 ±5 312* ±7 
Ethanol 318±4 320±2 
Corn oil control 356 ± 10 363 ± 11 
Dexamethasone 331 ± 14 278** f 13 
ß-Na hthoflavone 359 ± 12 358 f9 
* significantly lower than weight at the start of the study and saline 
control, p<0.05 (ANOVA with modified t-test) 
** significantly lower than weight at the start of the study, ß- 
naphthoflavone and corn oil control, p<0.05 (ANOVA with modified t- 
test) 
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Table 9.8 Liver weight, microsomal protein recovery and total P450 
content of the microsomes at the end of the induction study. Results are 
expressed as the mean ± sem (n = 5). 
Treatment group Weight of 
liver 
(% body 
weight) 
Weight of 
liver (g) 
Microsomal 
recovery 
(mg protein/ 
g liver) 
Total P450 
content 
(nmol/ mg 
protein) 
Saline control 5.04** ± 0.14 16.7 ± 0.46 12.2 ± 0.73 0.534 ± 0.06 
Phenobarbital 5.18 ± 0.18 16.1 ± 0.57 22.0@ ± 2.37 0.754© ± 0.07 
Ethanol 4.37a f 0.07 14. Oa ± 0.21 19.7@ ± 1.45 0.484 ± 0.03 
Corn oil control 4.59 ± 0.14 16.7 ± 0.52 15.3** ± 0.55 0.818** ± 0.03 
Dexamethasone 6.00* f 0.41 16.7 ± 1.15 16.4* ± 0.59 1.030* t 0.10 
ß-Na hthoflavone 5.09* ± 0.14 18.2* ± 0.49 13.5 ± 1.39 0.911 t 0.05 
Comparisons were by ANOVA with modified t-test. 
Weight of liver (% body weight) 
**saline control significantly higher than corn oil control, p<0.05 
a significantly lower than saline control, p<0.05 
* significantly higher than corn oil control, p<0.05 
Weight of liver 
a significantly lower than saline control, p<0.05 
* significantly higher than corn oil control, p<0.05 
Microsomal protein recovery 
**corn oil control significantly higher than saline control, p<0.05 
Q significantly higher than saline control, p<0.05 
* significantly higher than corn oil control, p<0.05 
Total P450 content of microsomes 
**corn oil control significantly higher than saline control, p<0.05 
© significantly higher than saline control, p<0.05 
* significantly higher than corn oil control, p<0.05 
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At the end of the study it was noted that the dexamethasone-treated 
animals, and to some extent the phenobarbital group, were eating poorly 
and demonstrated general malaise. This was corroborated post mortem 
since both these groups showed significantly lower body weights in 
comparison to the start of the study (table 9.8). It was observed that the 
animals in the ethanol group drank normally and showed no significant 
change in body weight. 
The corn oil control animals showed a significant loss in liver weight (as a 
percent of body weight), a higher microsomal protein recovery and a 
higher total P450 content compared to saline controls. 
9.3.3 The effect of induction on the cytochromes P450 and esterases 
The effect of inducers on total cytochrome P450 content is given in figure 
9.1. As expected, ethoxy- and pentoxyresorufin-O-dealkylase activities were 
enhanced (approximately 50-fold) by ß-naphthoflavone and phenobarbital 
pre-treatment, respectively, compared to their respective controls (figures 
9.2 and 9.3). Also as expected p-nitrophenol hydroxylase (figure 9.4) and 
nifedipine oxidase (figure 9.5) activities were increased (approximately 2- 
fold and 5-fold) by ethanol and dexamethasone pre-treatments, 
respectively. 
Unexpectedly, the corn oil control group showed lower pentoxyresorufin- 
O-dealkylase, p-nitrophenol hydroxylase and nifedipine oxidase 
activivities compared to saline controls. Conversely, the ethoxyresorufin- 
O-dealkylase activity of corn oil controls was not significantly different 
from the saline control group. These data are given in table 9.9. 
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** p<0.05, lower compared to corn oil control 
* p<0.05 compared to appropriate control 
(ANOVA with modified t test) 
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Figure 9.2 
Ethoxyresorufin-0-dealkylase activity 
of rat liver microsomes: 
INDUCER 
* p<0.05 compared to appropriate control 
(ANOVA with modified t test) 
Control 100%%l activities 
28.1 ± 2.4 pmoles/ min/ mg protein (Saline controls) 
27.8 ± 3.4 pmoles/ min/ mg protein (Corn oil controls) 
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Figure 9.3 
Pentoxyresorufin-0-dealkylase activity 
of rat livor mirrncnmPS 
INDUCER 
* p<0.05 compared to appropriate control 
(ANOVA with modified t test) 
Control (100%%) activities 
4.2 ± 0.33 pmoles/ min/ mg protein (Saline controls) 
2.2 ± 0.08 pmoles/ min/ mg protein (Corn oil controls) 
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Figure 9.4 
p-Nitrophenol hydroxylase activity 
INDUCER 
* p<0.05 compared to appropriate control 
(ANOVA with modified t test) 
Control 100%) activities 
0.707 ± 0.07 nmoles/ min/ mg protein (Saline controls) 
0.388 ± 0.05 nmoles/ min/ mg protein (Corn oil controls) 
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INDUCER 
* p<0.05, higher compared to appropriate control 
** p<0.05, lower compared to appropriate control 
(ANOVA with modified t test) 
Control (100%) activities 
1.74 ± 0.12 nmoles/ min/ mg protein (Saline controls) 
1.21 ± 0.08 nmoles/ min/ mg protein (Corn oil controls) 
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Figure 9.5 
Nifedipine oxidase activity of 
Table 9.9 The effects of corn oil pre-treatment on various cytochromes 
P450 of rat liver. Results are the mean ± sem for n=5 rats. 
Activity Saline controls Corn oil controls 
aEthoxyresorufin -O-dealk lase 28.1 ± 2.4 27.8 ± 3.4 
aPentox resorufin-O-dealk lase 4.2 ± 0.33 2.2 ± 0.08* 
bp-Nitro henol h drox lase 0.707 ± 0.07 0.388 f 0.05* 
bNifedipine oxidase 1.74 ± 0.12 1.21 f 0.08* 
* p<0.05, compared to saline control activity (students t-test) 
a pmol/ min/ mg protein 
b nmol/ min/ mg protein 
Unexpectedly, the corn oil control group showed lower liver paraoxonase 
activity (pH 9.0), whether expressed per mg protein (figure 9.6) or per gram 
of liver (figure 9.7), compared to the saline controls. This effect was not 
apparent when the activity was measured at physiological pH (pH 7.4) 
(figures 9.8 and 9.9). Conversely, when activity was expressed per gram of 
liver the rate of phenylvalerate hydrolysis was increased by corn oil pre- 
treatment (figures 9.10 and 9.11). 
At optimal pH (pH 9.0) for paraoxonase, ethanol and phenobarbital pre- 
treatments decreased the activity, whether expressed per mg protein or per 
gram of liver, compared to control. At physiological pH, dexamethasone 
caused a decrease in paraoxonase activity (whether expressed per mg 
protein or per gram of liver) while phenobarbital only had this effect 
when activity was expressed per mg protein. Ethanol pre-treatment 
increased the rate of hydrolysis of paraoxon at physiological pH, but this 
was true only when activity was expressed per gram of liver. 
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* p<0.05, lower compared to saline control 
** p<0.05, higher compared to corn oil control 
(ANOVA with modified t test) 
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Figure 9.6 
Rat liver paraoxonase activity (30°C) measured 
at pH 9.0 with 1mM paraoxon: 
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INDUCER 
* p<0.05, lower compared to saline control 
** p<0.05, higher compared to corn oil control 
(ANOVA with modified t test) 
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Figure 9.7 
Rat liver paraoxonase activity (30°C) measured 
at pH 9.0 with 1mM paraoxon: 
3.0 
Figure 9.8 
Rat liver paraoxonase activity (30°C) 
measured at pH 7.4 with 1mM paraoxon: 
the effect of pretreatment with various inducers 
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* p<0.05 compared to appropriate control 
(ANOVA with modified t test) 
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Figure 9.9 
Rat liver paraoxonase activiy (30°C) 
measured at pH 7.4 with 1 mM paraoxon: 
INDUCER 
* p<0.05 compared to appropriate control 
(ANOVA with modified t test) 
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Figure 9.10 
Rat liver phenylvalerate hydrolase (1.4mM) 
activity measured at pH 8.0: 
INDUCER 
* p<0.05 compared to corn oil control 
(ANOVA with modified t test) 
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Figure 9.11 
Rat liver phenylvalerate hydrolase (1.4mM) 
activity measured at pH 8.0: 
the effect of pre-treatment with various inducers 
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** p<0.05, higher compared to saline control 
(ANOVA with modified t test) 
" Corn oil control 
® Dexamethasone 
b Naphthoflavone 
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Dexamethasone pre-treatment decreased phenylvalerate hydrolase 
activity, whether expressed per mg protein or per gram of liver, compared 
to control. Ethanol and phenobarbital pre-treatments increased the rate of 
hydrolysis of phenylvalerate, but only when activities were expressed per 
gram of liver. 
9.3.4 The effect of induction on parathion metabolism 
Parathion (200µM) was metabolised to paraoxon (234.0 ± 28.1 and 155.1 ± 
13.6, pmol/ min/ mg protein for saline and corn oil-treated controls, 
respectively) and p-nitrophenol (407.8 ± 45.2 and 271.3 ± 22.4 pmol/ min/ 
mg protein by microsomes from saline and corn oil controls, respectively) 
by rat liver microsomes. The activities of saline and corn oil dosed 
animals were significantly different for both paraoxon and p-nitrophenol 
formation (figures 9.12 and 9.13), although the paraoxon/ p-nitrophenol 
ratio was similar for both control groups (figure 9.14). 
The formation of both paraoxon and p-nitrophenol from parathion by 
dexamethasone-treated livers was enhanced about 3-fold compared to corn 
oil controls, while the other regimens had a less pronounced effect. 
Notably, ß-naphthoflavone pre-treatment gave rise to a 2-fold increase in 
paraoxon formation and a smaller, but significant, increase in p- 
nitrophenol formation. Phenobarbital pre-treatment also significantly 
enhanced formation of paraoxon but failed to increase p-nitrophenol 
formation (p=0.07). Although ethanol pre-treatment did not enhance 
paraoxon or p-nitrophenol formation individually, it did significantly 
increase the paraoxon/ p-nitrophenol ratio (figures 9.12,9.13 and 9.14). 
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* p<0.05 compared to saline control 
** p<0.05 compared to corn oil control 
c p<0.05, higher compared to corn oil control 
(ANOVA with modified t test) 
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Figure 9.12 
The effect of inducers on production of paraoxon 
from parathion (200µM) by rat liver microsomes 
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Figure 9.13 
The effect of inducers on production of p-nitrophenol 
from parathion (200µM) by rat liver microsomes 
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Figure 9.14 
The effect of inducers on the production of 
paraoxon and p-nitrophenol from parathion 
by rat liver microsomes. Data is expressed as the ratio 
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9.4 Discussion 
Initial studies defined control activities for the cytochromes P450 and 
esterases which may be involved in the metabolism of parathion and 
found them to be comparable with literature reports. Since literature 
reports (Hodgson and Levi, 1992) of structure/ activity relationships 
suggested that FMO was not involved in parathion metabolism this 
pathway was investigated no further. 
Using the assay conditions described p-nitrophenol and paraoxon 
formation was entirely dependent on microsomal protein and NADPH 
which indicates P450-mediated reaction(s), rather than spontaneous 
degradation or carboxylesterase-mediated hydrolysis of the substrate. 
Parathion metabolism was determined at pH 7.4 which was optimal for 
cytochrome P450-mediated reactions. However, under these conditions 
hydrolysis of paraoxon by paraoxonase would be negligible since pH 9.0 is 
optimal for this esterase. These observations suggested that the p- 
nitrophenol and paraoxon levels determined in this study were directly 
the result of a cytochrome P450-mediated reaction(s). 
Unexpectedly, corn oil treatment caused a significant decrease in the ratio 
of liver weight to body weight compared to saline controls. Additionally, 
recovery of microsomal protein and P450 content of the corn oil-treated 
livers was significantly higher than in the saline control animals. This 
suggested induction of membrane proteins, including P450s, by corn oil 
with a concomitant decrease in liver weight. Other researchers have 
observed similar changes following treatment with corn oil. For example, 
a recent study by Kojo and co-workers (1996) demonstrated significantly 
lowered catalytic activities for the P450 2A and 2B subfamilies 24h after 
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corn oil treatment compared to untreated controls and speculated that this 
effect may be related to disturbances in fatty acyl homeostasis which can 
influence the function of membrane-bound proteins, such as the P450s 
(Kojo et al, 1996). This may be an explanation for the results seen in the 
present study and demonstrates the need for inclusion of appropriate 
vehicle controls when conducting such investigations. It was assumed 
that the effects of the inducers were so great compared to the effects of corn 
oil that the outcome of these compounds may be considered distinct from 
those of the oil. 
Ethanol treatment caused a significant decrease in liver weight and in the 
ratio of liver weight to body weight compared to saline controls. 
Microsomal protein recovery was increased but, since P450 content 
remained unchanged, presumably the level of other membrane proteins 
were preferentially increased with this treatment. Conversely, 
dexamethasone and ß-naphthoflavone treatment increased the ratio of 
liver weight to body weight compared to corn oil controls which relates to 
the observation that both these compounds gave rise to a mottled 
appearance to the livers. Dexamethasone, but not ß-naphthoflavone 
treatment, also caused an increase in microsomal protein recovery and 
total P450 content. Although phenobarbital treatment did not significantly 
increase the ratio of liver weight to body weight, it did significantly 
increase microsomal protein recovery and total P450 content compared to 
saline controls. 
The poor level of enhancement of p-nitrophenol hydroxylase activity by 
ethanol corroborates the observation that the total P450 content of these 
livers was not increased following this treatment. A regimen involving 
ethanol treatment by i. p. injection may have been a more efficient method 
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to induce CYP2E1. Low level (approximately equivalent to the plasma 
ethanol concentration after two units of alcoholic beverage) ethanol 
exposure has been shown to induce CYP3A (and CYP2E1) in human 
hepatocyte cultures in vitro (Kostrubsky et al, 19951. In this study, 
however, pre-treatment with ethanol had no effect on any of the CYPs 
measured, other than CYP2E1. 
In addition to the expected induction of pentoxyresorufin-O-dealkylation 
by phenobarbital (approximately 50-fold), this pre-treatment also enhanced 
p-nitrophenol hydroxylation (CYP2E1), by about 2-fold. Barbiturates, such 
as phenobarbital, are well known powerful inducers of cytochromes P450 
2B1/2 (as well as other enzyme systems) in rat liver (Parkinson, 1996). 
ß-Naphthoflavone pre-treatment, as expected, induced the rate of 
ethoxyresorufin-O-dealkylation (CYP1A), by about 50-fold, but also 
enhanced the O-dealkylation of pentoxyresorufin (approximately 5-fold). 
Conversely, this pre-treatment had no effect on p-nitrophenol 
hydroxylation and significantly lowered nifedipine oxidation. Treatment 
of rats with ß-naphthoflavone is known to give rise to prominent 
induction of CYP1A1, which is virtually undetectable in control liver, and 
also probably of the constitutive isoform, CYP1A2. Enhanced 
pentoxyresorufin-O-dealkylation following ß-naphthoflavone treatment 
has also been observed by Burke et al (1994) who confirmed that 
pentoxyresorufin is mainly metabolised by the CYP1A subfamily in ß- 
naphthoflavone-induced rat liver microsomes. 
The induction of nifedipine oxidase activity was mediated exclusively by 
dexamethasone and therefore metabolism of this substrate by these 
induced livers would have principally involved CYP3A1 (the inducible 
158 
CYP3A male rat liver isoform), since the constitutive CYP3A2 isoform is 
not affected by this inducer (Lindamood, 1991). The mechanism of 
dexamethasone induction involves transcriptional activation and mRNA 
stabilisation (Soucek and Gut, 1992). Other researchers (Soucek and Gut, 
1992) have suggested that CYP3A1 is also inducible by phenobarbital, 
although this was not indicated in the present study since nifedipine 
oxidation was not increased by phenobarbital pre-treatment. This anomaly 
may result from the choice of substrate for CYP3A activity since it is 
known that nifedipine is metabolised by CYP3A2 and CYP2C11 in control 
male rat liver (Guengerich et al, 1986) and paradoxically CYP2C11, the 
isoform of highest constitutive activity in male rat liver, is decreased by 
phenobarbital pre-treatment (Parkinson, 1996). 
Dexamethasone pre-treatment also enhanced ethoxyresorufin-O- 
dealkylase and pentoxyresorufin-O-dealkylase activities (3-fold and 15-fold, 
respectively) and, unexpectedly, induced p-nitrophenol hydroxylase 
activity to a greater extent (3-fold) than that observed by ethanol (2-fold). 
Induction of CYP2B (pentoxyresorufin-O-dealkylase) by dexamethasone 
has been well documented (Rao et al, 1990) although the mechanism of 
this induction is not yet understood. 
The esterase study showed that the rate of phenylvalerate hydrolysis was 
increased by corn oil pre-treatment when activity was expressed per gram 
of liver. However, the corn oil vehicle had no appreciable effect on 
paraoxonase activity at physiological pH, although activity was decreased 
at pH 9.0 compared to saline controls. The observed increase in 
phenylvalerate hydrolysis was contrary to a report by Watson et al (1994) 
which considered corn oil treatment responsible for lowered microsomal 
carboxylesterase activity compared to untreated controls. These authors 
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suggested that altered membrane properties may have affected the 
configuration of the carboxylesterase molecule and so caused the lowered 
activity. 
For several reasons measurement of esterase activity at physiological pH 
was more appropriate than determinations made at optimal pH. Firstly, 
data obtained at pH 7.4 would be more applicable to the situation in vivo, 
even though the concentration of paraoxon (in the case of paraoxonase 
measurement) used in vitro would be lethal if encountered in vivo. 
Although esterases often have non-physiological pH optima, this is not 
true of the cytochromes P450, which have a requirement for 
approximately pH 7.4. It follows that, when investigating metabolism of 
phosphorothioates in which P450 and esterase pathways function in 
parallel, the in vitro system utilised should be maintained at 
physiological pH. 
At physiological pH, dexamethasone, and possibly phenobarbital (when 
activity was expressed per mg protein), decreased paraoxonase activity. 
Taken in isolation, this suggested a decreased capacity to detoxify toxic 
oxons, such as paraoxon, following co-administration of these drugs. 
McCracken et al (1993), however, demonstrated that hepatic microsomal 
paraoxonase activity was enhanced approximately two-fold by 
phenobarbital pre-treatment, the reasons for the anomaly between the two 
sets of data are unknown. Conversely, ethanol pre-treatment increased the 
rate of hydrolysis of paraoxon (expressed per gram of liver) which, if taken 
per se, indicates enhanced detoxification capacity. 
When measurements were made at pH 9.0, which was optimal for 
paraoxonase activity, ethanol and phenobarbital pre-treatments were seen 
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to decrease the rate of hydrolysis of paraoxon. However, the decrease in 
paraoxonase activity by dexamethasone observed at physiological pH, was 
not seen at pH 9.0, although this result may have been confounded by the 
inhibitory effects of corn oil on the control group at this pH. 
Dexamethasone pre-treatment decreased carboxylesterase and 
cholinesterase activity, whether activity was expressed per mg protein or 
per gram of liver. Conversely, ethanol- and phenobarbital-treated livers 
had enhanced hydrolytic activity towards phenylvalerate, but only when 
expressed per gram of liver. Several research groups (eg Chambers et al, 
1994) have also observed an increase in carboxylesterase activity following 
phenobarbital treatment, however the effect of ethanol on these esterases 
has not been studied. These data suggest that administration of ethanol or 
phenobarbital may increase hepatic capacity to detoxify oxons by this 
pathway which may contribute to the attenuation of toxicity following 
exposure to phosphorothioates. 
The study of parathion metabolism suggested the participation of CYP3A 
in the reaction since paraoxon and p-nitrophenol formation was increased 
by dexamethasone in parallel with nifedipine oxidation (a CYP3A- 
mediated reaction). Cytochromes P450 1A1/2 also had the capacity to 
metabolise parathion following induction (with ß-naphthoflavone), 
although they are minor isoforms in untreated animals. The paraoxon/ p- 
nitrophenol ratio was also significantly perturbed following both 
dexamethasone and ß-naphthoflavone pre-treatments, possibly suggesting 
that the metabolites were not derived from a common intermediate or, 
perhaps, that further metabolism had taken place following induction. 
Interestingly, a recent study by Zerilli et al (1997) suggested that CYP3A was 
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responsible for about 50% of p-nitrophenol hydroxylation in liver 
microsomes from dexamethasone pre-treated rats. 
An investigation by O'Shaughnessy and Sultatos (1995) of the effects in 
vitro of ethanol on parathion metabolism in the mouse showed that this 
compound did not directly affect the P450-mediated metabolism of this 
phosphorothioate. However, ethanol was demonstrated to antagonise it's 
acute toxicity in vivo. The authors suggested that this attenuation of 
toxicity may have resulted from a reduced availability of molecular oxygen 
which decreased the P450-mediated activation of parathion in vivo. The 
data obtained in the present study for ethanol was puzzling since neither 
paraoxon nor p-nitrophenol formation was increased by ethanol pre- 
treatment, yet the paraoxon/ p-nitrophenol ratio was significantly 
perturbed. This indicates that CYP2E1 was not involved in the activation 
of parathion but, perhaps, increased levels of this P450 isoform was 
involved in the further metabolism of p-nitrophenol. 
The increase in paraoxon formation following phenobarbital treatment 
suggested that CYP2B may also play a role in parathion activation in the 
induced animal, although this compound has also been well documented 
to also induce CYP3A in the rat (Okey et al, 1990). Induction of CYP3A by 
phenobarbital was not confirmed in the present study since nifedipine 
oxidation was not increased. This result, however, may be an anomaly and 
due to the choice of substrate for CYP3A activity, rather than a lack of 
induction of CYP3A. p-Nitrophenol production was not significantly 
increased by phenobarbital pre-treatment and therefore did not parallel the 
enhanced paraoxon formation. However, the variability of these data were 
large and influenced the significance of the result. Alternatively, increased 
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levels of CYP2E1 may have been involved in further metabolism of p- 
nitrophenol. 
In conclusion, these data demonstrated that the respective P450s were 
effectively enhanced by the induction regimen. However, it was difficult 
to pinpoint the P450 isoform(s) responsible for the metabolism of 
parathion from the induction study alone, but P450s 3A, 1A and possibly 
2B were implicated in the induced animal. Interpretation of data was 
confounded by the fact that the substrates used were not specific for a 
particular isoform and that induction by a particular compound was not 
specific to an individual P450 isoform. 
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Chapter 10 
Chapter 10 Rat inhibition studies in vitro 
10.1 Introduction 
It was clear from the induction studies that parathion could be 
metabolised by a P450-mediated reaction(s) which involved the 
cytochromes P450 3A, 1A and possibly 2B in induced rat liver microsomes. 
It was also shown that the toxic oxon, paraoxon, was detoxified by several 
esterase pathways. In this chapter the ability of control rat liver 
microsomes to metabolise parathion was modulated by pre-incubation 
with various P450 inhibitors, in vitro. The aim of these studies was 
therefore to indicate the constitutive P450 isoform(s) involved in 
parathion metabolism. The inhibitors used in the study were chosen from 
the literature on the basis of effects on human P450 isoforms as little 
information was available for the rat orthologous forms. 
Since the induction study strongly implicated CYP3A in parathion 
metabolism, several inhibitors of this subfamily were used, namely 
naringenin, troleandomycin, quercetin and ketoconazole (Guengerich and 
Kim, 1990; Maurice et al, 1992 and Guengerich, 1990). Quinidine is an 
inhibitor of the human P450 2D6 subfamily (Guengerich et al, 1986) and a- 
naphthoflavone inhibited P450 1A reactions (Shimada and Guengerich, 
1991). Diethyldithiocarbamate (DEDC) is an inhibitor of cytochromes P450 
2E1 and 2A6 in man (Yamazaki et al, 1992), tolbutamide is a substrate for 
human P450 2C9 (Gonzales, 1992) and sulphaphenazole is an inhibitor of 
P450 2C9 (Baldwin et al, 1995). Metyrapone is a non-specific inhibitor of 
P450 2B. 
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Naringenin, quercetin and ketoconazole are reversible inhibitors of P450 
3A and troleandomycin is a mechanism-based inhibitor of this P450 
subfamily. Quinidine is a reversible inhibitor of P450 2D6 and a substrate 
for P450 3A at concentrations above 100µM. Diethyldithiocarbamate is a 
mechanism-based inhibitor of P450 2E1 and a-naphthoflavone, which 
was used in this study as an inhibitor of P450 1A, has also been shown to 
enhance some P450 3A reactions (Shou et al, 1994). 
Table 10.1 A list of the inhibitors /substrates used in the study and 
cytochromes P450 involved. 
Inhibitor/ Substrate P450 affected 
Naringenin 3A 
*Troleandomycin 3A 
Quercetin 3A 
Ketoconazole 3A 
Quinidine 2D6 
Metyrapone 2B 
a-Naphthoflavone 1A 
*Diethyldithiocarbamate 2E1 
©Tolbutamide 2C9 
Sulphaphenazole 2C9 
* mechanism-based inhibitor 
® substrate for 2C9 
Initial studies in this chapter determined the inhibition profile of 
nifedipine oxidation, the chosen marker reaction for CYP3A activity, with 
the various compounds in vitro. This was then compared to the profile 
for inhibition of parathion (20µM and 200µM) metabolism in order to 
indicate the constitutive P450 isoform(s) involved. 
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10.2 Methods 
Liver microsomes were prepared from 3 male Wistar rats weighing 
approximately 250g by the method described in chapter 7. The microsomal 
protein concentration of the preparations was determined by the method 
of Lowry adapted by Peterson (1977) using bovine serum albumin as 
standard, as described in chapter 7. Biochemical methods for nifedipine 
oxidation and parathion metabolism are described in chapter 8. Activities 
for each of the inhibitor treatments were compared to appropriate vehicle 
control measurements and percentage change in enzyme levels calculated. 
10.2.1 Inhibition of nifedipine oxidation 
Inhibitors 
Naringenin, troleandomycin and ketoconazole were dissolved in 
methanol, and quercetin and quinidine in dimethylsulphoxide (DMSO) to 
give 20mM stock solutions. The naringenin and troleandomycin stock 
solutions were then diluted in methanol to give 8mM solutions and 
ketoconazole stock diluted in methanol to give a 1mM solution. 
Inhibitors (5µl) or vehicle (5µl DMSO or methanol, control) were added to 
incubation tubes containing NADPH (0.6mg) and microsomal protein 
(approx. 0.4mg ) made up to 1ml with phosphate buffer (pH 7.4). This gave 
final inhibitor concentrations of 100µM (20mM stocks, n=3 rats), 40µM 
(8mM stocks, n=2 rats) and 5µM (1mM stock, n=2 rats). The tubes were pre- 
incubated with inhibitors or vehicle for 10min prior to starting the 
reaction by the addition of nifedipine (5µM and 100µM, final 
concentration). The reaction was terminated after 20min by addition of 
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400µ1 Tris buffer (pH 9.0) and formation of Ml determined by GC with 
electron capture detection. 
10.2.2 Inhibition of parathion metabolism 
Inhibitors 
Naringenin, ketoconazole, metyrapone, diethyldithiocarbamate and 
tolbutamide were dissolved in methanol, and a-naphthoflavone in 
dimethylsulphoxide (DMSO) to give 100mM stock solutions, then 1: 10 
dilutions of each were prepared to give 10mM stocks. Troleandomycin was 
dissolved in methanol, and quercetin and quinidine in DMSO to give 
10mM working stock solutions. Similarly, sulphaphenazole was dissolved 
in methanol to give a 10mM stock solution, this was diluted 1: 10 to give a 
1mM working stock. 
Inhibitors (5p1) or vehicle (5p1 DMSO or methanol, control) were added to 
incubation tubes containing NADPH (0.3mg) and microsomal protein 
(approx. 0.3mg) made up to 0.5m1 with Tris/ calcium buffer (pH 7.4). This 
gave final inhibitor concentrations of 1mM (100mM stocks, n=3 rats), 
100µM (10mM stocks, n=2 rats) and 10µM (1mM stock, n=3 rats). The tubes 
were pre-incubated with inhibitors or vehicle for 10min prior to starting 
the reaction by the addition of parathion (5µM [or 10µM 
sulphaphenazole], 20µM and 200gM, final concentration). The reaction 
was terminated after 10min (2.5min for 10µM sulphaphenazole/ 5µM 
parathion) by addition of 0.5m1 perchloric acid (20%, w/v) and formation 
of p-nitrophenol and paraoxon determined by HPLC with u. v. detection. 
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10.3 Results 
Individual data for inhibition of nifedipine oxidation and parathion 
metabolism are given in appendix I. 
Concerning nifedipine oxidation, initial studies with inhibitors (100µM) 
and a saturating nifedipine concentration (100µM) (figure 10.1) showed 
significantly reduced (by approximately 60%) formation of Ml following 
the inclusion of naringenin or quinidine in the incubation. The inclusion 
of ketoconazole or quercetin gave rise to complete inhibition of the 
reaction while troleandomycin had no effect. 
Later studies used naringenin (40µM), troleandomycin (40µM) and 
ketoconazole (5µM) with two concentrations of nifedipine, 5µM and 
100µM (figure 10.2). The profile of inhibition was similar for 5µM and 
100µM nifedipine and, although no statistical information was available 
(n=2 rats), the greatest inhibition was seen using naringenin 
(approximately 70%) and ketoconazole (approximately 65%), while 
troleandomycin produced approximately 50% inhibition. 
With reference to parathion (200gM) inhibition and inhibitors (1mM), 
formation of paraoxon (figure 10.3) and p-nitrophenol (figure 10.4) was 
significantly lower following pre-incubation with naringenin and 
ketoconazole (by approximately 50% and 20%, respectively). Activity 
following pre-incubation with metyrapone, a-naphthoflavone and 
tolbutamide was not significantly different from control, while inclusion 
of diethyldithiocarbamate in the incubation significantly increased 
activity. 
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Figure 10.1 
Nifedipine oxidase (100µM) activity of 
frr% I re+ liver mirrncnmac- 
INHIBITOR 
* p<0.05 compared to control activity (Students t test) 
Values are the mean ± sem of n=3 rat liver microsomes 
(triplicate determinations) 
Individual values are given in appendix I 
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(triplicate determinations) 
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Figure 10.2 
Nifedipine oxidase (5µM and 100µM) activity 
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Further studies with parathion (200µM) and inhibitors (100µM) showed 
that the CYP3A inhibitors, with the exception of troleandomycin, 
produced the greatest decrease in activity (figures 10.5 and 10.6). 
Naringenin had the greatest effect (approximately 40% inhibition) on 
formation of both paraoxon and p-nitrophenol from parathion while 
quercetin and ketoconazole inhibited formation of both metabolites by 
about 25%. The other compounds had little effect on formation of p- 
nitrophenol or paraoxon and they appeared to be affected in parallel by the 
inhibitors. 
Studies with parathion (20µM) and inhibitors (100µM) showed that 
troleandomycin slightly increased metabolite formation, whereas 
naringenin had the greatest inhibitory effect (approximately 50% 
inhibition) on formation of both paraoxon and p-nitrophenol (figures 10.7 
and 10.8). The profile of inhibition with quercetin and ketoconazole 
(approximately 25% inhibition) at this parathion concentration was 
similar to that observed with the 200µM substrate concentration. Again 
the other compounds had little effect on formation of p-nitrophenol or 
paraoxon. 
Sulphaphenazole had no inhibitory effect on paraoxon or p-nitrophenol 
formation from parathion (5µM and 200gM), in fact it produced slight 
increases in activity compared to control. Paraoxon and p-nitrophenol 
formation from 5µM parathion was increased by 7.7% ± 5.9% and 32% ± 
18.5%, respectively. Levels were increased by 21% ± 12.4% and 16.0% ± 
18.2%, respectively, from 200gM parathion. 
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* p<0.05, lower compared to control 
** p<0.05, higher compared to control 
(ANOVA with modified t test) 
Values are the mean ± sem of n=3 rat liver microsomes 
(duplicate determinations) 
Individual values are given in appendix I 
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Figure 10.3 
Production of paraoxon from parathion (200pM) 
by rat liver microsomes: 
Figure 10.4 
Production of p-nitrophenol from parathion (200µM) 
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Figure 10.5 
Production of paraoxon from parathion (200µM) 
15o by rat liver microsomes: 1 
the effect of inhibitors (100µM) 
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Values are the mean of 2 rat liver microsomal incubations 
Individual data are given in appendix I 
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Figure 10.6 
Production of p-nitrophenol from parathion (200µM) 
15o by rat liver microsomes: 1 
the effect of inhibitors (100µM) 
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Figure 10.7 
Production of paraoxon from parathion (20µM) 
15o by rat liver microsomes: 1 
the effect of inhibitors (100µM) 
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Values are the mean of 2 rat liver microsomal incubations 
Individual data are given in appendix I 
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Figure 10.8 
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Production of p-nitrophenol from parathion (20µM) 
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10.4 Discussion 
For many years chemical inhibitors have been used as convenient tools 
with which to study metabolism in vitro, mainly because they are usually 
widely available. Many studies using such compounds have been 
reported, often without careful consideration of their specificities. After 
initial studies using high inhibitor concentrations, this investigation 
focused on concentrations which were specific according to the literature. 
The initial studies using non-specific (100µM) inhibitor concentrations 
with nifedipine (100µM) demonstrated, as expected, complete inhibition 
with the CYP3A inhibitors ketoconazole and quercetin, and significantly 
decreased activity on inclusion of naringenin in the incubation mix. The 
decrease in activity observed with quinidine was probably the result of 
competitive inhibition for the CYP3A active site, rather than inhibition of 
CYP2D1, since this compound is a substrate for CYP3A at high (>100pM) 
concentrations (Guengerich et al, 1986). 
However, using specific inhibitor concentrations and nifedipine lesser 
decreases in activity were observed, the most effective inhibitors being 
naringenin and ketoconazole which gave rise to about 70% inhibition. 
The earlier induction study suggested that nifedipine was metabolised by 
CYP3A and probably CYP2C in the rat. Inhibitors of the CYP2C subfamily, 
such as sulphaphenazole which inhibits human CYP2C9, were not 
investigated, but it is possible that inclusion of both CYP3A and CYP2C 
inhibitors (or antibodies) in the incubation would have completely 
inhibited the reaction. 
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Literature reports are conflicting regarding the specificity of 
troleandomycin as an inhibitor of CYP3A reactions. For example, a study 
by Chang and co-workers (1994) using HepG2 hepatoma cells expressed 
with human cytochromes P450, demonstrated that a 20µM concentration 
of troleandomycin yielded maximal complex formed with P450 
haemoproteins. Conversely, others (Ono et al, 1996) using an in vitro 
system similar to Chang et al (and also human liver microsomes), 
reported that 1mM troleandomycin was necessary to inhibit CYP3A- 
mediated reactions. Troleandomycin appears to be very slow-acting in its 
role as a suicide inhibitor, with some researchers (Chang et al, 1994) 
reporting the necessity for pre-incubation times of thirty minutes or more. 
These experiments used a pre-incubation time of ten minutes which may 
have contributed to the lack of observed parathion inhibition. 
The CYP3A inhibitors appeared to have the greatest effect on parathion 
metabolism and, although they never produced complete inhibition, none 
of the other compounds were remarkable. Even CYP1A, which was 
implicated in parathion metabolism by the induction study, did not appear 
to be involved in the reaction in control rat microsomes since minimal 
inhibition was observed with a-naphthoflavone. However, it should be 
noted that constitutive levels of CYP3A2 and CYP1A2 are only 17% and 
2% of the total P450 pool, respectively, (Nedelcheva and Gut, 1994) and 
therefore maximal decreases in activity would not be possible with 
individual inhibitors unless parathion metabolism was exclusive to one 
of these isoforms. 
Further experiments with sulphaphenazole concentrated on investigating 
a role for CYP2C11 in parathion metabolism as this the major constitutive 
rat isoform. It has been demonstrated that CYP2C11 has 1.20 nmoles P450/ 
ýý `' 
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mg microsomal protein, and accounts for 54% of the total P450 pool 
(Nedelcheva and Gut, 1994), compared to 0.39 nmoles P450/ mg 
microsomal protein for CYP3A2 (Guengerich et al, 1982). Surprisingly, 
sulphaphenazole had no inhibitory effect on parathion metabolism at 
high (200µM) or low (5µM) substrate concentrations. Tolbutamide was 
also an ineffective inhibitor of the reaction. Recent studies (Eagling et al 
1998) comparing the selectivity of P450 inhibitors in human and rat liver 
microsomes appear to help elucidate the problem. Eagling et al 
demonstrated that sulphaphenazole was a selective inhibitor of 
tolbutamide hydroxylation in human liver microsomes but failed to 
inhibit the reaction in rat liver microsomes. Moreover, it has been 
suggested (Boobis et al, 1990) that competitive inhibitors (such as 
tolbutamide and sulphaphenazole) do not act via direct competition at the 
active site, and that the inhibitory site is different between species. 
In summary, CYP3A was shown to participate in parathion metabolism in 
control rat microsomes, but it was not the only P450 isoform involved. It 
is possible that CYP2C played a role in the reaction but the present data did 
not support this hypothesis. p-Nitrophenol and paraoxon formation 
appeared to be affected in parallel by the inhibitors which indicated that 
the same P450 isoform(s) may be involved in both the activation and 
detoxification of parathion. These studies also suggested that nifedipine, 
although used by many researchers (Niwa et al, 1995; Shimada et al, 1997) 
as a good marker substrate for rodent CYP3A activity, may not be specific 
for this cytochrome P450 subfamily in the rat. 
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Chapter 11 
Chapter 11 The kinetics of parathion metabolism 
11.1 Introduction 
It was recognised that enzyme activities measured in vitro using routine 
high substrate concentrations may not accurately reflect activities in vivo. 
Furthermore, high substrate concentrations may not be physiologically 
important, particularly in the case of highly toxic phosphorothioates. 
Therefore a kinetic analysis of parathion metabolism was undertaken on 
the premise that this should yield a better assessment of the in vivo 
significance of these reactions. Further studies investigated the kinetics of 
parathion metabolism in the presence of a concentration of ketoconazole 
which should specifically inhibit CYP3A in order to indicate involvement 
of this isoform at substrate concentrations closer to those potentially 
encountered in vivo. 
For most enzyme catalysed reactions, the rate of catalysis (v) varies with 
substrate concentration (s) in a saturable manner such that a plot of v 
against s shows a hyperbolic curve. At a fixed concentration of enzyme, v 
is linearly proportional to s when s is small, i. e. first order reaction 
kinetics. At high s, v is independent of s, i. e. zero order reaction kinetics. 
In 1913 Michaelis and Menten proposed a simple model to account for 
these kinetic characteristics. Thus: 
k 
E+S <=> ES ------> P 
where E is the enzyme, S is the substrate and ES is the enzyme-substrate 
complex and P is the product. The model assumes that the E+S= ES 
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step is in equilibrium. Briggs and Haldane (1925) realised that this may not 
always be the case and suggested the following adaptation of the Michaelis- 
Menten model: 
ki 
E+S<=> 
k2 
k3 
ES ------> E+P 
where substrate binding to the enzyme is reversible, but not necessarily in 
equilibrium. This development enabled the equation known as the 
Michaelis-Menten equation to be formulated to describe the kinetics of 
enzyme catalysed reactions: 
Vmax .s 
v= ---------- > 
Km +s 
where v is the reaction rate, s is the substrate concentration, Vmax is the 
maximal reaction rate at enzyme saturation and Km is the Michaelis 
constant. 
Km values range widely, for example the Km for CO2 binding to carbonic 
anhydrase is 8mM, while the Km for ATP binding to pyruvate carboxylase 
is 60µM. The Km value for an enzyme has two applications, firstly it is the 
concentration of substrate at which half the active sites are filled. Secondly, 
it reflects the affinity of an enzyme for a substrate, where a high Km shows 
low affinity, and vice versa. The Km is an intrinsic characteristic of 
enzyme-substrate binding and, within a given assay, is often referred to as 
the apparent Km, which is unaffected by enzyme concentration or 
localisation. 
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The Vmax is a direct measure of the maximum rate of the catalysed 
reaction when all the enzyme's active sites are filled and, as such, is 
dependent on the amount of enzyme present in the tissue under 
investigation. For most physiological pathways, substrate concentrations 
in vivo are usually well below those needed for Vmax conditions. In the 
case of xenobiotic metabolism, however, it is possible for substrate 
concentrations to reach these levels. For example the metabolism of 
ethanol by alcohol dehydrogenase, or paracetamol conjugation with 
glucuronide in overdose. The Vmax can be used to determine the turn 
over rate of an enzyme if the enzyme concentration is known. The 
turnover number is equivalent to the rate constant k3 in the above 
equation and is defined as the number of substrate molecules converted 
into product per unit time at fully saturable conditions. Like Km, turn 
over numbers can vary widely, for example, carbonic anhydrase has a 
turnover number of 6x 105 s-1 while glutathione-S-transferases have 
turnover numbers between 0.1 and 35 s-1. 
Km and Vmax parameters may be derived by using non-linear regression 
to fit the Michaelis-Menten equation to the data set. The determination is 
done by adjustment of the values of Vmax and Km for the known values 
of v and s until the sum of errors between the values of v and the 
calculated values of v is minimised. This is fairly easily achieved with the 
current widespread availability of computers. 
Other methods for the calculation of Km and Vmax rely on linear 
transformations of the Michaelis-Menten equation. The most popular is 
the double-reciprocal plot described by Lineweaver-Burke (1934). This plots 
1/v against 11s, where the y-axis intercept is equivalent to 1/Vmax and the 
x-axis intercept is equal to -1/Km. However, the plot distorts the 
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appearance of experimental error in the primary observations of v, 
especially at low substrate concentrations. 
Other straight line transformations have been developed that eliminate 
the error of the double-reciprocal plot, but are still not entirely free of 
distortion. For example, a plot of v against v/s results in a straight line, 
where the slope represents -Km and the y-axis intercept is the Vmax. This 
is known as the Eadie-Hofstee plot. The Eadie Hofstee plot is often used to 
to illustrate the involvement of multiple enzymes in a metabolic process. 
A single enzyme would be expected to yield a straight line while multiple 
enzymes would give rise to an intersecting series of lines or a characteristic 
"hockey-stick" appearance. 
11.2 Methods 
Liver microsomes were prepared from 3 male Wistar rats weighing 
approximately 250g by the method described in chapter 7. The microsomal 
protein concentration of the preparations was determined by the method 
of Lowry adapted by Peterson (1977) using bovine serum albumin as 
standard, as described in chapter 7. Paraoxon and p-nitrophenol formation 
from parathion (5µM - 500gM) was determined for control (vehicle only) 
and ketoconazole (5µM) inhibited activities by the method described in 
chapter 8. 
The kinetic parameters of parathion metabolism were investigated by 
fitting the data of paraoxon and p-nitrophenol formation verses substrate 
concentration for control and ketoconazole inhibited data using an 
iterative non-linear regression program using the built-in Solver function 
in Excel. The data points were not weighted. Eadie Hofstee plots were also 
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constructed and Vmax (y intercept) and apparent Km (slope) determined. 
Data was fitted by least squares linear regression where appropriate. 
One enzyme model V= Vmax S (1) 
Km+S 
Two enzyme model V= Vmax + Vmax(2) S (2) 
(Km(i) + S) (Km(2) + S) 
where Km(i), Vmax(i) correspond to high affinity, low capacity (substrate) 
site and Km(2), Vmax(2) correspond to low affinity, high capacity (substrate) 
site. 
11.2.1 The effect of ketoconazole on parathion kinetics 
Preliminary experiments 
The rates of p-nitrophenol and paraoxon formation had been shown to be 
linear with time and protein concentration to 10 minutes and 0.4mg 
protein per incubation, respectively, at saturating substrate concentrations. 
In order to define the kinetics of parathion metabolism, it was necessary to 
observe the rates of reaction over a 100-fold substrate range (5µM - 500µM). 
Preliminary experiments determined conditions of linearity for the lowest 
substrate concentration (5µM) using the method described in chapter 8. 
Using this parathion concentration the rate of p-nitrophenol and 
paraoxon formation was linear with time and protein concentration to 2.5 
minutes and 0.25mg protein per incubation, respectively (figures 11.1 and 
11.2). 
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Inhibitor 
Ketoconazole was dissolved in methanol to give a 100mM stock solution. 
This was then diluted 1: 10 in methanol, followed by a further 1: 20 
dilution to give a 0.5mM working stock. 
Ketoconazole (5p1 of 0.5mM stock) or methanol (5µl) was added to 
incubation tubes containing NADPH (0.3mg) and microsomal protein 
(approximately 0.25 - 0.3mg ) made up to 0.5m1 with Tris/ calcium buffer 
(pH 7.4). This gave a final inhibitor concentration of 5µM. The tubes were 
pre-incubated with inhibitor or vehicle for 10min prior to starting the 
reaction by the addition of parathion in 2µl aliquots (5,10,15,25,50,75, 
100,150,200,300,400 and 500µM, final concentrations). The reaction was 
terminated after 2.5min by the addition of 0.5m1 perchloric acid (20%, w/v) 
and formation of paraoxon and p-nitrophenol determined by HPLC with 
u. v. detection. 
11.3 Results 
The analytical limit of detection for p-nitrophenol and paraoxon was 
10pmol/incubation and 35pmol/incubation, respectively. Using the 
method described above, microsomal incubations produced about 
100pmoles and 90pmoles of p-nitrophenol and paraoxon, respectively, 
from 5µM parathion and this concentration was the limit of the assay 
sensitivity. 
Control and ketoconazole inhibited plots of paraoxon and p-nitrophenol 
formation verses substrate concentration for one rat are shown in figures 
11.3 and 11.4. Visual comparison of the inhibited plot with control 
suggested approximately 50% inhibition of paraoxon and p-nitrophenol 
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formation by ketoconazole at saturating substrate concentrations, ie those 
above 20µM. There was also complete inhibition of parathion metabolism 
at 5µM and 10µM substrate concentrations. 
Figure 11.5 gives the computer fit by non linear regression for the non- 
inhibited plots of paraoxon and p-nitrophenol formation verses substrate 
concentration for one rat. The computer non linear regression fit of the 
data gave Vmax's of 288 and 414 pmol/ min/ mg protein with Km's of 
14.1µM and 16.3µM for paraoxon and p-nitrophenol formation, 
respectively. These values were comparable with those derived from the 
Eadie Hofstee plots (table 11.1). Computer fitted values for ketoconazole 
inhibited paraoxon and p-nitrophenol formation were inappropriate as 
the plots showed a degree of deviation from typical Michaelis-Menten 
kinetics. 
Control and inhibited data transformed to Eadie Hofstee plots are given in 
figures 11.6 and 11.7 (paraoxon formation) and figures 11.8 and 11.9 (p- 
nitrophenol formation). The Eadie Hofstee plots of paraoxon and p- 
nitrophenol formation appeared to be monophasic for control liver 
microsomes but their appearance suggested a biphasic nature (i. e they 
contained two linear portions) following inhibition with ketoconazole. 
The kinetic parameters for parathion metabolism by three control liver 
microsomes were calculated from their Eadie Hofstee plots and are given 
in table 11.1. Similarly, the high and low substrate components of 
parathion metabolism kinetics following inhibition were calculated and 
are given in table 11.2. 
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Table 11.1 The Vmax and apparent Km values for paraoxon and p- 
nitrophenol formation by control rat liver microsomes (n = 3). Values are 
derived from Eadie Hofstee plots and are the mean ± sem. 
Metabolite Vmax apparent Km 
(pmol metabolite 
formed /min /mg (µM) 
protein) 
Paraoxon 283.0 ± 2.1* 10.4 ± 0.25 
p-Nitrophenol 349.7±11.2 8.2 ± 1.4 
* p<0.05, compared to formation of p-nitrophenol (paired t-test) 
Table 11.2 The kinetic parameters for parathion metabolism by rat liver 
microsomes (n = 3) pre-treated with ketoconazole (5µM) in vitro. Values 
were derived from Eadie Hofstee plots and are the mean ± sem. 
Low substrate component High substrate component 
Metabolite Vmax 
(pmol/ min/ 
mg protein) 
Km 
(µM) 
Vmax 
(pmol/ min/ 
mg protein) 
Km 
(µM) 
Paraoxon 95.1±12.5 42.8 ± 22.2 141.4±18.2 14.8±11.0 
p-Nitrophenol 103.30 21.4@ 187.8 ± 13.7 2.04 ± 1.34 
Qn =2 determinations 
The Vmax for p-nitrophenol formation by control rat liver microsomes 
was higher than paraoxon, although their apparent Km's were similar. 
Vmax's determined for paraoxon and p-nitrophenol formation at the high 
substrate component were lower than control values, by 49.7% ± 6.4% and 
46.3% ± 4.7%, respectively. 
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11.4 Discussion 
Early work by Norman et al (1974) using rat liver microsomes with [35S] 
and [14C] labelled parathion at physiological pH showed that the amount of 
sulphur bound to microsomes in the absence of an NADPH-generating 
system was only approximately 2% of that bound in the presence of the 
generating system. Moreover, the Vmax rate determined for sulphur 
binding was not statistically different from the Vmax rate for paraoxon 
formation. The authors suggested that these observations provided strong 
evidence that the sulphur binding was a result of P450-mediated 
metabolism of parathion and that this correlated with paraoxon 
formation. 
In the same publication Norman et al reported the rate of paraoxon 
formation by rat liver microsomes as 353 ± 26.7 pmol/ min/ mg protein 
and Km 17.5µM ± 4.3µM, which was similar to the values (283 ± 2.1 pmol/ 
min/ mg protein and Km 10.4µM ± 0.25µM) determined in this study. 
Likewise, early work by Nakatsugawa et al (1968) reported a Km of 10.2µM 
for paraoxon formation from parathion by rat liver microsomes. 
However, Norman et al also demonstrated that as much as 20% of the 
paraoxon formed in vitro could be bound to the microsomes and therefore 
accurate measurements of paraoxon formation should include the 
concentration of free metabolite in the incubation media plus the amount 
bound to the microsomes. 
In this study paraoxon standards prepared in the presence and absence of 
microsomal protein at the concentration used for incubations produced 
identical results inferring no loss of paraoxon by binding. Further 
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experiments using labelled parathion would be necessary to confirm this 
observation. 
A recent study by Ma and Chambers (1995) of control rat liver microsomes 
showed that the Vmax for p-nitrophenol formation from parathion was 
1.49 ± 0.15 nmol/ min/ mg and Km 56.0µM ± 18.8µM. The kinetics for 
paraoxon formation were biphasic and gave Km's of 0.23µM ± 0.10µM and 
71.3µM ± 16.4µM with Vmax's of 3.62 ± 0.16 nmol/ min/ mg and 4.56 ± 
1.38 nmol/ min/ mg, respectively. These researchers used a 
spectrophotometric technique to measure p-nitrophenol levels while 
production of paraoxon from parathion was measured indirectly by 
monitoring the amount of inhibition produced in an exogenous source of 
acetylcholinesterase (bovine brain) by the oxon generated. The different 
analytical techniques used in the Ma and Chambers investigation 
compared to this study may have contributed to the difference in kinetic 
values. 
The physiological importance of the Km's determined in this study for 
paraoxon and p-nitrophenol formation is difficult to assess without 
knowlege of the concentration of toxin at the enzyme site/ receptor in 
vivo. Under conditions of equilibrium the parathion concentration at 
hepatic enzyme sites may approximate to the unbound plasma 
concentration. However, putative hepatic levels are likely to be 
considerably higher than in the plasma during the absorption phase. 
Estimates of toxin concentration at the enzyme site are further 
complicated by the fact that it has been shown that suspended rat 
hepatocytes absorbed parathion rapidly and reversibly until the 
intracellular concentration was >300-fold the ambient level (Nakatsugawa 
et al, 1980). 
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Sultatos et al (1985) has shown that the hepatic portal blood concentration 
of parathion peaked at 8.9µM ± 1.9µM thirty minutes following an i. p. 
near lethal dose (13mg/ kg) to the mouse. In this extreme situation, and 
bearing in mind the potential for active hepatic uptake, parathion could be 
expected to be metabolised at Vmax rates since the substrate concentration 
would be saturating. 
The biphasic nature of the Eadie Hofstee plots following inhibition with 
ketoconazole suggested the presence of multiple forms of P450 which were 
capable of metabolising parathion to paraoxon and p-nitrophenol, but 
which were unequally sensitive to inhibition by ketoconazole. These data 
indicated that at least two enzymatic sites were involved, although 
allosteric changes of a single site could not be excluded. 
Approximately 50% of the high substrate component for paraoxon and p- 
nitrophenol formation was not inhibited by the ketoconazole 
concentration used. This corroborates the data obtained for incubations 
with 20µM and 200µM parathion and ketoconazole in which 
approximately 25% inhibition was observed. Taken together these data 
suggested that about 25%-50% of parathion metabolism was probably 
mediated by CYP3A in control rat liver at saturating substrate 
concentrations. At least a proportion of the low substrate component(s) 
was not inhibited by ketoconazole which precludes involvement of 
CYP3A in this constituent of the reaction. 
The Km determined for p-nitrophenol formation at the high substrate 
component appeared to be decreased by ketoconazole, but the high 
variability of the values precluded any real conclusions for this 
observation. However, the decrease in Km tends to corroborate the 
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deduction of others (Gibbs et al, 1997) that ketoconazole is a non- 
competitive inhibitor of CYP3A-mediated reactions. The observed 
decrease in Vmax may therefore have resulted from a conformational 
change in the enzyme's binding site. 
In summary, the kinetics of the reaction provided further evidence that 
several P450 isoforms are involved in parathion metabolism in control rat 
liver microsomes. It demonstrated that CYP3A was responsible for about 
50% of parathion metabolism at saturating substrate concentrations and 
that isoform(s) other than CYP3A were involved at lower concentrations. 
Further studies, possibly including specific P450 antibodies, would be 
required to elucidate participation of individual P450 isoforms in 
parathion metabolism in the rat. 
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Chapter 12 
Chapter 12 Parathion metabolism by human liver microsomes ' 
12.1 Introduction 
In this section of the thesis interindividual variations in capacity to 
metabolise parathion were determined in sixteen human liver 
microsomal preparations. Studies then concentrated on assessing the 
individual P450 isoform(s) involved in the reaction in man. 
Many different strategies are currently employed in the identification of 
P450 isoforms responsible for the biotransformation of xenobiotics. These 
include the use of selective chemical inhibitors of P450 isoforms, 
commercially available human P450-expressed microsomes, and 
correlation analyses between the rates of metabolism of the xenobiotic and 
model P450 substrates. A combination of these approaches was used in the 
following chapters. 
12.2 Methods 
12.2.1 The subjects 
Human livers (n = 16) were obtained from patients in Newcastle with 
approval of the joint Ethical Committee of Newcastle and North Tyneside 
Health Authority and University of Newcastle, and from Professor G. 
Hawksworth, Aberdeen with approval of the Joint Ethical Committee of 
the Grampian Health Board. The livers were flash-frozen as soon as 
possible after removal and then stored at -700C until use. Demographic 
details for the subjects are given in table 12.1. 
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Approximately 1g of liver was taken from each of the 16 human liver 
samples and microsomes prepared by differential centrifugation as 
described in chapter 7. The microsomal protein concentration of the 
preparations was determined by the method of Lowry adapted by Peterson 
(1977) using bovine serum albumin as standard, as described in chapter 7. 
A table of the microsomal protein recovery of the livers is given in 
appendix II . 
12.2.2 Biochemical characterisation 
Liver microsomes were characterised for cytochromes P450 3A4/5 (n = 16) 
and 1A1/2,2B6 and 2E1 (n = 7) activity using the in vitro marker substrates 
nifedipine (100µM), ethoxyresorufin (2µM), pentoxyresorufin (2µM) and 
p-nitrophenol (200µM). A-esterase and B-esterase activities of the 
microsomes (n = 7) were determined using the substrates paraoxon (1mM) 
and phenylvalerate (1.4mM). Glutathione-S-transferase activity was 
determined in 7 liver cytosol samples by measuring formation of the 
DNCB (1mM)/ glutathione (1mM) adduct. 
All enzyme activities were measured under pre-determined conditions of 
linearity with respect to protein concentration and time and used 
saturating substrate concentrations. Methods for each of the enzyme assays 
are described in chapter 8. 
Nifedipine oxidase activity 
Approximately 0.3mg microsomal protein in 1ml KCl/ phosphate buffer 
(pH 7.4) was incubated with nifedipine for 20min. The reaction was 
terminated by addition of 400gl Tris buffer (pH 9.0) and samples analysed 
for formation of the metabolite M1 by GC with electron capture detection. 
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Ethoxyresorufin- and pentoxyresorufin-O-dealkylase activity 
Approximately 0.1mg or 0.3mg microsomal protein was incubated with 
ethoxyresorufin or pentoxyresorufin, respectively, in 1ml phosphate 
buffer (pH 7.4). Formation of the common metabolite, resorufin, was 
monitored continuously at 370C for about 5min and the rate of reaction 
determined. 
p-Nitrophenol hydroxylase activity 
Approximately 0.25 - 0.5mg protein in 0.5m1 potassium phosphate buffer 
(pH 6.8) was incubated with p-nitrophenol for 30min at 37°C. Formation of 
4-nitrocatechol was determined by u. v. detection (250nm) following 
separation on reverse-phase HPLC. 
A-esterase (Paraoxonase) activity 
Approximately 0.3mg microsomal protein was incubated with paraoxon in 
a total volume of 3m1 glycine buffer (pH 9.0) held at 300C. Production of 
the metabolite, p-nitrophenol, was monitored continuously at 412nm for 
approximately 3min and the rate of reaction determined. 
B-esterase (phenylvalerate hydrolase) activity 
Liver microsomes were diluted appropriately so that approximately 0.39g 
microsomal protein was incubated with phenylvalerate in a total volume 
of 0.4m1 Tris/ EDTA buffer, pH 8.0. Incubations were terminated after 
10min and formation of phenol determined photometrically at 510nm. 
Glutathione-S-transferase activity 
Liver cytosols were diluted appropriately so that approximately 0.03mg 
protein was incubated with DCNB and reduced glutathione in a total 
volume of iml phosphate buffer (pH 6.5). Formation of the DCNB adduct 
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was monitored continuously at 340nm whilst held at 370C and the rate of 
reaction determined. 
12.2.3 Parathion metabolism 
Interindividual variations in parathion (200µM and 20µM) metabolism to 
paraoxon and p-nitrophenol was measured for the 16 human liver 
microsomal preparations. Substrate concentrations were chosen from the 
rat data to be saturating and approximately at the Km for the enzyme. 
Approximately 0.3mg microsomal protein was incubated for 10min in the 
presence of NADPH and parathion with Tris/ calcium buffer (pH 7.4) in a 
total volume of 0.5ml. Control incubations were carried out as described 
except that either microsomal protein or NADPH was omitted. Formation 
of p-nitrophenol and paraoxon was determined by u. v. detection (290nm) 
following separation on reverse-phase HPLC, as described in chapter 8. 
12.2.3.1 The kinetics of parathion metabolism 
The kinetic characteristics of parathion metabolism to paraoxon and p- 
nitrophenol was determined for 3 human liver microsomal preparations, 
M9, M13 and M16. Incubations were carried out as described above using 
six parathion concentrations (20µM - 1000µM). 
Approximately 0.3mg microsomal protein was incubated for 10min in the 
presence of NADPH and parathion (20,50,70,200,500,1000µM, final 
concentrations) with Tris/ calcium buffer (pH 7.4) to 0.5m1. The reaction 
was started by addition of parathion in 2µl aliquots of methanol, as before. 
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Michaelis-Menten, Lineweaver-Burke and Eadie Hofstee plots of paraoxon 
and p-nitrophenol formation were constructed for each of the human 
liver microsomes. Data points derived from the Lineweaver-Burke and 
Eadie Hofstee plots were fitted by least squares linear regression and Vmax 
and apparent Km values determined. 
12.2.3.2 Inhibition of parathion metabolism 
Inhibitors 
Microsomal liver preparations M15 and M16 were incubated with 
parathion (20gM and 200µM) and the inhibitors naringenin, 
troleandomycin, quercetin ketoconazole and quinidine. Microsomal liver 
preparations M9 and M11 were incubated with parathion (20gM and 
200µM) and the inhibitors metyrapone, a-naphthoflavone, 
diethyldithiocarbamate (DEDC) and tolbutamide. Liver microsomes (M11, 
M12 and M16) were incubated with parathion (200µM) and 
sulphaphenazole. Inhibitor concentrations were 100µM, except 
sulphaphenazole (10µM). 
Inhibitors (5µl) or vehicle (5µl DMSO or methanol, control) were added to 
incubation tubes containing NADPH (0.3mg) and microsomal protein 
(approx. 0.4mg) and made up to 0.5m1 with Tris/ calcium buffer (pH 7.4). 
The tubes were pre-incubated with inhibitors or vehicle for 10min prior to 
starting the reaction by the addition of parathion (20µM and 200µM, final 
concentration). The reaction was terminated after 10min by addition of 
0.5m1 perchloric acid (20%, w/v) and formation of p-nitrophenol and 
paraoxon determined by HPLC with u. v. detection, as described 
previously. 
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The nature of parathion inhibition by naringenin 
Competitive or non-competitive inhibition can be evaluated through the 
use of the Dixon plot, which calculates the enzyme inhibitor constant, Ki. 
A plot of 11v against inhibitor concentration, at constant substrate 
concentration, gives a straight line. When this is done at two or more 
different substrate concentrations, an intersection of the lines to the left of 
the vertical axis indicates a competitive inhibitor. The intersection point is 
equivalent to -Ki, the inhibitor constant. If the lines are parallel, the 
inhibition is non-competitive. 
The nature of naringenin inhibition of the paraoxon formed from 
parathion was assessed by use of the Dixon plot. In this study human liver 
microsomes (M11) were pre-incubated with a range of naringenin 
concentrations (5-100µM) at three concentrations of parathion (20,100 and 
200µM). The data points were fitted by least squares linear regression and 
the Ki determined. 
12.2.4 Inhibition of paraoxonase activity 
These experiments were designed to investigate the involvement of A- 
esterases in p-nitrophenol formation from parathion and paraoxon. 
Liver microsomes (M9, M15 and M16) were preincubated for 10min in the 
presence of EDTA (ethylenediaminetetra-acetic acid, 5mM) and 50mM Tris 
buffer pH 7.4 (without calcium) to 0.5ml, before addition of parathion 
(20µM or 200µM) or paraoxon (1µM, 3µM or 1000µM). Control incubations 
were carried out in parallel in 50mM Tris/ 1mM CaC12 buffer, pH 7.4 (no 
EDTA). Paraoxon and p-nitrophenol levels were measured by reverse- 
phase HPLC with u. v. detection, as described in chapter 8. 
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12.2.5 Correlations between parathion metabolism and P450 marker 
activities 
Correlation coefficients were calculated for the previously defined (chapter 
12.1.2) rates of nifedipine oxidation, ethoxyresorufin-O-dealkylation, 
pentoxyresorufin-O-dealkylation, p-nitrophenol hydroxylation, paraoxon 
hydrolysis and phenylvalerate hydrolysis with the rates of formation of 
paraoxon and p-nitrophenol from parathion (20µM and 200µM) (chapter 
12.1.3). 
The correlation coefficient (r) was calculated by least squares linear 
regression fit and from this values of t were determined. The data were 
also analysed by non-parametric statistics, the Spearman rank correlation 
coefficient. Values at p<0.05 or less were considered to be significant. 
12.2.6 Studies with P450-expressed microsomes 
Commercially (Gentest) available microsomes from cell lines expressing 
human P450s 3A4,3A5,1A1,2B6,2E1,2C8 and 2C9-Arg144 were assessed 
for their capacity to metabolise parathion and nifedipine (P450s 3A4 and 
3A5 only). 
Microsomes (20pmol P450/ incubation) were incubated for 2h in 0.5m1 
100mM phosphate buffer (pH 7.4) with NADPH (0.6mg/ml) and parathion 
(200µM), as described previously. Paraoxon and p-nitrophenol formation 
measured by HPLC with u. v. detection, as before. Microsomes expressing 
P450s 3A4 and 3A5 (20pmol P450) were also incubated with nifedipine 
(100µM) and formation of M1 measured by GC with electron capture, as 
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described previously. Appropriate control microsomes (vector only) were 
incubated under the same conditions. 
12.3 Results 
12.3.1 Biochemical characterisation 
Interindividual variations for the enzymes measured in human liver 
microsomes are given in table 12.2. Individual data are given in appendix 
III. 
Table 12.2 Enzyme activities for the panel of human liver microsomal 11, 
preparations. 
Enzyme reaction n Enzyme activity 
Range (median) Mean ± sem 
Nifedipine oxidation 16 0.055 - 5.72 (1.72) 2.57 ± 0.41 
nmol/ min/ mg protein 
Ethoxyresorufin-O- 7 10.0 - 124.4 (41.7) 54.7 ± 14.7 
dealkylation pmol/ min/ mg protein 
Pentoxyresorufin-O- 7 n. d. - 11.0 (4.7) 5.2 ± 2.0 
dealkylation pmol/ min/ mg protein 
p-Nitrophenol 7 0.662 - 1.32 (0.797) 0.913 ± 0.095 
hydroxylation nmol/ min/ mg protein 
Paraoxon hydrolysis 7 4.6 - 16.0 (7.3) 8.8 ± 1.6 
nmol/ min/ mg protein 
Phenylvalerate 7 6.34 - 14.9 (10.3) 10.8 ± 1.15 
hydrolysis µmol/ min/ mg protein 
DNCB/ glutathione 7 553 - 1190 (892) 880 ± 93.6 
conjugation nmol/ min/ mg protein 
n. d. = below the limit of detection (0.1pmol/ min) 
DNCB is 2,4-dinitro-l-chlorobenzene 
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The rate of nifedipine oxidation, to the metabolite M1, ranged from 0.055 
to 5.72 (median, 1.72) nmol/ min/ mg protein for the sixteen human liver 
microsomes which was similar to that found by other workers (Iribarne et 
al, 1996), although livers M3 and M4 were at the extreme of this range. The 
frequency distribution histogram for the formation of M1 from nifedipine 
(figure 12.1) clearly shows these two outliers. 
Ethoxyresorufin- and pentoxyresorufin-O-dealkylase activities for the 
panel of human liver microsomes were 10.0 - 124.4 and n. d. - 11.0 pmol/ 
min/ mg protein, respectively. Activities quoted in the literature for 
ethoxyresorufin-O-dealkylase activity, 160 ± 25 pmol/ min/ mg protein, 
(Weaver et al, 1994) compare favourably. Literature quotes for 
pentoxyresorufin-O-dealkylase activitiy range from 2.8 ± 2.1 (Waziers et al, 
1989) to 5.0 ± 5.0 pmol/ min/ mg protein (Shimada et al, 1997). 
Pentoxyresorufin-O-dealkylase activity was about ten fold lower than that 
obtained for the O-dealkylation of ethoxyresorufin. 
The range for formation of 4-nitrocatechol from p-nitrophenol was 0.662 - 
1.32 nmol/ min/ mg protein which was similar to the rate reported by 
Zerilli et al (1997), 2.38 ± 1.55 nmol/ min/ mg protein. 
Concerning glutathione-S-transferase activity, non-enzymatic formation 
of the DNCB adduct was less than 5% of that produced enzymatically, 
although this value tended to increase during the course of the day as 
reagents deteriorated. The range determined in this study, 553 - 1190 
nmol/ min/ mg cytosolic protein, for a small population of human livers 
was similar to the range of 480 - 2820 nmol/ min/ mg protein reported by 
Temellini et al, 1995 for 93 livers of mixed gender. 
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Figure 12.1 
Frequency distribution histogram for the formation 
.. + +k" möt hr, litc M1 frnm nifadinine 
(100äM1 
Human liver microsomes were characterised for paraoxonase activity at 
pH 9.0 since preliminary experiments (see chapter 8) had shown that this 
provided optimal conditions. There is a paucity of literature information 
concerning liver esterase activities, particularly for human data. However, 
McCracken et al (1993) reported a range of 25 - 80 nmol/ min/ g liver for 
human liver paraoxonase activity measured at optimal pH, which relates 
favourably to the values determined in this study. 
12.. 3.2 Interindividual variations in parathion metabolism 
Parathion was metabolised to paraoxon and p-nitrophenol by human liver 
microsomes (table 12.3). The reaction was entirely dependent on the 
presence of NADPH and microsomal protein indicating a P450 mediated 
reaction and that there was no spontaneous hydrolysis of the substrate 
under the conditions described. 
Table 12.3 Parathion (20µM and 200µM) metabolism to paraoxon and p- 
nitronhenol by 16 human liver microsomal nrevarations. 
Parathion Paraoxon formation p-Nitrophenol formation 
conc. (gM) (pmol/ min/ mg protein) (pmol/ min/ mg protein) 
Range (median) Mean ± sem Range (median) Mean ± sem 
20 23.3 -199.3 90.3 ± 12.5 321.1 - 769.2 538.0 ± 26.8$ 
(70.8) (513.1) 
200 18.7-310.3 153.2* ± 21.3 406.2 ± 778.3 583.2 ± 26.3@ 
(117.3) (558.1) 
*p<0.05 compared to paraoxon formation from 20µM parathion 
$p<0.05 compared to paraoxon formation from 20µM parathion 
@p<0.05 compared to paraoxon formation from 200µM parathion 
(statistics by paired t-test) 
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Paraoxon was formed from 20gM and 200µM parathion at 23.3-199.3 (70.8, 
median) and 18.7-310.3 (117.3, median) pmol/ min/ mg protein, 
respectively, which indicates a 9-fold and 16-fold interindividual variation 
in activation capacity by microsomes from 16 human livers (table 12.3). p- 
Nitrophenol was also formed at 321.1-769.2 (513.1, median) and 406.2-778.3 
(558.1, median) pmol/ min/ mg protein, indicating a twofold 
interindividual variation regardless of substrate concentration. 
Paraoxon levels were higher at 200gM parathion compared to the lower 
concentration while p-nitrophenol levels were similar at both substrate 
concentrations. p-Nitrophenol formation was greater than paraoxon at 
both parathion concentrations. The ratio of paraoxon to p-nitrophenol 
from parathion (20µM and 200gM) was 0.036-0.468 (median 0.154) and 
0.036-0.593 (median 0.257), respectively. Individual paraoxon/ p- 
nitrophenol ratios for the sixteen liver microsomes are given in figure 
12.2 (20gM parathion) and figure 12.3 (200gM parathion). 
12.3.3 The kinetic parameters of parathion metabolism 
The Km and Vmax values for paraoxon and p-nitrophenol formation 
derived from Lineweaver-Burke plots are given in table 12.4 for 3 human 
liver microsomal preparations. 
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Figure 12 .2 
Paraoxon and p-nitrophenol formation from parathion (20µM) 
for 16 human liver microsomes. 
Individual paraoxon/ p-nitrophenol ratios (vertical orientation) 
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Figure 12.3 
Paraoxon and p-nitrophenol formation from parathion (200µM) 
for 16 human liver microsomes. 
Individual paraoxon/ p-nitrophenol ratios (vertical orientation) 
are given in ascending order 
Subject number 
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Table 12.4 Kinetic parameters for paraoxon and p-nitrophenol formation 
from parathion by 3 human liver microsomal preparations. Values were 
aerivea r rom Lineweaver-aurae plots or t he aata. 
Paraoxon formation p-Nitrophenol formation 
Liver Vmax 
(pmol/ min/ mg 
protein) 
Km (gM) Vmax 
(pmol/ min/ mg 
protein) 
Km (gM) 
M9 167.8 9.0 206.2 32.3 
M13 143.1 13.7 -- -- 
M16 313.5 15.9 255.8 31.3 
Range 167.8 - 313.5 9.0-15.9 206.2 - 255.8 31.3-32.3 
Mean 
± sem 
208.1 ± 53.2 12.9 ± 2.0 231.0 31.8* 
-- plot not interpretable 
*P<0.05, compared to Km for paraoxon formation (students t-test). 
The Vmax for paraoxon formation was 208.1 ± 53.2 pmol/ min/ mg 
protein and 231.0 pmol/ min/ mg protein for p-nitrophenol formation. 
However, the apparent Km for p-nitrophenol formation (31.8µM) was 
higher than that for paraoxon, 12.9µM ± 2.0µM. The Lineweaver-Burke 
plot of p-nitrophenol formation by liver M13 was not interpretable which 
may have resulted from distortion of V at the lower substrate 
concentrations, well recognised with this type of plot. 
Michaelis-Menten, Lineweaver-Burke and Eadie Hofstee plots of paraoxon 
and p-nitrophenol formation by liver M9 are given in figures 12.4,12.5, 
12.6 and 12.7, respectively. Visual inspection of the Eadie Hofstee plot of 
paraoxon and p-nitrophenol formation suggested monophasic kinetics 
over the substrate range studied. The Eadie-Hofstee plot for liver M9 
produced Vmax values of 167.7 and 203.3 pmol/ min/ mg protein for 
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Figure 12.4 
A Michaelis-Menten plot of paraoxon and p-nitrophenol formation 
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Figure 12.6 
Lineweaver-Burke plot for human liver microsomes M9: 
p-nitrophenol kinetics 
0.008 
0.007 
C 0 
0 
CL 
cm 0.006 
E 
ö 
0.005 
0.004 
0.003 f-- 
-0.02 
1/[parathion] 
Data fitted by least squares linear regression 
220 
-0.01 0.00 0.01 0.02 0.03 0.04 0.05 0.06 
Figure 12.7 
An Eadie Hofstee plot of paraoxon and p-nitrophenol 
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paraoxon and p-nitrophenol formation, respectively, which is in complete 
agreement with those derived from the Lineweaver-Burke plot (table 
12.4). 
The Lineweaver-Burke and Eadie Hofstee plots for liver M9 produced 
identical Kms for paraoxon formation, 9.0µM. However, the Eadie Hofstee 
plot presented a Km of 11.7µM for p-nitrophenol formation, which was 
dissimilar to the value of 32.3µM produced from the Lineweaver-Burke 
plot. The anomaly may have resulted from distortions in V with the 
Lineweaver-Burke plot, especially at low substrate concentrations, which 
are not so apparent with Eadie Hofstee plot transformations. 
12.3.4 Inhibition of parathion metabolism 
The inhibition profiles of paraoxon production from 20µM and 200µM 
parathion are given in figures 12.8 and 12.9, and figures 12.10 and 12.11, 
respectively. Individual values for paraoxon and p-nitrophenol inhibition 
are given in appendix IV. 
Ketoconazole, quercetin and naringenin had the greatest effect on 
paraoxon formation from 20gM parathion, demonstrating 74-87%, 75-88% 
and 54-59% inhibition, respectively. However, troleandomycin and 
quinidine inhibited the reaction by only 9-26% and 12-33%. Metyrapone, 
diethyldithiocarbamate and tolbutamide did not greatly inhibit parathion 
(20gM) activation but a-naphthoflavone produced 35-36% inhibition. 
Troleandomycin had slightly less inhibitory effect (10-15%) for paraoxon 
formation at the high (200µM) compared to the low (20µM) parathion 
concentration. Ketoconazole, quercetin and naringenin inhibited 
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Figure 12.8 
Production of paraoxon from parathion (20µM) 
by two human liver microsomal preparations 
100 - (M16 and M15): the effect of inhibitors (100µM). 
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Values are the mean of duplicate determinations 
Control (100%) values are given in appendix III 
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Figure 12.9 
Production of paraoxon from parathion (20µM) 
by two human liver microsomal preparations 
IM4 and M1M, the effect of inhibitors (100uM). 
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Figure 12.11 
Production of paraoxon from parathion (200µM) 
by two human liver microsomal preparations 
(M9 and M11): the effect of inhibitors (100µM). 
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parathion (200µM) activation to the extent of 50-57%, 60-67% and 31-35%, 
respectively. Metyrapone (11-28%), a-naphthoflavone (16-17%), 
diethyldithiocarbamate (10-22% increase in activity) tolbutamide (10% 
decrease - 23% increase in activity) and quinidine (6-13%) produced little 
inhibition of parathion activation at 200µM. 
The profile of p-nitrophenol inhibition was similar to that observed for 
paraoxon for all inhibitors tested. 
Sulphaphenazole inhibition of parathion (200µM) metabolism was 
variable for the 3 liver microsomes examined. Inhibition ranged from 2.8- 
57.9% and 1.4-77.1% for paraoxon and p-nitrophenol formation, 
respectively. Data for paraoxon and p-nitrophenol inhibition by 
sulphaphenazole are given in tables 12.5 and 12.6. 
Table 12.5 Inhibition of paraoxon formation from parathion (200µM) by 
sulphaphenazole (10µM) for 3 human liver microsomal preparations. 
Values are vercent of control activity (mean of duplicate estimations). 
Liver Control activity 
(pmol/ min/ mg protein) 
Paraoxon formation 
(% control) 
M11 210.2 97.2 
M12 150.3 42.1 
M16 315.7 88.0 
Range 150.3 - 315.7 42.1-97.2 
Mean ± sem 225.4 ± 48.3 75.8 ± 13.9 
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Table 12.6 Inhibition of p-nitrophenol formation from parathion (200µM) 
by sulphaphenazole (10µM) for 3 human liver microsomal preparations. 
Values are percent of control activity (mean of duplicate estimations). 
Liver Control activity 
(pmol/ min/ mg protein) 
p-Nitrophenol formation 
(% control) 
M11 543.1 98.6 
M12 560.2 22.9 
M16 462.9 98.0 
Range 462.9 - 560.2 22.9-98.6 
Mean ± sem 522.1 ± 30.0 73.2 ± 25.1 
A Ki value of 21µM for naringenin inhibition of parathion was estimated 
from the Dixon plot (figure 12.12). The plot suggested competitive 
inhibition at low (20µM) substrate concentration and non-competitive 
inhibition at the higher (100µM and 200µM) concentrations where the plot 
produced lines which were parallel. 
12.3.5 Inhibition of paraoxonase activity 
Incubations of liver microsomes with parathion (20µM or 200µM) in the 
presence of 5mM EDTA did not affect the levels of paraoxon and p- 
nitrophenol formed compared to control. p-Nitrophenol was not detected 
following incubation with the concentrations of paraoxon (1µM or 3µM) 
produced from 20µM or 200µM parathion whether EDTA was present or 
not. However, incubations with saturating concentration of paraoxon 
(1mM) and EDTA produced 72% of control p-nitrophenol levels. Results 
are given in table 12.7. 
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Figure 12.12 
Dixon plot illustrating the inhibitory effect of naringenin 
on parathion activation to paraoxon by human liver microsomes (M11) 
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Table 12.7 The effect of EDTA (5mM) on the metabolism of parathion and 
paraoxon by human liver microsomes. Values are the mean ± s. e. m. (n=3). 
Substrate Enzyme activity 
Control EDTA 
Parathion (20µM) 148.2 ± 27.6a 149.4 ± 23.8a 
461.0 ± 25.1b 490.2 ± 29.3b 
Parathion (200µM) 272.1 ± 31.2a 289.4 ± 45.4a 
577.0±72.1b 579.3±93.4b 
Paraoxon (1µM) n. d. b n. d. b 
Paraoxon (3µM) n. d. b n. b. b 
Paraoxon (1000µM) 1765 ± 333b 1270 ± 240b* 
a pmol paraoxon formed min-1 mg protein-1 
b pmol p-nitrophenol formed min-1 mg protein-1 
n. d. below the limit of detection (10pmol p-nitrophenol) 
*p<0.05, compared to control activity 
12.3.6 Correlations between parathion metabolism and P450 marker 
activities 
Correlations between the enzyme activities measured and paraoxon and p- 
nitrophenol formation from parathion (200µM) are given in table 12.8. 
There was significant (p<0.02) correlation between activation of parathion 
(200µM) to paraoxon and oxidation of nifedipine (100µM) to M1 (figure 
12.13). However, correlation between parathion metabolism at low 
substrate (20µM) and nifedipine oxidation (figure 12.14) did not reach 
statistical significance, but did achieve significance (p<0.05) when the two 
outliers were omitted (r = 0.571 and Spearman rank correlation coefficient 
= 0.495). Correlation between p-nitrophenol formation from parathion 
(200µM) and nifedipine oxidation was also significant (p<0.05) when the 
two outliers were omitted (r = 0.560 and Spearman rank correlation 
coefficient = 0.604). 
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Figure 12.13 
Correlation between the activation of parathion (200µM) and nifedipine 
(100µM) oxidation by 16 human liver microsomal preparations. 
Arrows denote the two outliers. 
231 
0 100 200 300 400 
Figure 12.14 
6 
5 
=4 
C 'd 
o "- 
ca a- 
-a CL 
C) 
QE3 
c- 
d 
c2 
1 
C 
Parathion (20µM) activation to paraoxon 
(pmol/min/mg protein) 
Figure 12.14 
Correlation between the activation of parathion (20µM) and nifedipine 
(100µM) oxidation by 16 human liver microsomal preparations. 
Arrows denote the two outliers. 
232 
0 50 100 150 200 
C 
0 
cc 
ý. c 
Yd 
O 
CL 
110 
O °n 
.E C1 
E 
0, 
(D -6 CD E 
>% C. 
0 
W 
140 
120 
100 
80 
60 
40 
20 
C 
Figure 12.15 
Correlation between the activation of parathion (200µM) 
to naraoxon and ethoxvresorufin-0-dealkvlation 
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Correlation between nifedipine oxidation and 
pentoxyresorufin-0-dealkylation for 
Nifedipine oxidation 
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Table 12.8 Correlations between enzyme activities and paraoxon and p- 
nitronhenol formation from parathion (200uM). 
Enzyme reaction n 
Correlation with Correlation with 
paraoxon formation p-nitrophenol 
formation 
Nifedipine oxidation 16 r=0.582* r=0.288 
Rho = 0.657** Rho = 0.369 
Ethoxyresorufin-O- 7 r=0.690 r=0.253 
dealkylation Rho = 0.714 Rho = 0.286 
Pentoxyresorufin-O- 7 r=0.708 r=0.258 
dealkylation Rho = 0.714 Rho = 0.286 
p-Nitrophenol 7 r=0.513 r=0.302 
hydroxylation Rho = 0.393 Rho = -0.107 
Paraoxon hydrolysis 7 r= -0.057 r= -0.510 
Rho = -0.036 Rho = 0.321 
Phenylvalerate 7 r= -0.142 r= -0.137 
hydrolysis Rho = -0.179 Rho = 0.00 
Glutathione 7 r= -0.057 r= -0.510 
conjugation Rho = -0.036 Rho = -0.321 
*p <0.02 
**p<0.05 
Rho = Spearman rank coefficient 
Correlations for parathion (200µM) activation with metabolism by the 
other substrates was determined for seven of the human liver microsomal 
preparations (table 12.8). Correlations with ethoxyresorufin-O-dealkylation 
and pentoxyresorufin-O-dealkylation just failed to achieve statistical 
significance (p>0.05) (figures 12.15 and 12.16). The correlations were not 
significant with p-nitrophenol hydroxylation, paraoxon hydrolysis, 
phenylvalerate hydrolysis or glutathione conjugation. Correlation 
between nifedipine oxidation and pentoxyresorufin-O-dealkylation (r = 
0.574 and Spearman rank correlation coefficient = 0.679) just failed to 
achieve statistical significance (p>0.05) (figure 12.17). 
r* 
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12.3.7 Studies with P450-expressed microsomes 
The microsomal preparations from human P450-expressed cell lines 
activated parathion to paraoxon at different rates. Data are presented in 
table 12.9. 
Table 12.9 Metabolic activity of microsomes prepared from human P450- 
expressed cell lines. Values are the mean of two determinations. 
Enzyme activity 
Microsomes 
expressing 
Substrate Paraoxon 
formeda 
P- 
nitrophenol 
formedb 
M1 
formed 
CYP3A4 Parathion 11.7 17.8 -- 
CYP3A5 Parathion 8.8 n. d. -- 
CYP1A1 Parathion 4.1 n. d. -- 
CYP2B6 Parathion 4.3 n. d. -- 
CYP2E1 Parathion n. d. n. d. -- 
CYP2C8 Parathion 2.4 n. d. -- 
CYP2C9-Argl4t Parathion n. d. n. d. -- 
CYP3A4 Nifedipine -- -- 65.0 
CYP3A5 Nifedipine -- -- 28.9 
a pmol paraoxon formed hr-1 pmol P450-1 from 200µM parathion 
b pmol pnitrophenol formed hr-1 pmol P450-1 from 200µM parathion 
C pmol Ml formed hr-1 pmol P450-1 from 100µM nifedipine 
-- not determined 
n. d. below the limit of detection (35pmol paraoxon and lOpmol 
pnitrophenol) 
P450s 3A4 and 3A5 were the most efficient at producing paraoxon (11.7 and 
8.8 pmol/ hr/ pmol P450, respectively), although P450s 1A1,2B6 and 2C8 
also catalysed the reaction. Formation of paraoxon by P450s 2E1 and 2C9 
P' 
ý4 
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was below the analytical limit of detection. p-Nitrophenol formation was 
only detectable with P450 3A4, at a rate of 17.8 pmol/ hr/ pmol P450. As 
expected, nifedipine was metabolised by P450s 3A4 and 3A5 and this was 
approximately five-fold more rapid than parathion activation. 
12.4 Discussion 
Initial studies with human liver microsomes defined interindividual 
variations in the cytochromes P450 and esterases which may be involved 
in the metabolism of parathion and found them to be comparable with 
literature reports. 
Human liver microsomes were also shown to catalyse NADPH-dependent 
formation of paraoxon from parathion with nine- and sixteeen-fold ranges 
in activity, depending on substrate concentration. However, the range for 
p-nitrophenol formation was only twofold, regardless of substrate 
concentration. The kinetic data indicated similar Km's for paraoxon and p- 
nitrophenol formation, and both reactions appeared to be monophasic in 
nature. 
It seems reasonable to suggest that a high paraoxon/ p-nitrophenol ratio 
may give an indication of increased susceptibility to parathion toxicity 
since these individuals appear to have a greater capacity to activate the 
phosphorothioate. However, it also seems possible that p-nitrophenol was 
further metabolised, although it is unlikely that this was exclusively 
mediated by CYP2E1 since the p-nitrophenol levels (approximately 5µM) 
attained were below the Km for this isoform, 26.3µM (Tassaneeyakul et al, 
1993). A study by Zerilli et al (1997) demonstrated that CYP3A made a 
significant contribution to p-nitrophenol metabolism, especially in 
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individuals with high levels of this isoform, and it is possible that CYP3A 
contributed to the further metabolism of p-nitrophenol in this study. 
The studies with naringenin, quercetin and ketoconazole at high and low 
substrate concentrations suggested that the CYP3A subfamily was 
involved in parathion activation by human liver microsomes. 
Troleandomycin was a weak inhibitor of the reaction. Other workers have 
also found troleandomycin to be an ineffective inhibitor of the 
metabolism of several CYP3A substrates such as dapsone (Fleming et al, 
1992) and taxol (Kumar et al, 1993). The exact reasons for this are not 
known but it has been suggested (Koley et a1,1995) that P450 3A is prone to 
allosteric effects, moreover troleandomycin has been shown to be very 
slow-acting in its role as a suicide inhibitor (Chang et al, 1994). The lesser 
inhibitions observed with a-naphthoflavone and metyrapone implied 
some involvement of P450s 1A and 2B6, respectively. 
Inhibition with sulphaphenazole was variable in the three microsomal 
preparations examined and highlights the problems of investigating small 
sample numbers. Interestingly, one liver, characterised as having very low 
CYP3A (nifedipine oxidase; 0.055 nmol/ min/ mg protein) and high 
CYP2C activity (Prof. G Hawksworth, personal communication) 
demonstrated a high capacity to activate parathion (112 pmol/ min/ mg 
protein). This data implies that CYP2C may be involved in parathion 
activation in livers low in CYP3A. Unfortunately, the human liver panel 
was not characterised for CYP2C activity and therefore it was not possible 
to assess a correlation between parathion metabolism and this subfamily. 
Previous studies (Butler and Murray, 1997), however, demonstrated a poor 
correlation between tolbutamide hydroxylation (a CYP2C9-mediated 
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reaction) and parathion metabolism for eleven human liver microsomal 
preparations. 
The inhibition data were in agreement with those of Butler and Murray 
(1997) who also observed inhibition of parathion metabolism by CYP3A 
inhibitors. They showed about 60% inhibition with ketoconazole (25µM), 
but little effect with troleandomycin (500µM) or a-naphthoflavone 
(100µM). These researchers suggested that CYP1A2, as well as CYP3A4, was 
involved in parathion metabolism since these isoforms were most 
susceptible to loss of holo-P450 following preincubation with parathion in 
the presence of NADPH. 
Incubations with human P450-expressed microsomes showed that CYPs 
3A4 and 3A5 were capable of activating parathion and oxidising nifedipine 
and that 3A4 was two-fold more active than 3A5 in metabolising both 
substrates. P450s 1A1,2B6 and 2C8 were also capable of activating 
parathion, albeit less efficiently than P450s 3A4 and 3A5, but P450 3A4 
alone had the capacity to also detoxify the phosphorothioate to p- 
nitrophenol. O'Shaughnessy and Sultatos (1995) demonstrated the capacity 
of human P450 2B6 expressed microsomes to form both paraoxon and p- 
nitrophenol from parathion and a very low rate of formation of both 
metabolites by P450 2E1 although activities were not based on P450 
content. 
Using a conversion value of 250pmol CYP3A/ mg microsomal protein 
(Guengerich and Turvy, 1990), the rate of formation of paraoxon by the 
panel of human liver microsomes, 75-1241 pmol/ min/ nmol 3A, was 
similar to that of the CYP3A4-expressed cells (195 pmol/ min/ nmol 3A4). 
Moreover, the ratio of activation to detoxification of parathion by CYP3A4 
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expressed microsomes was 0.66 and compared favourably to that calculated 
for the panel of human livers. 
The study showed a positive correlation between parathion (200gM) 
activation to paraoxon and nifedipine oxidation, indicating the 
involvement of CYP3A in the reaction. This corroborates another study of 
human liver microsomes in which a significant correlation between 
parathion metabolism and testosterone 6ß-hydroxylation (a CYP3A 
reaction) was disclosed (Butler and Murray, 1997). In the study with the 
smaller group of liver microsomes the correlations between parathion 
activation and ethoxyresorufin-O-dealkylation and pentoxyresorufin-O- 
dealkylation just failed to achieve statistical significance. However, the 
relationship with pentoxyresorufin-O-dealkylation may have been 
confounded by the non-specificity of this reaction since pentoxyresorufin 
has been shown to be a substrate for CYP3A4, as well as CYP2B6, in human 
liver microsomes (Waziers et al, 1990). Indeed, the correlation between 
nifedipine oxidation and pentoxyresorufin-O-dealkylation just failed to 
achieve statistical significance. 
Hydrolysis of paraoxon in vitro has been shown to be mediated by the 
calcium-dependent A-esterase (paraoxonase) of human plasma (Mackness, 
1989) and liver (Gil et al, 1993) at high substrate concentrations (1-5mM). 
However, recent studies (Chambers et al, 1994) with rat liver microsomes 
have suggested that paraoxonase is not functionally important in vitro or 
in vivo at toxicologically relevant nM concentrations of paraoxon, since 
these are well below the Km of the enzyme, 0.4mM (Gil et al, 1993). 
Experiments were therefore established to determine the role of 
paraoxonase in the formation of p-nitrophenol from paraoxon at the 
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levels (1-3µM) achieved in incubations with 20µM and 200µM parathion. 
p-Nitrophenol was not detected in incubations with paraoxon (1-3µM) 
alone or including 5mM EDTA, a paraoxonase inhibitor. Conversely, 
incubations with a saturating concentration of paraoxon (1mM) and EDTA 
produced 72% of control p-nitrophenol levels. Moreover, there was a very 
poor correlation between parathion (200µM) activation and paraoxonase 
(1mM paraoxon) activity for the panel of human liver microsomes. There 
was also a very poor correlation with phenylvalerate hydrolase activity, 
perhaps suggesting that these esterases do not play an important role in 
the detoxification of paraoxon by hydrolysis, although their role in 
removing oxons by covalent binding could not be assessed. An activity 
range was also determined for glutathione-S-transferases, although these 
enzymes are not now believed to be important in parathion detoxification, 
in vivo (Sultatos, 1992; Chambers et al, 1994). This observation seems to be 
supported by the poor correlation obtained for parathion metabolism and 
glutathione-S-transferase activity, albeit for a small population of human 
livers. 
These experiments indicated that paraoxonase was not functionally 
important at the low levels of paraoxon formed from parathion, but that 
the enzyme was involved in the reaction at saturating substrate 
concentrations. However, it is possible that the paraoxon levels measured 
in vitro were reduced by binding to carboxylesterases, although there was 
no difference between levels of paraoxon measured in the presence and 
absence of microsomal protein. 
Several of these studies with human liver microsomes tend to support the 
hypothesis first proposed by Nakatsugawa and Dahm (1967) that both 
paraoxon and p-nitrophenol are produced from parathion by way of a 
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"common intermediate". P450 was proposed to donate a singlet oxygen to 
the sulphur moiety of parathion to produce an unstable 
phosphooxythiran intermediate which then spontaneously rearranged to 
produce the two metabolites (figure 3.6). An alternative pathway for 
metabolite formation would be parathion--> paraoxon--> p-nitrophenol. 
Firstly, these studies demonstrated similar Kms for paraoxon and p- 
nitrophenol formation. It is possible that p-nitrophenol followed P450- 
mediated dearylation of parathion, but this seems unlikely since it would 
have had to be carried out with the same affinity as parathion 
desulphuration (to form paraoxon). Also, the inhibition studies showed 
that p-nitrophenol and paraoxon were affected in parallel by the 
compounds investigated. Moreover, it seems more likely that p- 
nitrophenol was produced directly from a common intermediate since A- 
esterases did not appear to be involved in the detoxification of paraoxon at 
biologically relevant concentrations of parathion. 
Elucidation of the "common intermediate" theory has important 
implications for parathion toxicity. Confirmation of the theory would 
suggest that a P450-mediated reaction is responsible for both the activation 
and detoxification of this phosphorothioate, at least following low level 
exposures, although other pathways will be involved in further 
metabolism of the metabolites, eg carboxylesterase-mediated covalent 
binding of the oxon. 
Considered as a whole, CYP3A4/5 is strongly implicated as the principle 
catalyst of parathion metabolism, although the possibility exists that 
CYP1A1/2 may make a contribution, particularly following induction. 
Participation of CYPs 2B6 and 2C8 cannot be ruled out. Unfortunately, due 
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to availability of microsomes, the P450-expressed microsome studies were 
not extended to include assessment of kinetic parameters. Determination 
of a Km for parathion metabolism by individual P450s would allow an 
evaluation of their relative importance in vivo. If the Km values are 
similar, then the contribution to metabolism by the more abundant 
form(s) will predominate in the liver. Minor isoforms, eg CYP2B6, will 
only contribute significantly to metabolism if this is mediated with 
relatively high affinity. In contrast to CYP3A, hepatic levels for CYPs 
1A1/2 and 2B6 are only about 13% and 1%, respectively (Shimada et al, 
1994), and therefore, referring to their relative liver content, and if affinity 
is similar between the isoforms, CYP3A would be the major P450 
subfamily involved in parathion metabolism in vivo. Further studies are 
needed to confirm or refute the participation of CYP2C8 in the reaction, 
but the CYP2C subfamily is recognised as a major P450, being 20% 
abundant (Shimada et al, 19941. 
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SECTION IV: 
GENERAL DISCUSSION 
Chapter 13 
Chapter 13 General discussion 
13.1 General discussion 
This research determined interindividual variations in the capacity of 
human liver microsomes to metabolise parathion and investigated the 
enzyme pathways involved in its biotransformation to paraoxon and p- 
nitrophenol. The animal component of the research intended to 
complement the data obtained from the limited supply of human liver. In 
many ways this aim was achieved, but the study also highlighted some of 
the many problems associated with extrapolation of animal data to man. 
The levels of individual P450 isoforms, and indeed the expression of 
distinct isoforms, are different in the rat compared to man and this led to 
differences in the metabolism of alleged probe substrates between the 
species. Notably, the induction and inhibition studies suggested that 
nifedipine was not specific for CYP3A activity in the rat. Other substrates 
would perhaps have been better. For example, it has been shown that 
individual pathways of testosterone oxidation are specific for many rat 
P450 isoforms (Sonderfan et al, 1987). Sonderfan et al (1987) demonstrated 
that 2a-, 7a and 16ß-hydroxylation of testosterone accurately reflects the 
levels of CYPs 2C11,2A1 and 2B1/2, respectively, while the 2ß-, 6ß- and 
15ß-hydroxylation pathways collectively reflect the levels of CYPs 3A1 and 
3A2. 
In addition, these differences influenced the selectivity of the inhibitors 
used in the study. For example, sulphaphenazole had no effect on 
parathion metabolism in the rat, even though the inhibition studies 
suggested that CYP3A was not the sole isoform responsible for catalysis of 
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this phosphorothioate and that CYP2C11 was probably also involved. 
Sulphaphenazole inhibited parathion metabolism in the human liver 
microsomes investigated, albeit variably. The variability in inhibitory 
potential of sulphaphenazole between species has also been demonstrated 
by Veronese et al (1990) and others (eg Eagling et al, 1998) in their 
comparative studies of CYP2C-mediated reactions in human, rat and 
rabbit. 
It is well recognised that humans often differ from rodents in their 
responsiveness to P450 inducers. For example, rifampicin is a CYP3A 
inducer in humans but not mice or rats (Pichard et al, 1990); PCN and 
mephenytoin are CYP3A inducers in rats but do not appear to induce these 
P450 isoforms in humans (Parkinson, 1996); barbiturates, such as 
phenobarbital, are well known powerful inducers of cytochromes P450 
2131/2 (as well as other enzyme systems) in rat liver, whereas drug 
interactions with phenobarbital in man are thought to stem largely from 
induction of the CYP3A and CYP2C subfamilies (Parkinson, 1996). As well 
as the recognised species differences in response to inducers, interpretation 
of the induction data in this study was confounded by the fact that 
induction by a particular compound was not specific to an individual P450 
isoform. For example, dexamethasone increased ethoxyresorufin-O- 
dealkylase, pentoxyresorufin-O-dealkylase and p- nitrophenol hydroxylase 
activities, as well as nifedipine oxidation. 
In terms of parathion's acute toxic potential, several researchers have 
shown that phenobarbital pre-treatment in rodents protects against the 
adverse effects of this, and other, phosphorothioates (Alary and Brodeur, 
1969; Sultatos, 1986; Chambers et al, 1994). The literature suggests, 
however, that the action of phenobarbital on parathion toxicity cannot be 
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attributed exclusively to alterations in P450-mediated oxidative 
desulphuration since phenobarbital has also been shown to antagonise the 
toxicity of paraoxon (Vitarius et al, 1995a). The present rat studies 
corroborated the well known observation that exposure of animals to 
phenobarbital substantially increases hepatic P450 levels, and the data 
showed that both CYP2B activity and paraoxon formation from parathion 
were increased by this pre-treatment. 
The phenobarbital-treated liver was enlarged, had a greatly increased level 
of microsomal proteins, which would include microsomal 
carboxylesterases (Chambers et al, 1994), and an increased capacity for 
carboxylesterase-mediated hydrolysis. This would infer a substantially 
increased hepatic capacity for detoxification of parathion in vivo, despite 
the fact that activation would also be increased. All of these detoxification 
pathways probably contribute to the attenuation of parathion toxicity 
observed following phenobarbital pre-treatment. However, covalent 
binding of the oxon to carboxylesterases would possibly be of greatest 
importance in limiting the amount of toxin leaving the liver and entering 
the systemic circulation, particularly since phenobarbital decreased hepatic 
paraoxonase activity, an observation also noted by others (Vitarius et al, 
1995). Sultatos (1986) also demonstrated that, despite increased paraoxon 
production in the phenobarbital-treated mouse, there was no increase in 
paraoxon exiting the perfused liver, while there were increases in 
detoxified metabolites. 
Ethanol has also been shown to antagonise the acute toxicity of parathion 
(O'Shaughnessy et al, 1995). O'Shaughnessy et al (1995) hypothesised that 
chronic ethanol exposure leads to an increased rate of oxygen 
consumption in the rat which may result in reduced availabilty to the 
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hepatic P450s, and compromised parathion activation. The present study 
showed no increase in paraoxon production from parathion compared to 
control and increased CYP2E1 activity, although this isoform did not 
appear to be involved in parathion metabolism. However, protein 
recovery (but not P450 recovery) was substantially increased, although this 
was rather counter-balanced by a decrease in liver weight. These data again 
emphasise the importance of covalent binding to the carboxylesterases in 
attenuation of toxicity, although ethanol pre-treatment did also increase 
paraoxonase activity. 
The animal component of the study therefore emphasised the necessity 
for preliminary "in house" validation of the substrates and inhibitors of 
interest. Failure to do so may lead to the incorrect assignment of P450 
involvement if animal studies alone are used as a model for human drug 
metabolism. Even though caution should be exercised when extrapolating 
animal data to the human situation, the studies indicated that CYP3A 
played a role in parathion metabolism in control rat microsomes, but it 
was not the only P450 isoform involved. It is possible that CYP2C also 
participated in the reaction, but the present data could not support this 
hypothesis. Cytochromes P450 3A, 1A and possibly 2B were implicated in 
the induced animal. 
The animal component of this research, and other animal studies, have 
shown that P450-dependent activation of parathion plays a critical role in 
controlling the extent of acetylcholinesterase inhibition following 
exposure (Chambers and Chambers, 1990; Sawyer et al, 1992). This will, 
however, be a balance between the various detoxification pathways 
outlined in the previous studies. It follows that factors which alter the 
metabolism of such phosphorothioates could potentially alter their acute 
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toxicity. Unlike inbred animals, however, human individuals will vary 
greatly in their toxic response to phosphorothioates and this variability 
was investigated in the second part of the thesis. 
The human section of this research concentrated on studies with human 
liver microsomal preparations and commercially available human P450- 
expressed microsomes. Taken together, these data indicated the 
involvement of CYPs 3A4/5,1A1/2 and possibly 2C8 in parathion 
metabolism in man, although CYP3A4/5 was strongly implicated as the 
principle catalyst. However, CYP1A could also be of importance in vivo, 
particularly in individuals with high levels of this isoform, for example 
following induction, and if the reaction was mediated with relatively high 
affinity. This is particularly important since CYP1A1 (and to some extent 
CYP1A2) is well known for its potent inducibility by various aromatic 
hydrocarbons, and an apparent polymorphism with respect to inducibility 
of CYP1A1 by 3-methylcholanthrene has been described (Kellerman et al, 
1973). Further studies would be necessary to assess participation of CYP2C8 
in the metabolism of parathion and to determine the relative affinities of 
all the P450s involved in the reaction. 
Without exception, the levels and activity of each of the P450 isoforms 
will vary in the individuals studied, due to the many environmental 
and/or genetic factors described in the earlier chapters. In particular, this 
study showed a typically wide range in nifedipine oxidase activity which 
reflected the wide (>tenfold) interindividual variation observed in levels 
of hepatic CYP3A protein (Shimada et al, 1989). The wide range in 
nifedipine oxidase activity may be the result of several factors, including 
variability in glucocorticoid levels (which induce CYP3A4) and CYP3A5 
expression, although whether there is a genuine polymorphism in 
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CYP3A4 remains to be established. Although one individual in this study 
had very low CYP3A activity determined phenotypically, there is no 
evidence for the existence of any individual who completely lacks CYP3A 
activity. 
In the present study paraoxon formation from parathion by human liver 
microsomes in vitro was mediated with nine- and sixteeen-fold ranges in 
activity, depending on substrate concentration. It is attractive to suggest 
that those individuals shown to have a greater capacity to produce 
paraoxon in vitro, which paralleled higher activities for CYP3A4/5 and/or 
CYP1A, may be more susceptible to parathion toxicity in vivo. This is 
obviously an over-simplification and takes no account of the many 
modifying factors described in the earlier chapters. 
These studies were conducted using in vitro systems, but the situation 
would be further complicated in vivo because of variable expression of the 
phase 2 enzymes, which were not investigated in this thesis. Both the UDP 
glucuronosyltransferases and sulphotransferases could be expected to 
participate in the further metabolism of p-nitrophenol, in vivo. 
Classically, sulphotransferase is a detoxification pathway of high affinity 
but low capacity, whereas glucuronidation has a lower affinity but a higher 
capacity. In terms of Km, it has been proposed that at concentrations below 
10µM p-nitrophenol will be primarily sulphated, while glucuronidation 
will predominate above 10µM (Sultatos and Minor, 1985). The 
considerable variation in sulphotransferase activity between individuals, 
particularly P-PST activity which has been shown to vary due to several 
allelic variants in man, may be of importance for parathion toxicity in 
vivo (Coughtrie, 1996). 
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An accurate estimation of the concentration of parathion that may be 
encountered in man in vivo is difficult to establish. However, it has been 
suggested that the minimum acute lethal dose of parathion in adults 
could be as little as 4mg/ kg (Gosselin et al, 1984). This value relates to a 
study of mice (Sultatos et al, 1985) in which the hepatic portal blood 
concentration of parathion reached a peak of 9µM thirty minutes after a 
near lethal dose (13mg/ kg). This transiently high level of parathion was 
decreased to 2.3µM forty-five minutes post dose. 
There is a paucity of information in the literature regarding the possible 
body burden of parathion following occupational exposure. This will 
obviously be far lower than the suggested minimum acute lethal dose, 
although exposure will probably be multiple in nature. The literature 
indicates that occupational exposure to phosphorothioates will be mainly 
dermal and perhaps also via the pulmonary and/ or oral routes in some 
instances, such as following use of aerosols in confined spaces, splashing 
during the sheep-dipping process etc., if insufficient protective clothing is 
employed. Studies carried out by Niven et al (1993) and Nutley and Cocker 
(1993) have indicated a low internalised dose of phosphorothioates as 
measured by blood enzymes and urinary metabolite levels. Such studies 
have also suggested that there is widespread lack of compliance with 
regard to the guidelines for worker protection during occupational use of 
phosphorothioates, but measurements are not always taken during the 
times of non-compliance. 
Following low-level, multiple exposures to an animal by the oral route, 
the carboxylesterases could be expected to covalently bind much of the 
hepatically generated oxon, and it seems unlikely that appreciable 
amounts of toxin would reach target tissues. Occupational exposure 
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following the dermal route, however, would not be subject to first pass 
metabolism in the liver, and therefore it is possible that some unaltered 
phosphorothioate (and oxon) may reach the brain. The sensitivity of the 
brain to toxic insult and its low margin of safety may mean that "little" 
may be "enough" to produce adverse effects. An in vitro study by Sorrano 
and Sultatos (1992) has shown parathion to be metabolised to p- 
nitrophenol by the brain although no paraoxon was detected, presumably 
because it was covalently bound to the tissue carboxylesterases and 
therefore not extractable. 
Several studies by Chambers and co-workers (Chambers et al, 1989; 
Chambers et al, 1991; Chambers, 1992) with rats have suggested that the 
ability of the brain to locally activate phosphorothioate pesticides greatly 
influences manifest acute toxicity in this animal. They base this theory on 
studies with six phosphorothioates, including parathion, and 
demonstrated that those pesticides that were most toxic in the whole 
animal were activated by brain to the greatest extent. Chambers also 
speculated that while brain activation of phosphorothioates is probably of 
little consequence in severe acute poisoning due to the large amounts of 
hepatically generated oxon, it may be of significance following single or 
multiple low dose exposures such as experienced by man in the workplace 
situation. 
The cytochromes P450 of the lung have also been shown to be capable of 
activating parathion, with a Km of 7.9 µM, which is similar to that 
determined in this thesis for hepatic metabolism (Norman and Neal, 1976; 
Lessire et al, 1996). Several researchers have shown that the lung 
metabolises parathion very rapidly (Law et al, 1974; Norman and Neal, 
1976; Lessire et al, 1996). For example, Law et al (1974) demonstrated that it 
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took less than three minutes for paraoxon to appear in a recirculating 
perfusion system where rabbit lungs were dosed with parathion. 
Therefore, even relatively low, occupational levels of parathion which 
may enter the lung by inhalation could be rapidly activated to the oxon 
and would then be available to exert anti-cholinesterase effects at this 
target tissue. The lung appears to be particularly important in this respect 
since the cause of death in acute poisoning is respiratory failure resulting 
from paralysis of the muscles of respiration, bronchioconstriction, 
accumulation of fluid in the lungs, as well as central nervous system 
effects (Neal, 1972). 
In conclusion, this research has determined marked variability in capacity 
to metabolise parathion by human liver microsomal preparations, in 
vitro. There is potential for the alteration of parathion disposition by co- 
administration of drugs or food products which are either inducers or 
competing substrates of the CYP3A and CYP1A subfamilies. Inducers 
would include the drugs dexamethasone and phenobarbital (CYP3A), and 
cigarette smoke condensate (CYP1A1) while natural flavonoids such as 
naringenin and quercetin and the drugs nifedipine and erythromycin 
could be expected to compete for the CYP3A active site. 
These data suggest that a higher hepatic capacity to activate parathion may 
influence the toxicity of this phosphorothioate, particularly following a 
high acute dose, but the results should be applied with caution. Additional 
toxicological studies using low level multiple doses of parathion 
paralleled by an investigation of human capacity to metabolise such 
phosphorothioates, in both hepatic and extrahepatic tissues, are necessary 
to further elucidate interindividual differences in toxic outcome following 
exposure. 
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13.2 Future studies 
This research has suggested several areas for future study. Firstly, the P450- 
expressed microsome studies should be extended to include determination 
of individual Km's for the isoforms proposed to participate in parathion 
metabolism in man, that is CYPs 3A4,3A5,1A1,1A2 and possibly CYPs 
2C8 and 2B6. Using a pure enzyme source in this way would determine 
the affinity of each isoform in the reaction. The information obtained 
could then be improved by taking into account the extent to which the 
individual isoforms are expressed in human liver microsomes 
(Guengerich and Turvy, 1990). This would then allow for assessment of 
the relative contribution of the isoforms to parathion metabolism in vivo. 
Preliminary studies in the department using rat lung microsomes 
confirmed the observation of others (Norman and Neal, 1976) that this 
tissue is capable of activating and detoxifying parathion, at about 20% of 
the rate produced by liver microsomes (13.0. ± 1.5 and 18.2 ± 3.8 pmoles/ 
min/ mg protein for paraoxon and p-nitrophenol formation, respectively). 
The reaction was entirely dependent on NADPH and preliminary 
inhibition studies suggested participation of CYP2B, although it was not 
the only isoform involved. Several samples of human lung have yet to be 
studied. Studies with rat skin microsomes suggested that parathion 
metabolism in this tissue was below the limit of detection using the 
method described previously. One experiment using human brain 
microsomes showed nifedipine oxidation activity to also be below the 
limit of detection. In view of these observations, further studies should 
include development of more sensitive techniques to ascertain parathion 
metabolism in these extrahepatic tissues and to determine involvement of 
the individual P450 isoforms. Other, more occupationally relevant 
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phosphorothioates, such as diazinon, chlorpyrifos and propetamphos, 
should then be investigated using similar techniques in order to predict 
individual susceptibility to the toxic effects of these pesticides. 
An animal component should be carried out in parallel to determine 
blood and target tissue levels of phosphorothioate/ oxon with markers of 
effect (target/ erythrocyte acetylcholinesterase inhibition and urinary 
metabolites) following low-level, multiple exposure. This could be studied 
alongside experiments to assess hepatic and brain/ lung capacity to 
metabolise the phosphorothioate in vitro. 
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SECTION V: 
APPENDICES and REFERENCES 
Chapter 14 
Appendix I 
This appendix relates to rat inhibition results described in chapter 10. 
Table 1 Inhibition of M1 formation from nifedipine (5µM and 100µM) by 
rat liver microsomal preparations (n=2, except where indicated). Values 
are percent of control activity (mean ± sem). 
Inhibitor (conc. ) Nifedipine concentration 
5µM 100µM 
None (control) 0.245 
(nmol/ min/ mg protein) 
1.69 ± 0.10* 
(nmol/ min/ mg protein) 
Narin enin (100µM) -- 35.3 ± 9.0* 
TAO (100µM) -- 104.7 ± 22.0* 
KCZ (100µM) -- n. d. 
Quercetin (100µM) -- n. d. 
Quinidine (100µM) -- 33.0 ± 8.0* 
Naringenin (40µM) 34.0 28.0 
TAO (40µM) 44.0 50.0 
KCZ (40µM) 24.0 37.0 
* n=3 
-- not determined 
n. d. = below the limit of detection (0.01 nmol Ml/ incubation) 
TAO = troleandomycin 
KCZ = ketoconazole 
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Table 2 Inhibition of paraoxon and p-nitrophenol formation from 
parathion (200µM) by rat liver microsomal preparations (n=3). Values are 
percent of control activity (mean ± sem). 
Inhibitor (1mM) Paraoxon formation 
(% control) 
p-Nitrophenol formation 
(% control) 
None (control) 248 ± 10 
(pmol/ min/ mg protein) 
227 ± 18 
(pmol/ min/ mg protein) 
Naringenin 52.3 ± 6.5 52.7 ± 3.9 
Ketoconazole 81.5 ± 2.1 70.8 ± 3.4 
Met ra one 97.0 ± 3.1 83.7 ± 0.9 
a-Na hthoflavone 83.0 ± 11.7 87.8 ± 5.1 
Diethyldithiocarbamate 124.0 ± 6.6 121.0 ± 4.1 
Tolbutamide 115.0 ± 11.3 98.8 ± 9.6 
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Table 3 Inhibition of paraoxon and p-nitrophenol formation from 
parathion (200µM) by rat liver microsomal preparations (n=2). Values are 
percent of control activity (mean). 
Inhibitor (100µM) Paraoxon formation 
(% control) 
p-Nitrophenol formation 
(% control) 
None (control) 262 ± 10 
(pmol/ min/ mg protein) 
232 ± 18 
(pmol/ min/ mg protein) 
Naringenin 66.6 58.4 
Ketoconazole 80.0 89.0 
Met ra one 113.0 107.0 
a-Na hthoflavone 107.4 97.0 
Dieth ldithiocarbamate 91.3 99.7 
Tolbutamide 111.5 111.5 
Troleandomycin 112.5 129.5 
Quercetin 85.3 77.0 
Quinidine 100.5 117.5 
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Table 4 Inhibition of paraoxon and p-nitrophenol formation from 
parathion (20µM) by rat liver microsomal preparations (n=2). Values are 
percent of control activity (mean). 
Inhibitor (100µM) Paraoxon formation 
(% control) 
p-Nitrophenol formation 
(% control) 
None (control) 210 ± 10 
(mol/ min/ mg protein) 
212 ± 15 
(pmol/ min/ mg protein) 
Naringenin 56.2 57.3 
Ketoconazole 80.7 78.0 
Metyrapone 98.0 106.3 
a-Naphthoflavone 89.8 90.5 
Diethyldithiocarbamate 70.7 97.1 
Tolbutamide 98.6 103.9 
Troleandomycin 128.0 111.5 
Quercetin 78.1 74.8 
Quinidine 122.5 98.8 
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Appendix II 
This appendix relates to studies described in chapter 12.2. 
Table 1 Microsomal protein recovery from approximately 1g of liver for 16 
human livers. 
Laboratory number 
Lowry protein 
(mg / ml) 
Protein recovery 
(mg protein/ g liver) 
Mi 6.0 19.6 
M2 4.5 19.1 
M3 10.2 20.3 
M4 4.0 15.6 
M5 3.9 12.4 
M6 5.8 13.4 
M7 3.5 17.6 
M8 4.7 8.5 
M9 8.0 15.1 
M10 6.6 10.3 
Mil 6.4 11.5 
M12 6.7 12.9 
M13 5.7 10.7 
M14 7.6 12.6 
M15 7.5 15.0 
M16 9.6 17.2 
Mean ±sem 6.3 ± 0.49 14.5±0.89 
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Appendix III 
This appendix relates to results described in chapter 12.3. 
Table 1 Nifedipine oxidase activities of human liver microsomes. Results 
are the mean ± sem and range with median in parenthesis for n=16 
samples. The substrate concentration was 100uM. 
Laboratory number ACTIVITY 
(nmol/ min/ mg protein) 
M1 0.902 
M2 3.10 
M3 5.43 
M4 5.72 
M5 1.89 
M6 3.25 
M7 2.92 
M8 1.39 
M9 2.45 
M10 1.19 
M11 1.68 
M12 0.529 
M13 0.055 
M14 0.729 
M15 3.89 
M16 3.51 
Mean ± sem 2.57 ± 0.41 
Range (median) 0.055 - 5.72 (1.72) 
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Table 2 Ethoxy- and pentoxyresorufin-O-dealkylase activities of human 
liver microsomal fractions. Results are the mean ± sem and range with 
median in parenthesis for n=7 samples. The substrate concentrations were 
2aM. 
Laboratory number 
FOR activity 
(pmol/ min / mg 
protein) 
POR activity 
(pmol/ min / mg 
protein) 
M1 10.0 n. d. 
M2 23.1 0.5 
M3 41.7 4.7 
M4 79.9 10.2 
M5 38.0 3.5 
M6 124.4 11.0 
M7 65.5 6.5 
Mean ±sem 54.7±14.7 5.2 ± 2.0 
Range (median) 10.0 -124.4 (41.7) 0 -11.0 (4.7) 
n. d. = below the analytical limit of detection (0. lpmol/ min) 
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Table 3 p-Nitrophenol hydroxylase activities of human liver microsomal 
fractions. Results are the mean ± sem and range with median in 
parenthesis for n=7 samples. The substrate concentration was 200µM. 
Laboratory number 
ACTIVITY 
(nmol/ min / mg protein) 
Mi 0.838 
M2 1.32 
M3 0.797 
M4 1.22 
M5 0.772 
M6 0.785 
M7 0.662 
Mean ± sem 0.913 ± 0.095 
Range (median) 0.662 - 1.32 (0.797) 
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Table 4 Paraoxonase activity of human liver microsomal fractions. 
Results are the mean ± sem and range with median in parenthesis for n=7 
samples. The substrate concentration was 1mM. 
Laboratory number 
ACTIVITY 
(nmol/ min / mg 
protein) 
ACTIVITY 
(nmol/ min /g 
liver) 
M1 7.3 141.0 
M2 6.6 94.5 
M3 16.0 327.0 
M4 5.0 59.5 
M5 4.6 57.5 
M6 9.3 124.0 
M7 12.7 166.0 
Mean ±sem 8.8±1.6 138.5 ± 34.9 
Range (median) 4.6 -16.0 (7.3) 57.5 - 327.0 (124.0) 
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Table 5 Phenylvalerate hydrolase activities of human liver microsomal 
fractions. Results are the mean ± sem and range with median in 
parenthesis for n=7 samples. Substrate concentration was 1.4mM. 
Laboratory number 
ACTIVITY 
(gmol/ min / mg 
protein) 
ACTIVITY 
(gmol/ min /g 
liver) 
M1 14.9 291.5 
M2 8.42 121.3 
M3 9.48 193.3 
M4 10.3 120.5 
M5 6.34 79.5 
M6 12.9 172.2 
M7 13.4 124.7 
Mean ± sem 10.8±1.15 157.6±26.4 
Range (median) 6.34 -14.9 (10.3) 79.5 - 291.5 (124.7) 
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Table 6 Glutathione-S-transferase activities of human liver cytosol. 
Results are the mean ± sem and range with median in parenthesis for n=7 
samples. The substrate concentration was 1mM. 
Laboratory number 
ACTIVITY 
(nmol/ min / mg 
cytosolic protein) 
ACTIVITY 
(gmol/ min /g 
liver) 
Mi 859 72 
M2 553 41 
M3 568 45 
M4 1120 81 
M5 1190 72 
M6 892 61 
M7 978 76 
Mean ± sem 880 ± 93.6 64 ± 5.9 
Range (median) 553 -1190 (892) 41-81(72) 
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Table 7 Parathion activation to paraoxon by human liver microsomes. 
Results are the mean ± sem and range with median in parenthesis for 
=1Ic livers. The substrate concentrations were 20uM and 200uM 
Laboratory number 
ACTIVITY from 20µM 
parathion 
(pmol paraoxon/ min/ 
mg protein) 
ACTIVITY from 200µM 
parathion 
(pmol paraoxon/ min/ 
mg protein) 
M1 49.8 18.7 
M2 57.6 156.3 
M3 52.8 144.4 
M4 80.6 244.5 
M5 23.3 53.1 
M6 173.6 229.2 
M7 70.8 58.7 
M8 29.0 110.3 
M9 104.5 210.3 
M10 64.1 93.0 
Mil 125.5 175.5 
M12 104.9 122.3 
M13 107.0 112.0 
M14 60.9 117.3 
M15 140.7 310.3 
M16 199.3 295.7 
Mean ± sem 90.3 ± 12.5 153.2 ± 21.3 
Range (median) 23.3 - 199.3 (70.8) 18.7 - 310.3 (117.3) 
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Table 8 Parathion detoxification to p-nitrophenol by human liver 
microsomes. Results are the mean ± sem and range with median in 
parenthesis for n=16 samples. The substrate concentrations were 20µM 
and 200uM 
Laboratory number 
ACTIVITY from 20µM 
parathion 
(pmol p-nitrophenol/ 
min/ mg protein) 
ACTIVITY from 200µM 
parathion 
(pmol p-nitrophenol/ 
min/ mg protein) 
Mi 487.6 515.2 
M2 605.7 715.6 
M3 321.1 406.2 
M4 726.8 746.3 
M5 656.9 687.8 
M6 644.8 616.9 
M7 769.2 778.3 
M8 593.2 671.2 
M9 446.6 511.4 
M10 452.1 494.6 
Mil 530.7 578.2 
M12 510.9 496.6 
M13 517.8 538.3 
M14 432.0 441.4 
M is 508.5 721.5 
M16 426.5 499.5 
Mean ± sem 538.0 ± 26.8 583.2 ± 26.3 
Range (median) 321.1- 769.2 (513.1) 406.2 - 778.3 (558.1) 
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Appendix IV 
This appendix relates to results described in chapter 12.3. 
Table 1 Inhibition of paraoxon formation from parathion (20µM) by two 
human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M15 Liver M16 Mean 
None (control) 140.7 
(pmol/ min/ mg 
protein) 
199.3 
(pmol/ min/ mg 
protein) 
100% 
Naringenin 41.2 46.4 43.8 
Troleandom cin 74.0 90.8 82.4 
Quercetin 11.6 24.5 18.1 
Ketoconazole 13.0 25.8 19.4 
Quinidine 66.5 87.7 77.1 
Table 2 Inhibition of paraoxon formation from parathion (20µM) by two 
human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M9 Liver M11 Mean 
None (control) 104.5 
(pmol/ min/ mg 
protein) 
125.5 
(pmol/ min/ mg 
protein) 
100% 
Met ra one 84.9 91.5 88.2 
a-Na hthoflavone 64.4 63.5 64.0 
DEDC 111.2 81.5 96.4 
Tolbutamide 98.4 91.5 95.0 
DEDC = Diethyldithiocarbamate 
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Table 3 Inhibition of p-nitrophenol formation from parathion (20µM) by 
two human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M15 Liver M16 Mean 
None (control) 508.5 
(pmol/ min/ mg 
protein) 
426.5 
(pmol/ min/ mg 
protein) 
100% 
Naringenin 64.8 60.4 62.6 
Troleandomycin 84.4 71.0 77.7 
Quercetin 47.6 43.9 45.8 
Ketoconazole 49.2 40.7 45.0 
Quinidine 97.4 87.5 92.5 
Table 4 Inhibition of p-nitrophenol formation from parathion (20µM) by 
two human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M9 Liver M11 Mean 
None (control) 446.6 
(pmol/ min/ mg 
protein) 
530.7 
(pmol/ min/ mg 
protein) 
100% 
Met ra one 81.9 111.6 96.8 
a-Na hthoflavone 74.0 107.0 90.5 
DEDC 101.6 72.6 87.1 
Tolbutamide 97.1 103.0 100.1 
DEDC = Diethyldithiocarbamate 
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Table 5 Inhibition of paraoxon formation from parathion (200µM) by two 
human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M15 Liver M16 Mean 
None (control) 310.3 
(pmol/ min/ mg 
protein) 
295.7 
(pmol/ min/ mg 
protein) 
100% 
Naringenin 69.2 65.3 67.3 
Troleandomycin 90.1 84.6 87.4 
Quercetin 40.2 33.0 36.6 
Ketoconazole 42.7 50.4 46.6 
Quinidine 93.5 86.5 90.0 
Table 6 Inhibition of paraoxon formation from parathion (200µM) by two 
human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M9 Liver M11 Mean 
None (control) 210.3 
(pmol/ min/ mg 
protein) 
175.5 
(pmol/ min/ mg 
protein) 
100% 
Met ra one 71.7 89.2 80.5 
a-Na hthoflavone 82.8 84.1 83.5 
DEDC 110.2 122.3 116.3 
Tolbutamide 89.8 122.7 106.3 
DEDC = Diethyldithiocarbamate 
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Table 7 Inhibition of p-nitrophenol formation from parathion (200µM) by 
two human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M15 Liver M16 Mean 
None (control) 721.5 
(pmol/ min/ mg 
protein) 
499.5 
(pmol/ min/ mg 
protein) 
100% 
Naringenin 53.2 48.1 50.7 
Troleandomycin 86.7 86.5 86.6 
Quercetin 48.4 45.0 46.7 
Ketoconazole 28.2 36.2 32.2 
Quinidine 113.0 99.0 106.0 
Table 8 Inhibition of p-nitrophenol formation from parathion (200µM) by 
two human liver microsomal preparations. Values are percent of control 
activity (mean of duplicate estimations). 
Inhibitor (100µM) Liver M9 Liver M11 Mean 
None (control) 511.4 
(pmol/ min/ mg 
protein) 
578.2 
(pmol/ min/ mg 
protein) 
100% 
Met ra one 85.1 76.0 80.6 
a-Na hthoflavone 80.5 101.7 91.1 
DEDC 118.3 120.5 119.4 
Tolbutamide 100.0 115.0 107.5 
DEDC = Diethyldithiocarbamate 
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A typical chromatogram produced following incubation of rat liver 
microsomes with parathion (200µM). The retention times for p-nitrophenol, 
paraoxon and parathion are 23.8min, 30.8min and 33.5min. 
273 
Kurd tt t. l-:; FP t'ýb)i ý1t y»t 
i 
3-30 
. 16 0 
A typical chromatogram produced following incubation of rat or human liver 
microsomes with nifedipine (100µM). The retention times for MI, unknown 
metabolite, nifedipine and nitrendipine (IS) are 3.3min, 4.0min, 5.6min and 
7.4min. 
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